<SEC-DOCUMENT>0001193125-23-063024.txt : 20230307
<SEC-HEADER>0001193125-23-063024.hdr.sgml : 20230307
<ACCEPTANCE-DATETIME>20230307164253
ACCESSION NUMBER:		0001193125-23-063024
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		7
CONFORMED PERIOD OF REPORT:	20230420
FILED AS OF DATE:		20230307
DATE AS OF CHANGE:		20230307

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PLUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001095981
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330827593
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34375
		FILM NUMBER:		23713212

	BUSINESS ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756
		BUSINESS PHONE:		737.255.7194

	MAIL ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTORI THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050712

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MACROPORE INC
		DATE OF NAME CHANGE:	20010320
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d417044ddef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML><HEAD>
<TITLE>DEF 14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a Party other than the Registrant&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT> </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material Pursuant under &#167; <FONT STYLE="white-space:nowrap">240.14a-12</FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>PLUS THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified in Its Charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules
<FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> and <FONT STYLE="white-space:nowrap">0-11.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
   <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g417044dsp1a.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4200 Marathon Blvd. Suite 200, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Austin, TX 78756 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(737) <FONT
STYLE="white-space:nowrap">255-7194</FONT> </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 7, 2023 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To Our Stockholders: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2022 was a year of significant progress
for Plus Therapeutics. We made considerable clinical and regulatory advances for our lead program, created momentum for our earlier stage programs and, even during a turbulent time in the U.S. capital markets, reached a new level of balance sheet
strength. All the while, the radiotherapeutics market continues to gain attention as an opportunity to potentially transform patients&#146; lives. 2023 provides a great outlook for the Plus team! </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead investigational targeted radiotherapeutic drug, rhenium (<SUP STYLE="font-size:75%; vertical-align:top">186</SUP>Re) obisbemeda, previously known as <FONT
STYLE="white-space:nowrap">Rhenium-186</FONT> NanoLiposome, or <SUP STYLE="font-size:75%; vertical-align:top">186</SUP>RNL, is currently being evaluated in our <FONT STYLE="white-space:nowrap">ReSPECT-GBM</FONT> Phase 2b trial for patients with
recurrent glioblastoma (GBM). This Phase 2b multi-center trial, funded by the National Institute of Health (NIH), is designed to evaluate the safety, tolerability, distribution and efficacy of rhenium
(<SUP STYLE="font-size:75%; vertical-align:top">186</SUP>Re) obisbemeda infused directly into the tumor via convection-enhanced delivery catheters in patients with recurrent GBM progressing after conventional treatment. We enrolled the first patient
in this trial late 2022. The Phase 2b trial is expected to enroll up to 31 total patients with small- to <FONT STYLE="white-space:nowrap">medium-sized</FONT> tumors in approximately 24 months. The initiation of our Phase 2b trial follows positive
interim results reported from our <FONT STYLE="white-space:nowrap">ReSPECT-GBM</FONT> Phase 1/2a dose escalation trial of rhenium (<SUP STYLE="font-size:75%; vertical-align:top">186</SUP>Re) obisbemeda in recurrent GBM disclosed in 2022. In the
Phase 1/2a dose escalation trial, we showed rhenium (<SUP STYLE="font-size:75%; vertical-align:top">186</SUP>Re) obisbemeda can be safely administered and that there is a statistically significant correlation between overall survival and both
absorbed radiation dose to the tumor and percent tumor volume in the treated volume. The strength of this correlation is unusually positive for a Phase 1/2a trial and we are optimistic that these safety and efficacy signals will be confirmed in the
ongoing Phase 2b trial. The U.S. Food and Drug Administration (&#147;FDA&#148;) granted both Orphan Drug designation and Fast Track designations to rhenium (<SUP STYLE="font-size:75%; vertical-align:top">186</SUP>Re) obisbemeda for the treatment of
patients with GBM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2022, the <SUP STYLE="font-size:75%; vertical-align:top">186</SUP>RNL program made substantial strides on its path towards being a
leader for the treatment of patients with leptomeningeal metastases (LM). A <FONT STYLE="white-space:nowrap">3-year,</FONT> $17.6&nbsp;million grant was awarded to Plus Therapeutics by the Cancer Prevention&nbsp;&amp; Research Institute of Texas
(CPRIT). Further, Plus Therapeutics completed enrollment of Cohort 1 in late 2022 and Cohort 2 in 2023 in the <FONT STYLE="white-space:nowrap">ReSPECT-LM</FONT> Phase 1/2a dose escalation trial. The FDA has also granted Fast Track designation to
rhenium (<SUP STYLE="font-size:75%; vertical-align:top">186</SUP>Re) obisbemeda for the treatment of LM. At the 2022 Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology, Plus Therapeutics presented Phase 1 data from the <FONT
STYLE="white-space:nowrap">ReSPECT-LM</FONT> trial demonstrating that a single administered dose of rhenium (<SUP STYLE="font-size:75%; vertical-align:top">186</SUP>Re) obisbemeda was feasible, safe and well-tolerated across two dosages in four
patients from Cohorts 1 and 2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beyond LM, we also hope to expand our programs by obtaining FDA Investigational New Drug (&#147;IND&#148;) approval to
evaluate rhenium (<SUP STYLE="font-size:75%; vertical-align:top">186</SUP>Re) obisbemeda in patients with pediatric brain cancer (&#147;PBC&#148;), specifically ependymoma and high-grade glioma, as part of the
<FONT STYLE="white-space:nowrap">ReSPECT-PBC</FONT> Phase 1 clinical trial. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we began evaluating <FONT STYLE="white-space:nowrap">Rhenium-188</FONT> NanoLiposome
Biodegradable Alginate Microsphere (<SUP STYLE="font-size:75%; vertical-align:top">188</SUP><FONT STYLE="white-space:nowrap">RNL-BAM)</FONT> to treat a variety of solid organ tumors such as primary liver cancer, hepatocellular carcinoma, and
secondary liver cancer, metastatic colorectal cancer. We have licensed patents and technologies for the development of <SUP STYLE="font-size:75%; vertical-align:top">188</SUP><FONT STYLE="white-space:nowrap">RNL-BAM</FONT> from The University of
Texas Health Science Center at San Antonio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2022, we also made significant progress building a resilient and redundant supply chain through strategic
partnerships that enable the development, manufacturing and future potential commercialization of our products. Our current supply chain and key partners are positioned to supply cGMP rhenium
(<SUP STYLE="font-size:75%; vertical-align:top">186</SUP>Re) obisbemeda for ongoing and planned Phase 2 and Phase 3 clinical trials in patients with GBM, LM and PBC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Looking forward to the remainder of 2023, anticipated milestones include continuing enrollment in our <FONT STYLE="white-space:nowrap">ReSPECT-GBM</FONT>
Phase 2b and our <FONT STYLE="white-space:nowrap">ReSPECT-LM</FONT> Phase 1/2a dose escalation trials for rhenium (<SUP STYLE="font-size:75%; vertical-align:top">186</SUP>Re) obisbemeda, completing key CMC and FDA
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for <SUP STYLE="font-size:75%; vertical-align:top">188</SUP><FONT STYLE="white-space:nowrap">RNL-BAM,</FONT> as well as exploring new indications for our rhenium<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP>(<SUP STYLE="font-size:75%; vertical-align:top">186</SUP>Re) obisbemeda program such as pediatric brain cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From all of our employees and our board of directors, I would like to express our appreciation for our stockholders and various partners for their help and
support in 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g417044g0224071627751.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Marc H. Hedrick</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>President&nbsp;&amp; Chief Executive Officer</I></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
   <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g417044dsp1a.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF 2023 ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON APRIL&nbsp;20, 2023 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PLUS THERAPEUTICS, INC.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Headquarters</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4200 MARATHON BLVD. SUITE 200,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">AUSTIN, TX 78756</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MEETING LOCATION:</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U>www.virtualshareholdermeeting.com/PSTV2023</U></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Plus Therapeutics, Inc. Stockholder: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You are cordially invited to attend the 2023 Annual Meeting of the stockholders of Plus Therapeutics, Inc. (the &#147;Annual Meeting&#148;).
The Annual Meeting will be held on April&nbsp;20, 2023, commencing at 9:00 a.m., Central Time, and will be a completely virtual meeting of stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The items of business for the meeting are to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">elect members of our board of directors (the &#147;Board&#148;) for a
<FONT STYLE="white-space:nowrap">one-year</FONT> term; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the 2023 fiscal
year; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provide a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on the compensation of our named
executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provide a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on the frequency of holding future <FONT
STYLE="white-space:nowrap">non-binding</FONT> advisory votes on executive officer compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">approve an amendment to our Amended and Restated Certificate of Incorporation, as amended (the
&#147;Charter&#148;), to effect a reverse stock split of our issued and outstanding shares of common stock, at a specific ratio, ranging from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-three</FONT></FONT> (1:3) to <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-fifteen</FONT></FONT> (1:15); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">approve the third amendment and restatement of the Company&#146;s 2020 Stock Incentive Plan; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transact such other business as may be properly brought before the meeting or any adjournment or postponement
thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board recommends that shareholders (a) elect each board member nominee; (b) vote to approve items (ii),
(iii), (v) and (vi); and (c) vote in favor of &#147;one year&#148; for item (iv). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In light of our successful virtual annual meetings
of&nbsp;stockholders in 2021 and 2022, the Annual Meeting will be held via live webcast only again this year. We believe that the virtual meeting format also expands stockholder access and participation and improves communications. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You will be able to attend and participate in the Annual Meeting online, vote your shares
electronically, and submit your questions prior to and during the meeting by visiting: <U>www.virtualshareholdermeeting.com/PSTV2023</U>. To vote at the meeting, you must have your control number that is shown on your proxy card. There will not be a
physical meeting location and you will not be able to attend the annual meeting in person. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only stockholders of record at the close
of business on March 3, 2023 are entitled to notice of, and to vote while attending the Annual Meeting on the Internet. For 10 days prior to the Annual Meeting, a complete list of stockholders entitled to vote at the Annual Meeting will be available
at the Secretary&#146;s office at 4200 Marathon Blvd. Suite 200, Austin, TX 78756. We expect to commence mailing these proxy materials to our security holders on or about March&nbsp;7, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>You are cordially invited to attend the Annual Meeting live via the Internet. It is important that your shares are represented at the
Annual Meeting. Even if you plan to attend the Annual Meeting live via the Internet, we hope that you will promptly vote by dating, signing, and returning the enclosed proxy card or vote via the Internet or by telephone. This will not limit your
ability to attend or vote during the Annual Meeting. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By Order of the Board,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g417044g0224071627751.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">MARC H. HEDRICK</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>President&nbsp;&amp; Chief Executive Officer</I></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Austin, Texas, USA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 7, 2023 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PAGE </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx417044_1">DIRECTORS AND EXECUTIVE OFFICERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx417044_2">CORPORATE GOVERNANCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx417044_3">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx417044_4">PAY VERSUS PERFORMANCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx417044_5">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx417044_6">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx417044_7">AUDIT MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx417044_8">PROPOSAL #1 ELECTION OF DIRECTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx417044_9">PROPOSAL #2 RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
 FIRM</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx417044_10">PROPOSAL #3 NON-BINDING ADVISORY VOTE ON EXECUTIVE
COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx417044_11">PROPOSAL #4 <FONT STYLE="white-space:nowrap">NON-BINDING</FONT> ADVISORY VOTE
 ON FREQUENCY OF HOLDING FUTURE <FONT STYLE="white-space:nowrap">NON-BINDING</FONT> ADVISORY VOTES ON EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx417044_12">PROPOSAL #5 APPROVAL OF AN AMENDMENT TO OUR AMENDED AND RESTATED CERTIFICATE OF
 INCORPORATION, AS AMENDED, TO EFFECT A REVERSE STOCK SPLIT OF OUR ISSUED AND OUTSTANDING SHARES OF COMMON STOCK, AS A SPECIFIC RATIO, RANGING FROM <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ONE-FOR-THREE</FONT></FONT> (1:3)
TO <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ONE-FOR-FIFTEEN</FONT></FONT> (1:15)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx417044_13">PROPOSAL #6 APPROVAL OF THE THIRD AMENDMENT AND RESTATEMENT OF THE 2020 STOCK
 INCENTIVE PLAN</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx417044_14">OTHER MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4200 Marathon Blvd. Suite 200, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Austin, TX 78756 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(737) <FONT
STYLE="white-space:nowrap">255-7194</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY
STATEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2023 ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022 is being made available
to stockholders together with these proxy materials on or about March 7, 2023. </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Proxy Statement is being furnished in
connection with the solicitation of proxies by Plus Therapeutics, Inc. (the &#147;Company,&#148; &#147;Plus,&#148; or &#147;we&#148;) to be used at our 2023 Annual Meeting of Stockholders to be held on April&nbsp;20, 2023 at 9:00 a.m., Central Time
(&#147;Annual Meeting&#148;), and at any adjournment or postponement of the Annual Meeting, for the purposes set forth in the accompanying notice of Annual Meeting. The Annual Meeting will be a completely virtual meeting of stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have fixed the close of business on March 3, 2023 as the record date for the determination of the stockholders entitled to notice of and to
vote at the Annual Meeting (the &#147;Record Date&#148;). Only holders of record of shares of our common stock on that date are entitled to notice of and to vote at the Annual Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You will be able to attend and participate in the Annual Meeting online, vote your shares electronically, and submit your questions prior to
and during the meeting by visiting: <U>www.virtualshareholdermeeting.com/PSTV2023</U>. To vote at the meeting, you must have your control number that is shown on your proxy card. There will not be a physical meeting location and you will not be able
to attend the annual meeting in person. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Questions and Answers about the Meeting and Voting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Q: What is a proxy statement and why has this Proxy Statement been provided to me? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A: A Proxy Statement is a document that Securities and Exchange Commission (&#147;SEC&#148;) regulations require us to give you when we ask
you to provide a proxy to vote your shares at the Annual Meeting. Among other things, this Proxy Statement describes the proposals on which stockholders will be voting and provides information about us. We are soliciting your proxy to vote at the
Annual Meeting and at any adjournment or postponement of the Annual Meeting. We will use the proxies received in connection with proposals to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">elect members of our Board for a <FONT STYLE="white-space:nowrap">one-year</FONT> term; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the 2023 fiscal
year; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provide a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on the compensation of our named
executive officers; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provide a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on the frequency of holding future <FONT
STYLE="white-space:nowrap">non-binding</FONT> advisory votes on executive officer compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">approve an amendment to our Amended and Restated Certificate of Incorporation, as amended (the
&#147;Charter&#148;), to effect a reverse stock split of our issued and outstanding shares of common stock, at a specific ratio, ranging from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-three</FONT></FONT> (1:3) to <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-fifteen</FONT></FONT> (1:15); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">approve the third amendment and restatement of the Plus Therapeutics, Inc. 2020 Stock Incentive Plan; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transact such other business as may be properly brought before the meeting or any adjournment or postponement
thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Q: What is a proxy? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A: A proxy is your legal designation of another person to vote the stock you own. That designee is referred to as a proxy holder. Designation
of a particular proxy holder can be effected by completion of a written proxy card, or by voting via the Internet or by telephone. If you return a proxy card, or vote by phone or internet, our President and Chief Executive Officer, Marc H. Hedrick,
M.D., and our Chief Financial Officer, Andrew Sims, will act as your designated proxy holder at the Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Q: How can I
attend the Annual Meeting? </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A: The Annual Meeting will be a virtual meeting of stockholders, which will be conducted exclusively
by webcast. You are entitled to participate in the Annual Meeting only if you were a stockholder of the Company as of the close of business on March 3, 2023, or if you hold a valid proxy for the Annual Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No physical meeting will be held. You will be able to attend the Annual Meeting online and submit your questions during the meeting by
visiting <U>www.virtualshareholdermeeting.com/PSTV2023</U>. You also will be able to vote your shares online by attending the Annual Meeting webcast. To participate in the Annual Meeting, you will need the sixteen-digit control number provided on
your proxy card. For more information, review the information included on your proxy card, or the instructions that accompanied your proxy materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The online meeting will begin promptly at 9:00 a.m., Central Time, on April&nbsp;20, 2023. We encourage you to access the meeting prior to the
start time, leaving ample time for the check in. Please follow the instructions in this Proxy Statement and on your proxy card. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Q:
What is the difference between a stockholder of record and a beneficial owner who holds stock in street name? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A: You are a
stockholder of record, or a &#147;registered holder&#148;, if your shares are registered in your own name through our transfer agent. If you have a stock certificate, you are also a stockholder of record. You are a beneficial owner of our stock in
street name if you hold your shares through a broker, bank or other third-party institution (in this situation, the banks, brokers, etc. are the stockholders of record). The vast majority of our stockholders hold their shares in street name. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Q: What different methods can I use to vote? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A: Stockholders who are a registered holder may vote by virtually attending the proxy meeting, submitting votes electronically over the
Internet, by telephone or by completing and mailing a proxy card. The website identified on the proxy card provides specific instructions on how to vote electronically over the Internet. Those stockholders who receive a paper proxy by mail, and who
elect to vote by mail, should complete and return the mailed proxy card in the prepaid and addressed envelope that was enclosed with the proxy materials. Stockholders who vote over the Internet or by telephone need not return a proxy card or voting
instruction form by mail, but may incur costs, such as usage charges, from telephone companies or Internet service providers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are
the beneficial owner of stock held in street name, follow the instructions from your broker, bank or other nominee to vote your shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders who have previously elected to access our proxy materials and annual report electronically over the Internet will continue to
receive an <FONT STYLE="white-space:nowrap">e-mail,</FONT> referred to in this Proxy Statement as an <FONT STYLE="white-space:nowrap">&#147;e-mail</FONT> notice&#148;, with information on how to access the proxy information and voting instructions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only proxy cards and voting instruction forms that have been signed, dated and timely returned and only proxies that have been timely
voted electronically or by telephone will be counted in the quorum and voted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may also vote your shares at the Annual Meeting. If you
are a registered holder you must join live online at <U>www.virtualshareholdermeeting.com/PSTV2023</U>. The webcast will start at 9:00 a.m., Central Time. You may vote and submit questions while attending the meeting online. You will need the
control number included on your proxy card (if you received a printed copy of the proxy materials) to vote during the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you
receive more than one email notice, proxy card or voting instruction form because your shares are held in multiple accounts or registered in different names or addresses, please vote your shares held in <I>each account </I>to ensure that all of your
shares will be voted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Q: What is the Record Date and what does it mean? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A: The Record Date for the Annual Meeting is March 3, 2023. The Record Date is established by our Board as required by Delaware General
Corporation Law. Owners of our common stock at the close of business on the Record Date are entitled to receive notice of the meeting and to vote at the meeting and any adjournment or postponement of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Q: How can I change my vote? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A: You may revoke your proxy and change your vote at any time before the final vote at the meeting. You can revoke a proxy by delivering
written notice of revocation to our Corporate Secretary, following the Internet voting instructions, delivering a later dated proxy, or voting at the meeting. However, your attendance at the Annual Meeting will not automatically revoke your proxy
unless you vote again at the meeting or specifically request in writing that your proxy be revoked. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Q: What are my voting choices when
voting for director nominees and what vote is needed to elect directors? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A: In voting on the election of director nominees to serve
until the 2024 Annual Meeting, stockholders may vote in favor of each nominee, or may withhold votes as to each nominee. In addition, if any other candidates are properly nominated at the meeting, stockholders of record who attend the meeting could
vote for the other candidates. Directors are elected by a plurality vote, which means that the six nominees receiving the most affirmative votes will be elected. Stockholders are not entitled to cumulative voting rights with respect to the election
of directors. Only votes &#147;FOR&#148; or &#147;WITHHELD&#148; will affect the outcome. We do not expect any broker <FONT STYLE="white-space:nowrap">non-votes</FONT> in connection with this proposal since we expect brokers to have discretionary
authority to vote on this proposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Q: What are my voting choices when voting to ratify the appointment of our independent
registered public accounting firm, and what vote is needed to ratify the appointment? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A: In voting on the ratification of the
appointment of our independent registered public accounting firm, stockholders may vote in favor of or against the ratification or may abstain from voting on the ratification. The affirmative vote of a majority of the common stock having voting
power present at the meeting or represented by proxy at the meeting is required to approve this proposal. Abstentions will be counted as present for purposes of determining a quorum and are considered shares present and entitled to vote and thus
will have the effect of a vote &#147;AGAINST&#148; this proposal. We do not expect any broker <FONT STYLE="white-space:nowrap">non-votes</FONT> in connection with this proposal since we expect brokers to have discretionary authority to vote on this
proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This vote is advisory, and therefore not binding on the Board. Although the vote is
<FONT STYLE="white-space:nowrap">non-binding,</FONT> the Board will review the voting results, seek to determine the cause or causes of any significant negative voting, and take them into consideration when making decisions regarding our independent
registered public accounting firm for this fiscal year and future fiscal years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Q: What are my voting choices when voting to approve,
on an advisory basis, the compensation of the Company&#146;s named executive officers? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. In voting on the approval, on an advisory
basis, of the compensation of our named executive officers, stockholders may vote in favor or against the proposal, or they may abstain from voting on this proposal. The affirmative vote of a majority of the common stock having voting power present
at the meeting or represented by proxy at the meeting is required to approve this proposal. Abstentions will be counted as present for purposes of determining a quorum and are considered shares present and entitled to vote and thus will have the
effect of a vote &#147;AGAINST&#148; this proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This vote is advisory, and therefore not binding on the Board. Although the vote is <FONT
STYLE="white-space:nowrap">non-binding,</FONT> the Board will review the voting results, seek to determine the cause or causes of any significant negative voting, and take them into consideration when making future decisions regarding executive
compensation programs. We do not expect any broker <FONT STYLE="white-space:nowrap">non-votes</FONT> in connection with this proposal since we expect brokers to have discretionary authority to vote on this proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Q:&nbsp;What are my voting choices when voting, on an advisory basis, on the frequency of holding future
<FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on executive officer compensation? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A:&nbsp;In voting, on an
advisory basis, on the frequency of holding <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on executive officer compensation, or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-pay,&#148;</FONT></FONT> stockholders may vote to have the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> vote every year,
every two years, or every three years, or may abstain from voting. The option of every year, every two years or every three years that receives the affirmative vote of holders of a majority of shares present in person virtually or by proxy and
entitled to vote on the proposal will be the frequency recommended by stockholders for the advisory vote on the compensation of our executive officers, unless none of the frequency options receives a majority vote, in which case the option that
receives the highest number of votes will be considered to be the frequency recommended by stockholders. Abstentions have the same effect as a vote against each of the frequency options. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are
not counted for any purpose in determining which frequency option has been recommended by stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This vote is advisory, and therefore not binding on the Board. Stockholders may choose among
the four choices (every year, every two years, every three years or abstain from voting).&nbsp;The Board will consider any significant vote in favor of one frequency over the other options and will evaluate the appropriate next step. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Q: What are my voting choices when voting to approve an amendment to our Charter to effect a reverse stock split of our issued and
outstanding shares of common stock. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A: In voting to approve an amendment to our Charter to effect a reverse stock split of our issued
and outstanding shares of common stock, stockholders may vote in favor of or against the proposal, or may abstain from voting on this proposal. The holder of record of the one (1)&nbsp;outstanding share of Series F Preferred Stock will be entitled
to 50,000,000 votes for such share of our Series F Preferred Stock held on the Record Date, and has the right to vote only on the reverse stock split proposal described below, provided that such votes will automatically be voted, without action by
the holder, in the same proportion as the shares of common stock voted on the reverse stock split proposal. As an example, if 50.5% of the shares of common stock voted at the Annual Meeting are voted FOR the reverse stock split proposal, 50.5% of
the votes cast by the holder of the Series F Preferred Stock will be cast as votes FOR the reverse stock split proposal. Holders of common stock and Series F Preferred Stock will vote on the reverse stock split proposal as a single class. The
presence, in person virtually or by proxy, of the holders on the Record Date entitled to cast at least one third of the total votes entitled to be cast by the holders of all outstanding capital stock of the Company, present in person or by proxy,
shall constitute a quorum for the reverse stock split proposal at the Annual Meeting and any adjournment thereof. This proposal must be approved, in person virtually or by proxy, by the holders on the Record Date of a majority of the voting power of
the outstanding shares of our common stock and Series F Preferred Stock, voting together as a single class. As a result, abstentions will have the same effect as a vote &#147;AGAINST&#148; such proposal. Broker
<FONT STYLE="white-space:nowrap">non-votes</FONT> are not counted for any purpose in determining whether to approve the amendment to our Charter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Q: What are my voting choices when voting to approve the third amendment and restatement of the Plus Therapeutics, Inc. 2020 Stock
Incentive Plan? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A: In voting on the approval of the third amendment and restatement of the Plus Therapeutics, Inc. 2020 Stock
Incentive Plan, stockholders may vote in favor of or against the proposal or they may abstain from voting on the proposal. The affirmative vote of a majority of the common stock having voting power present in person or represented by proxy at the
meeting is required to approve this proposal. Abstentions will be counted as present for purposes of determining a quorum and are considered shares present and entitled to vote and thus will have the effect of a vote &#147;AGAINST&#148; this
proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Q: How will a proxy get voted? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A: If you properly complete and return a proxy card or vote by Internet or by telephone, the designated proxy holders will vote your shares as
you have directed. If you sign a proxy card but do not make specific choices or if you vote by Internet or telephone but do not make specific choices, the designated proxy holders will vote your shares as recommended by the Board as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>FOR</B>&#148; the election of each listed director nominee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>FOR</B>&#148; ratification of the appointment of BDO USA, LLP as our independent registered public
accounting firm for the 2023 fiscal year; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>FOR</B>&#148; approval, on an advisory basis, of the compensation of our named executive officers;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for approval of the frequency of holding future <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory
votes on executive officer compensation <B>EVERY YEAR</B>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>FOR</B>&#148; approval of an amendment to our Amended and Restated Certificate of Incorporation, as
amended, to effect a reverse stock split of our issued and outstanding shares of common stock, at a specific ratio, ranging from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-three</FONT></FONT> (1:3) to <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-fifteen</FONT></FONT> (1:15); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>&#147;FOR&#148; </B>approval of the third amendment and restatement of the Plus Therapeutics, Inc. 2020 Stock
Incentive Plan. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the election of directors, if any nominee is unable or declines to serve, or for good
cause will not serve, as a director at the time of the Annual Meeting, an event not currently anticipated, the designated proxy holders will have the express discretionary authority to vote for a replacement nominee designated by our Board, and
proxies will be voted for any nominee designated by our Board to fill the vacancy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Q: How are abstentions and broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> counted? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A: Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will
be counted as present for purposes of determining a quorum. An abstention occurs when a stockholder chooses to &#147;ABSTAIN&#148; from voting on a matter. A broker <FONT STYLE="white-space:nowrap">non-vote</FONT> occurs when a broker, bank, or
other stockholder of record, in nominee name or otherwise, exercising fiduciary powers submits a proxy for the Annual Meeting, but does not vote on a particular proposal because that holder does not have discretionary voting power with respect to
that proposal and has not received voting instructions from the beneficial owner. Under the rules that govern brokers who are voting with respect to shares held in street name, brokers have the discretion to vote those shares on routine matters, but
not on <FONT STYLE="white-space:nowrap">non-routine</FONT> matters. We expect the proposals relating to the ratification of the appointment of our independent registered public accounting firm and the reverse stock split to be routine matters, and
therefore, broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are not expected to exist with respect to these proposals. We expect the other proposals described in this proxy statement to be <FONT STYLE="white-space:nowrap">non-routine.</FONT>
Brokers and nominees do not have discretionary voting power over these <FONT STYLE="white-space:nowrap">non-routine</FONT> proposals and, therefore, broker <FONT STYLE="white-space:nowrap">non-votes</FONT> may exist with respect to these proposals.
Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will not affect the outcome of any of these <FONT STYLE="white-space:nowrap">non-routine</FONT> matters that are being voted on at the Annual Meeting, assuming that a quorum is obtained.
However, we strongly encourage you to submit your proxy and exercise your right to vote as a stockholder to ensure your shares are voted in the manner in which you want them voted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Q: Who pays for the solicitation of proxies? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A: We will pay the entire cost of the solicitation of proxies for the Annual Meeting. This includes preparation, assembly, printing, and
mailing of the Notice, this Proxy Statement and any other information we send to stockholders. We have engaged Alliance Advisors, LLC to assist in the solicitation of proxies and provide related advice and information support, for a services fee and
the reimbursement of customary disbursements, which are not expected to exceed $70,000 in the aggregate. In addition, we may supplement our efforts to solicit your proxy in the following ways: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may contact you using the telephone or electronic communication; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our directors, officers or other regular employees may contact you personally; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Alliance Advisors, LLC or any other third parties we may hire as agents for the sole purpose of contacting you
regarding your proxy, may contact you. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not pay directors, officers or other regular employees any additional compensation
for their efforts to supplement our proxy solicitation. We anticipate banks, brokerage houses and other custodians, nominees and fiduciaries will forward soliciting material to the beneficial owners of shares of common stock entitled to vote at the
Annual Meeting and that we will reimburse those persons for their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in performing such services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Q: What constitutes a quorum? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A: For business to be conducted at the Annual Meeting, a quorum must be present. A quorum exists when the holders of at least 33<SUP
STYLE="vertical-align:top">1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% of the shares of our common stock issued, outstanding and entitled to vote are represented at the meeting. Shares of common stock represented in person virtually or
by proxy (including broker <FONT STYLE="white-space:nowrap">non-votes</FONT> and shares that abstain or do not vote with respect to one or more of the matters to be voted upon) will be counted for the purpose of determining whether a quorum exists.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Q: How many votes may I cast? How many shares are eligible to be voted? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A: You may cast one vote for every share of our common stock that you owned on the Record Date. As of the Record Date, March 3, 2023, there
were 35,418,165&nbsp;shares of common stock outstanding, each of which is entitled to one vote. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Q: How will voting on any
&#147;other business&#148; be conducted? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A: Although we do not know of any business to be considered at the Annual Meeting other than
the proposals described in this Proxy Statement, if any additional business is presented at the Annual Meeting, your proxy gives authority to the designated proxy holders to vote on such matters according to their best judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Q: Where can I find the voting results of the Annual Meeting? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A: We will publish the final voting results in a current report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> which we expect to file
with the SEC within four business days of the Annual Meeting. If the final voting results are unavailable in time to file a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> with the SEC within four business days after the Annual
Meeting, we intend to file a Form <FONT STYLE="white-space:nowrap">8-K</FONT> to disclose the preliminary results and, within four business days after the final results are known, we will file an additional current report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> with the SEC to disclose the final voting results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx417044_1"></A>DIRECTORS AND EXECUTIVE OFFICERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board consists of six
(6)&nbsp;directors. The term of each director expires each year at our Annual Meeting of Stockholders. Each director also continues to serve as a director until his or her successor is duly elected and qualified, or until he or she sooner dies,
resigns, or is removed. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the name, age, and committee appointments of each of our current directors as
of March 3, 2023: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="62%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Position(s)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Howard Clowes(1)(2)(3)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">69</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">An van <FONT STYLE="white-space:nowrap">Es-Johansson,</FONT> M.D.(1)(3)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">62</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Richard J. Hawkins</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">74</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chairman of the Board</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Marc H. Hedrick, M.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">60</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">President, Chief Executive Officer and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Robert Lenk, PhD(3)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">74</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Greg Petersen(1)(2)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">60</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE></DIV> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the audit committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the governance and nominating committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The names of the nominees and certain biographical information about each current director standing for election at the Annual Meeting,
including a description of his or her business experience, qualifications, education and skills that led our Board to conclude that such individual should serve as a member of our Board, are set forth below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Howard Clowes. </I>Mr.&nbsp;Clowes has served on our Board since April&nbsp;1, 2020. From January 2005 until he retired as a lawyer in
December 2018, Mr.&nbsp;Clowes was a partner in the law firm DLA Piper (US) LLC. From 1982 until the formation of DLA Piper in 2005, he was an associate and then a partner in the predecessor firms of DLA Piper, holding various management positions,
including serving on its board of directors. Mr.&nbsp;Clowes served on the board of Equalize Health and as Chair of its Governance Committee from January 2018 to May 2022 and serves on the board of AFRAC, each of which are nonprofit corporations
focused on global healthcare. Mr.&nbsp;Clowes served on the board of the Law Foundation of Silicon Valley, a <FONT STYLE="white-space:nowrap">non-profit</FONT> organization located in San Jose, California, that provides free legal services to
Silicon Valley residents in need, from 2008 until December 2018, serving during that period in various positions, including President of its board of directors, and Chair of a Strategic Planning and CEO Search Committee. From 2017 to 2021,
Mr.&nbsp;Clowes served as a Lecturer at U.C. Berkeley&#146;s Berkeley School of Law, teaching a course in International Business Negotiations. Mr.&nbsp;Clowes earned his J.D. at U.C. Berkeley and his B.A. in Experimental Psychology at U.C. Santa
Barbara. We believe Mr.&nbsp;Clowes&#146; qualifications to serve on the Board include his extensive experience as a lawyer advising boards of directors and their audit, compensation and governance committees on a wide range of matters, his
experience with a wide range of transactions, and his experience serving on various boards of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>An van <FONT
STYLE="white-space:nowrap">Es-Johansson,</FONT> M.D</I>. Dr.&nbsp;van <FONT STYLE="white-space:nowrap">Es-Johansson</FONT> has served on our Board since January&nbsp;1, 2020. Dr.&nbsp;van <FONT STYLE="white-space:nowrap">Es-Johansson</FONT> served
as the Chief Medical Officer for AlzeCure Pharma, a Swedish pharmaceutical company with a primary focus on Alzheimer&#146;s disease, from September 2018 through March&nbsp;1, 2021 following which she has continued to serve AlzeCure Pharma as a
Senior Advisor beginning in March 2021. From May 2005 to September 2018, Dr.&nbsp;van <FONT STYLE="white-space:nowrap">Es-Johansson</FONT> served in a range </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of executive roles of increasing responsibility at Sobi, an international rare disease company headquartered in Stockholm, Sweden, including as Vice President and Head of EMENAR Medical Affairs
for Specialty Care and Partner Products from March 2013 to January 2018. Prior to her time at Sobi, Dr.&nbsp;van <FONT STYLE="white-space:nowrap">Es-Johansson</FONT> served in leadership positions within large pharmaceutical and smaller
biotechnology companies, including Roche, Pharmacia, Eli Lilly, Active Biotech, and BioStratum. From 2004 to 2016, she was a member of the Scientific Advisory Board of Uppsala Bio and currently serves on the board of directors of IRLAB AB (NASDAQ
IRLAB Stockholm), Savara, Inc. (NASDAQ: SVRA), Lumos Pharma, Inc. (NASDAQ: LUMO) and privately held Agendia BV. She also served on the board of directors at BioInvent International AB (NASDAQ OMX Stockholm), from June 2016 to February 2021.
Dr.&nbsp;van <FONT STYLE="white-space:nowrap">Es-Johansson</FONT> received a M.D. from Erasmus University, Rotterdam, The Netherlands. We believe Dr.&nbsp;van <FONT STYLE="white-space:nowrap">Es-Johansson&#146;s</FONT> qualifications to serve on our
board include her extensive medical knowledge and experience in the pharmaceutical industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Richard J. Hawkins</I>. Mr.&nbsp;Hawkins
has served on our Board since December 2007 and as Chairman of our Board since January 2018. In 1982, Mr.&nbsp;Hawkins founded Pharmaco, a clinical research organization, or CRO, where he served as its Chairman, President and Chief Executive Officer
until 1991 when it merged with the predecessor of <FONT STYLE="white-space:nowrap">PPD-Pharmaco.</FONT> In 1992, Mr.&nbsp;Hawkins <FONT STYLE="white-space:nowrap">co-founded</FONT> Sensus Drug Development Corporation, or SDDC, a privately-held
company focused on the development of drugs to treat endocrine disorders, which developed and received regulatory approval for SOMAVERT, a growth hormone antagonist approved for the treatment of acromegaly, which is now marketed by Pfizer, Inc.,
where he served as Chairman until 2000. In 1994, <FONT STYLE="white-space:nowrap">Mr.&nbsp;Hawkins&nbsp;co-founded&nbsp;Corning</FONT> Biopro, a contract protein manufacturing firm, where he served on its board until Corning BioPro&#146;s sale to <FONT
STYLE="white-space:nowrap">Akzo-Nobel,&nbsp;N.V.,</FONT> a publicly-held producer of paints, coatings and specialty chemicals, in 2000. In September 2003, Mr.&nbsp;Hawkins founded LabNow, Inc., a privately held company that <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">develops&nbsp;lab-on-a-chip&nbsp;sensor</FONT></FONT></FONT> technology, where he served as the Chairman and Chief Executive Officer until October 2009. In
February 2011, Mr.&nbsp;Hawkins became Chief Executive Officer, and is currently Chief Executive Officer, president and chairman of Lumos Pharma, Inc. (NASDAQ: LUMO). Mr.&nbsp;Hawkins served on the board of SciClone Pharmaceuticals, Inc. (HKD:
SCLN), a publicly-held specialty pharmaceutical company, from October 2004 through December 2017. He also served on the Presidential Advisory Committee for the Center for Nano and Molecular Science and Technology at the University of Texas in
Austin, and was inducted into the Hall of Honor for the College of Natural Sciences at the University of Texas. Mr.&nbsp;Hawkins is a member of the National Ernst&nbsp;&amp; Young Entrepreneur of the Year Hall of Fame. Mr.&nbsp;Hawkins graduated cum
laude with a B.S. in Biology from Ohio University, where he later received the Ohio University Konneker Medal, the highest award given to a faculty member or former student for entrepreneurial excellence. We believe Mr.&nbsp;Hawkins&#146;s
qualifications to serve on our Board include his executive experience working with life sciences companies, his extensive experience in pharmaceutical research and development, his knowledge, understanding and experience in the regulatory
development and approval process, and his service on other public company boards and committees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Marc H. Hedrick, M.D.</I>
Dr.&nbsp;Hedrick joined the Company in October 2002 as Chief Scientific Officer. In May 2004, he was appointed as President of the Company and in April 2014 he was appointed as its Chief Executive Officer. Dr.&nbsp;Hedrick has served as a member of
our Board since joining the Company in October 2002. Previously, Dr.&nbsp;Hedrick served in a number of executive leadership positions, including President and Chief Executive Officer of StemSource from 2001 to 2003 and Chief Scientific Officer and
Medical Director of Macropore Biosurgery from 2002 to 2004. Dr.&nbsp;Hedrick has also served as a board member for a number of public and private companies since 2000. Prior to his corporate career, Dr.&nbsp;Hedrick was Associate Professor of
Surgery and Pediatrics at the University of California, Los Angeles. While at the University of California, Los Angeles, Dr.&nbsp;Hedrick&#146;s academic research received both NIH funding as well as private and public capitalization and was widely
acknowledged through scientific publications and the media. Dr.&nbsp;Hedrick also has first-hand experience as a physician, practicing general, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
vascular and craniofacial surgery. Dr.&nbsp;Hedrick has a medical degree from The University of Texas Southwestern Medical School and a Master of Business Administration from The UCLA Anderson
School of Management and is a trained general, vascular and plastic surgeon. We believe Dr.&nbsp;Hedrick&#146;s qualifications to serve on our Board include his executive, financial, governance and operational leadership experience in medical and
pharmaceutical product development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Robert Lenk</I>. Dr.&nbsp;Lenk has served on our Board since April&nbsp;1, 2020. Since 2016, he
has served as President of Lenk Pharmaceuticals, LLC, consulting to clients in the pharmaceuticals industry. Dr.&nbsp;Lenk <FONT STYLE="white-space:nowrap">co-founded</FONT> the Liposome Company, in Princeton, New Jersey in 1981 until it was later
acquired by Elan Pharmaceuticals. After the Liposome Company went public, he <FONT STYLE="white-space:nowrap">co-founded</FONT> Argus Pharmaceuticals, a drug delivery company focused on cancer and infectious diseases, in 1989 as Vice President of
Research&nbsp;&amp; Development, until it merged with two other companies to become Aronex Pharmaceuticals.&nbsp;From 1995 to 2003, Dr.&nbsp;Lenk served as President and Chief Executive Officer of Therapeutics 2000, Inc. which was later sold to
Coller Capital. Dr.&nbsp;Lenk joined Luna Innovations in 2004 where he served as President of its Nanoworks Division until 2010. In 2010, Dr.&nbsp;Lenk joined MediVector, Inc. as Chief Science Officer until 2016 when he started Lenk Pharmaceuticals,
LLC, a pharmaceutical development consulting company where he currently works. He also currently serves on the board of PoP Biotechnology, a private company that develops vaccines and cancer therapies based on proprietary porphyrin liposome
nanoparticle technology. Dr.&nbsp;Lenk received both his PhD and BSc. from the Massachusetts Institute of Technology. We believe Dr.&nbsp;Lenk&#146;s qualifications to serve on our Board include his broad experience in translating research
candidates into products, especially in the fields of nanotechnology and liposomal drug products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Greg Petersen.</I> Mr.&nbsp;Petersen
has served on our Board since February&nbsp;14, 2020. Mr.&nbsp;Petersen is an accomplished executive and board member with more than 25 years of strategy, operations, finance and compliance leadership experience. His 10 years of board of directors
experience includes his current roles as compensation committee chair and audit committee member of PROS Holdings, Inc. (NYSE: PRO), a software company, and as audit committee chair of Mohawk Group Holdings (NASDAQ: MWK), a consumer product
manufacturing company. Mr.&nbsp;Petersen previously served on the boards of publicly traded companies Diligent Corporation (NZX: DIL), a software as a service company, from 2013 to 2016, and Piksel, Inc. (OTC US: PIKL), a video management software
and services company, from 2012 to 2017. During his career, Mr.&nbsp;Petersen has served as Executive Vice Chairman of Diligent Corporation and as Chief Financial Officer of Lombardi Software (now part of IBM) and Activant Solutions (now part of
Epicor). He has also held executive positions at American Airlines and other corporations. Mr.&nbsp;Petersen has a BA from Boston College and an MBA from Duke University&#146;s Fuqua School of Business. We believe Mr.&nbsp;Petersen&#146;s
qualifications to serve on our Board include his extensive experience as an executive and a director, including as a director on other public company boards, as well as his strategic, operations, finance, and compliance leadership experience. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Diversity Matrix </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
demographic makeup of our Board, as disclosed by the Board members themselves, is as follows as of March 3, 2023: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Female</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Male</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>Gender:</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="8"><B><I>Number of Directors who identify in Any of the Categories Below:</I></B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B><I>&nbsp;</I></B></P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">White</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows information about our executive officers and their ages as of March 3, 2023: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="43%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Position(s)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>Executive Officers</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc H. Hedrick, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>President, Chief Executive Officer and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Sims</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Norman LaFrance, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Medical Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following presents biographical information for each of our executive officers listed in the table above,
other than Dr.&nbsp;Hedrick whose information is presented above under &#147;Directors&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Andrew Sims</I>.<I> </I>Mr.&nbsp;Sims<I>
</I>joined us as Chief Financial Officer in February 2020. Prior to his appointment as our Chief Financial Officer, Mr.&nbsp;Sims held roles at several private equity-backed companies. Between 2012 and 2017, Mr.&nbsp;Sims was Chief Financial Officer
of Amplify LLC, an advisory and management consulting services firm. Following his time at Amplify, Mr.&nbsp;Sims served as Chief Financial Officer of Verbatim Support Services LLC, a litigation support company, from 2017 to 2019. His focus has been
on mergers and acquisitions, integrations, corporate capitalization, and building out and managing teams to support global growth. Previously, Mr.&nbsp;Sims was Partner at Mazars, a global accounting, advisory, audit, tax and consulting firm.
Working from both the Oxford, England and New York offices, Mr.&nbsp;Sims audited and advised global public clients, including a variety of healthcare companies, with average annual revenues in excess of $1&nbsp;billion. Further, he was the lead
partner on over 50 acquisitions ranging from $5&nbsp;million to $4&nbsp;billion in purchase price. He is a Certified Public Accountant in the U.S. and a Chartered Accountant in England and Wales. Mr.&nbsp;Sims is a graduate of Buckingham University
in the United Kingdom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Norman LaFrance, M.D.</I> Dr.&nbsp;LaFrance joined us as Chief Medical Officer in November 2021. Prior to
joining the Company, Dr.&nbsp;LaFrance served as Chief Medical Officer and Senior Vice President at Jubilant Pharma Ltd. from 2012 to 2022 where he was responsible for all Pharma Medical&nbsp;&amp; Regulatory Affairs activities. Dr.&nbsp;LaFrance
has spent more than four decades in the pharmaceutical and healthcare industry, academia and medical practice. His background includes strategic planning and management of pharmaceutical development for approval by the FDA as well as clinical and
academic experience. In addition, Dr.&nbsp;LaFrance practiced medicine for 10 years and held academic faculty appointments at Johns Hopkins University School of Medicine in the Departments of Medicine and Radiology and the Department of Radiological
Sciences in the Johns Hopkins School of Hygiene and Public Health. He is double board certified in internal medicine and nuclear medicine. He is a graduate of the medical school at the University of Arizona and received his Bachelor of Science and
Master of Engineering degrees in Nuclear Engineering and Science from Rensselaer Polytechnic Institute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships
among any of our directors or executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx417044_2"></A>CORPORATE GOVERNANCE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2022: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Board held 5 meetings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the audit committee held 4 meetings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the compensation committee held 2 meetings; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the governance and nominating committee held 2 meetings. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each member of the Board attended at least seventy-five percent (75%) or more of the
aggregate of (i)&nbsp;the total number of Board meetings held during the period of such member&#146;s service and (ii)&nbsp;the total number of meetings of committees of the Board on which such member served, during the period of such member&#146;s
service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All Board members are encouraged to attend our annual meetings of stockholders in person virtually. In 2022, all of our
directors virtually attended our 2022 Annual Meeting of Stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board has unanimously determined that Mr.&nbsp;Clowes, Dr.&nbsp;van <FONT STYLE="white-space:nowrap">Es-Johansson,</FONT> Mr.&nbsp;Hawkins,
Dr.&nbsp;Lenk and Mr.&nbsp;Petersen are &#147;independent&#148; under the applicable standards of The Nasdaq Stock Market LLC (&#147;Nasdaq&#148;) and the SEC. Dr.&nbsp;Hedrick does not qualify as independent because he serves as our President and
Chief Executive Officer. Each of the audit committee, the compensation committee and the governance and nominating committee is comprised entirely of independent directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Leadership Structure </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our bylaws
and governance principles provide the Board with the flexibility to combine or separate the positions of Chairman and Chief Executive Officer. Historically, these positions have been separate. Mr.&nbsp;Hawkins currently serves as the Chairman of our
Board. Our Board believes that the separation of these positions strengthens the independence of our Board and allows us to have a Chairman focused on the leadership of the Board while allowing our Chief Executive Officer to focus more of his time
and energy on managing our operations. The Board currently believes this structure works well to meet the leadership needs of the Board and of the Company. Dr.&nbsp;Hedrick, our President and Chief Executive Officer, has comprehensive industry
expertise and is able to devote substantial time to the Company, and Mr.&nbsp;Hawkins, our Chairman, is able to focus on longer term and strategic matters, and to provide related leadership to the Board. As a result, we do not currently intend to
combine these positions; however a change in this leadership structure could be made if the Board determines it is in the best interests of our company, including based upon a departure of either our Chief Executive Officer or Chairman. For example,
if the two roles were to be combined, we believe that the independence of the majority of our directors, and the three fully independent Board committees, would provide effective oversight of our management and the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Board&#146;s Role in Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board&#146;s role in risk oversight includes assessing and monitoring risks and risk management. The Board reviews and oversees strategic,
financial and operating plans and holds management responsible for identifying and moderating risk in accordance with those plans. The Board fulfills its risk oversight function by reviewing and assessing reports from members of management on a
regular basis regarding material risks faced by us and applicable mitigation strategy and activity. The reports cover the critical areas of operations, sales and marketing, development, regulatory and quality affairs, intellectual property, clinical
development, legal and financial affairs. The Board and its committees (described below) consider these reports, discuss matters with management and identify and evaluate any potential strategic or operational risks, and appropriate activity to
address those risks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board has standing audit, compensation, and governance and nominating committees. Each standing committee has a written Charter and all
their members are independent directors under the applicable SEC and Nasdaq rules. While each committee has designated responsibilities, the committees act on behalf of the entire Board and regularly report on their activities to the entire Board.
Details concerning the role and structure of the Board and each Board committee are contained in the Corporate Governance Guidelines and the committee charters, available on the &#147;For Investors &#150; Governance&#148; section of our website at
<U>www.plustherapeutics.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation committee currently consists of Mr.&nbsp;Petersen and the compensation committee chair, Mr.&nbsp;Clowes. The Board has
determined that all members of the compensation committee are independent for purposes of service on the compensation committee as provided in SEC and Nasdaq rules, as applicable. The compensation committee chair is responsible for setting the
compensation committee&#146;s calendar and meeting agenda. The charter of the compensation committee has been established and approved by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The functions of the compensation committee include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and implementing compensation programs for our executive officers and other employees, subject to the
discretion of the full Board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing base salary rates, benefits and other compensation matters for each of our executive officers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administering our equity compensation plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the relationship between our performance and our compensation policies and assessing any risks
associated with such policies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and advising the Board on director compensation matters and on regional and industry-wide compensation
practices and trends in order to assess the adequacy of our executive compensation programs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing compensation related disclosures with management and making a recommendation to the
Board regarding the inclusion of such disclosures in our annual proxy statement or Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as applicable. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The processes and procedures followed by our compensation committee in considering and determining executive and director compensation are
described below under the &#147;Director Compensation&#148; and the &#147;Executive Compensation&#148; sections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Chief Executive
Officer attends some of the meetings of the compensation committee upon invitation, but does not participate in the executive sessions of the compensation committee or in any discussions regarding Chief Executive Officer compensation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit
committee currently consists of Mr.&nbsp;Clowes, Dr.&nbsp;van <FONT STYLE="white-space:nowrap">Es-Johansson</FONT> and the audit committee chair, Mr.&nbsp;Petersen. The Board has determined that all members of the audit committee are independent for
purposes of service on the audit committee as provided in SEC and Nasdaq rules, as applicable. The Board has determined that Mr.&nbsp;Petersen is an &#147;audit committee financial expert&#148; within the meaning of Item 407(d)(5) of SEC Regulation <FONT
STYLE="white-space:nowrap">S-K.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The functions of the audit committee include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review management&#146;s and our independent auditor&#146;s report on their assessment of the effectiveness of
internal control over financial reporting as of the end of each fiscal year; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selecting our auditors and reviewing the scope of the annual audit; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">resolving any disagreements between management and the auditor regarding financial reporting;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving the audit fees and <FONT STYLE="white-space:nowrap">non-audit</FONT> fees to be paid to our auditors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing our financial accounting controls with the staff and the auditors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and monitoring management&#146;s enterprise risk management assessment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with management and the auditor, our audited financial statements including our
disclosures under &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing our earnings press releases as well as financial information and earnings guidance provided to analysts
and rating agencies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving our annual budget; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing all related person transactions which are required to be reported under applicable SEC regulations.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Governance and Nominating Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our governance and nominating committee currently consists of Mr.&nbsp;Clowes, Dr.&nbsp;Lenk and the governance and nominating committee chair,
Dr.&nbsp;van <FONT STYLE="white-space:nowrap">Es-Johansson.</FONT> The governance and nominating committee is comprised solely of independent directors, as defined by Nasdaq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The functions of the governance and nominating committee include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analyzing the expertise and experience of the Board and ensuring the membership of the Board consists of persons
with sufficiently diverse and independent backgrounds; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, recruiting, evaluating and recommending to the Board individuals qualified to become members of the
Board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the Board committee structure and recommending to the Board changes to such structure;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and reassessing the adequacy of our Corporate Governance Guidelines and recommending any proposed
changes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing the annual self-evaluations of the Board and Board committees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with management disclosures in our annual proxy statement regarding director
independence; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing succession planning and processes for our Chief Executive Officer. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Nominations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Criteria for Board Membership </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
governance and nominating committee is responsible for annually reviewing the applicable skills and characteristics required of Board nominees with the Board in the context of the current Board composition and our circumstances. In making its
recommendations to the Board, the governance and nominating committee considers, among other things, the qualifications of individual director candidates in light of the Board&#146;s membership criteria as set forth in our Corporate Governance
Guidelines. The governance and nominating committee may utilize a variety of sources, including stockholder recommendations, Board member recommendations, executive search firms, management recommendations or other reasonable means to identify
director candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The governance and nominating committee considers candidates recommended by our Board and management, as well as
candidates submitted by our stockholders (as discussed below). Members of the Board or management who wish to recommend that a person be considered for Board membership are required to provide relevant qualifications and other information regarding
the prospective candidate to the governance and nominating committee along with their recommendations and reasons why they believe such person should be considered. The governance and nominating committee then reviews each of the proposed candidates
and determines whether or not to add such person to the proposed candidates list. In the event the Board determines to add an additional Board member, the governance and nominating committee shall select candidates from this list in addition to
candidates drawn from any search firm that the committee deems necessary to retain for this purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The criteria used in selecting Board
candidates include the candidate&#146;s integrity, business acumen, commitment, reputation among our various constituencies and communities, ability to make independent analytical inquiries, understanding of our business environment, and willingness
to devote adequate time to Board duties. The Board has also determined that gender and ethnic diversity of the Board will be an important factor in its evaluation of candidates for director nominations. There are no other <FONT
STYLE="white-space:nowrap">pre-established</FONT> qualifications, qualities or skills at this time that any particular director nominee must possess and nominees are not discriminated against on the basis of race, religion, national origin, sexual
orientation, disability or any other basis proscribed by law. The governance and nominating committee does not assign specific weights to any particular criteria, nor has it adopted specific requirements. Rather, the Board believes that the
backgrounds and qualifications of the directors, considered as a group, should provide a composite mix of experience, knowledge and abilities that will allow the Board to fulfill its responsibilities. The goal of the governance and nominating
committee is to assemble a Board that brings a variety of skills derived from high quality businesses and professional experience. The governance and nominating committee seeks to ensure that at least a majority of the directors are independent
under Nasdaq rules, that members of the Company&#146;s audit committee meet the financial literacy and sophistication requirements under the Nasdaq rules, and at least one of them qualifies as an &#147;audit committee financial expert&#148; under
the rules of the SEC, and that members of the compensation and governance and nominating committee meet applicable independence and other requirements under the Nasdaq rules and rules of the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholder Recommendations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The governance and nominating committee is responsible for the consideration of any written stockholder recommendations for candidates for the
Board, which recommendations should be delivered or mailed, postage prepaid, to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Governance and Nominating Committee </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Plus Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">4200
Marathon Blvd. Suite 200, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Austin, TX 78756 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CC: Chief Financial Officer </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholder recommendations must include the following information to be considered by our governance and nominating committee: (a)&nbsp;all
information relating to such recommended candidate as would be required to be disclosed for a director nominee pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;) (including such
person&#146;s written consent to being named in the proxy statement as a nominee and to serving as a director if elected) and as required for stockholder nominations of director candidates pursuant to the Company&#146;s Amended and Restated Bylaws
(&#147;Bylaws&#148;); (b) the names and addresses of the stockholders making the recommendation and the number of shares of the Company&#146;s common stock which are owned beneficially and of record by such stockholders; and (c)&nbsp;other
appropriate biographical information and a statement as to the qualification of the nominee. There are no <FONT STYLE="white-space:nowrap">pre-established</FONT> qualifications, qualities or skills at this time that any particular director nominee
must possess and nominees are not discriminated against on the basis of race, religion, national origin, sexual orientation, disability or any other basis proscribed by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any recommendations received from our security holders will be evaluated in the same manner that potential nominees suggested by Board
members, management or other parties are evaluated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Communications with our Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders may contact an individual director, the Board as a group, or a specified Board committee or group, including the independent
directors as a group, by the following means: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mail:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman of the Board</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Plus Therapeutics,
Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4200 Marathon Blvd. Suite 200,</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Austin, TX 78756</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">cc: Chief Financial Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chairman@plustherapeutics.com</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each communication should specify the applicable addressee or addressees to be contacted as well as the
general topic of the communication. The Chairman of the Board will initially receive and process communications before forwarding them to the addressee. Communications also may be referred to other departments within the Company. The Chairman of the
Board generally will not forward to the directors a communication that he determines to be primarily commercial in nature or related to an improper or irrelevant topic, or that requests general information about us. Concerns about questionable
accounting or auditing matters or possible violations of the Plus Code of Business Conduct and Ethics should be reported pursuant to the procedures outlined in the Code of Business Conduct and Ethics, which is available on the Company&#146;s website
in the Investor Relations section under &#147;Corporate Governance Materials.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a Code of Business Conduct and Ethics that applies to all of our directors, officers and employees, including our principal
executive officer, principal financial officer and principal accounting officer. This Code of Business Conduct and Ethics has been posted on our website at <U>www.plustherapeutics.com</U>. We intend to post amendments to this code, or any waivers of
its requirements, on our website at <U>www.plustherapeutics.com</U> under &#147;For Investors&#150; Governance,&#148; as permitted under SEC rules and regulations. To date, there have been no waivers under our Code of Business Conduct and Ethics.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Hedging and Pledging Prohibition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our Insider Trading and Communications Policy, our directors, officers, employees, consultants and contractors (and each such
individual&#146;s family members, other members of a person&#146;s household and entities controlled by a person covered by this policy, as described in the policy) are prohibited from engaging in the following transactions at any time:
(i)&nbsp;engaging in short sales of our securities; (ii)&nbsp;trading in put options, call options or other derivative securities involving our securities on an exchange or in any other organized market; (iii)&nbsp;engaging in hedging or
monetization transactions involving our securities, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds; and (iv)&nbsp;holding our securities in a margin account or otherwise
pledging our securities as collateral for loan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, our Board believes that the level of director compensation should be based on time spent carrying out Board and committee
responsibilities and be competitive with comparable companies. In addition, the Board believes that a significant portion of director compensation should align director interests with the long-term interests of stockholders. The Board makes changes
in its director compensation practices only upon the recommendation of the compensation committee, and discussion and approval by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board, following the compensation committee&#146;s recommendation, has approved the compensation of our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors, as described below<B><I>. </I></B>For 2022, an increase of $7,500 in the compensation of our Chairman of the Board was recommended by our compensation committee and approved by our
Board and an increase of $2,500 in the compensation of the members of our audit committee was recommended by our compensation committee and approved by our Board. The compensation of our other <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors remained the same as in 2021. The compensation committee believes that our <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation remains aligned with director compensation practices at our peer companies while
considering the ongoing cash constraints of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The cash component of our <FONT STYLE="white-space:nowrap">non-employee</FONT> director
compensation for 2022 is as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$40,000 annual cash retainer for Board members; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$37,500 annual cash retainer for the Chairman of the Board; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$27,500 annual cash retainer for the Chairman of the audit committee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$15,000 annual cash retainer for the Chairman of our compensation committee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$10,000 annual cash retainer for the Chairman of our governance and nominating committee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$5,000 annual cash retainer for each <FONT STYLE="white-space:nowrap">non-Chairman</FONT> committee member; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Additional $2,500 annual retainer for each <FONT STYLE="white-space:nowrap">non-Chairman</FONT> audit committee
member. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each new director is also eligible for an initial option grant, upon commencement of services, to purchase
40,000 shares of our common stock, vesting over two years in equal, annual installments as measured from the grant date. However, the grant of options for 40,000 shares to Mr.&nbsp;Clowes and Dr.&nbsp;Lenk, and a portion of the options granted to <FONT
STYLE="white-space:nowrap">Dr.&nbsp;Es-Johansson</FONT> with respect to 34,000 shares were granted in June 2020 after the stockholders approved our 2020 Stock Incentive Plan because there were not enough shares available under our 2014 Stock
Incentive Plan prior to approval of the 2020 Stock Incentive Plan. Mr.&nbsp;Hawkins received an option grant to purchase 40,000 shares on June&nbsp;25, 2020 so that his outstanding equity incentives would be consistent with the awards granted to the
new directors. In addition, the options to purchase 40,000 shares granted to Messrs. Hawkins and Clowes and Dr.&nbsp;Lenk vest in equal monthly installments over the <FONT STYLE="white-space:nowrap">two-year</FONT> period following grant, and the
option to purchase 34,000 shares granted to <FONT STYLE="white-space:nowrap">Dr.&nbsp;Es-Johansson</FONT> vests in 19 equal monthly installments following grant. For 2021, each director was granted options to purchase 6,336 shares on May&nbsp;25,
2021 (except Mr.&nbsp;Hawkins whose options were issued on June&nbsp;11, 2021). The options vest in monthly equal installments over 12 months, provided that the options vest in full on the date of the Company&#146;s next regularly scheduled annual
meeting of stockholders. Mr.&nbsp;Hawkins, as the Chairman of our Board, was granted an option to purchase an additional 40,000 shares on June&nbsp;11, 2021. This second issuance to Mr.&nbsp;Hawkins vests in monthly equal installments over 36
months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For 2023, the cash compensation of the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation will remain the same as in
2022. On February&nbsp;15, 2023, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director was awarded a grant of options for 20,182 shares as equity compensation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2022 Director Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table summarizes director compensation awarded to, earned by or paid to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors who served on our Board during fiscal year 2022: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Director
Name<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees Earned</B><br><B>or Paid in</B><br><B>Cash</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard J. Hawkins, Chairman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Howard Clowes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,500.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,500.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">An van <FONT STYLE="white-space:nowrap">Es-Johansson</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,500.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,500.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Lenk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greg Petersen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,500.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,500.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Hedrick is not included in this table as he is our chief executive officer and receives no extra
compensation for his service as a director. The compensation received by Dr.&nbsp;Hedrick in his capacity as our chief executive officer is set forth in the 2022 Summary Compensation Table and further described in the &#147;Narrative Disclosures to
Summary Compensation Table.&#148; </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx417044_3"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers, or NEOs, for fiscal year 2022 are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Marc H. Hedrick, M.D., our President and Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Andrew Sims, our Chief Financial Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Norman LaFrance, M.D., our Chief Medical Officer. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investors are encouraged to read the compensation discussion below in conjunction with the
compensation tables and related notes, which include more detailed information about the compensation of our NEOs for 2021 and 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2022 Summary
Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information concerning compensation earned during 2022 and 2021 for services
rendered to us by our NEOs. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Awards<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT></B><br><B>Incentive
Plan</B><br><B>Compensation<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other</B><br><B>Compensation<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc H. Hedrick, M.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and Chief</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">535,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">361,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">954,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">510,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">773,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">364,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,667,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Sims</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">305,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">446,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">260,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">467,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">845,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Norman LaFrance, M.D.<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Medical Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">440,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">152,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">637,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">205,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">292,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts in this column reflect the aggregate grant date fair value of stock options granted in the
applicable year. Pursuant to SEC rules, the amounts shown exclude the impact of estimated forfeitures related to service-based vesting conditions computed in accordance with Topic 718. Assumptions used in the calculation of these amounts are
included in Note 13 to our consolidated financial statements included in our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts in this column represent annual <FONT STYLE="white-space:nowrap">performance-based</FONT> bonuses
for 2022 and 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column includes life insurance premiums paid by the Company for each of the NEOs as well as other personal
benefits and perquisites. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;LaFrance became our Chief Medical Officer on November&nbsp;11, 2021. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative Disclosure to Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;13,
2020 we entered into Amended and Restated Executive Employment Agreements with each of Dr.&nbsp;Hedrick (the &#147;Hedrick Employment Agreement&#148;) and Mr.&nbsp;Sims (the &#147;Sims Employment Agreement&#148;). On September&nbsp;7, 2021, we
entered into an Executive Employment Agreement with Dr.&nbsp;LaFrance, which was amended on November&nbsp;8, 2021 (the &#147;LaFrance Employment Agreement&#148; and, together with the Hedrick Employment Agreement and the Sims Employment Agreement,
the &#147;Executive Employment Agreements&#148;). The Executive Employment Agreements generally provide for a minimum </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
base salary, a discretionary annual cash bonus based on the achievement of Company performance goals and the ability to participate in, subject to applicable eligibility requirements, all of our
benefit plans and fringe benefits and programs that may be provided to our executives from time to time. Dr.&nbsp;Hedrick is also eligible for certain severance payments as described further below under&nbsp;&#147;Additional Narrative Disclosure:
Termination Based-Compensation&#148; below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the process of determining compensation for our NEOs, the compensation committee considers the current financial position of the Company,
the strategic goals of the Company, and the performance of each of our NEOs. The compensation committee retained Larry Setren&nbsp;&amp; Associates in December 2022, to perform an independent compensation review and to provide compensation research,
analysis and recommendations. In addition, from time to time, the compensation committee considers the various components (described below) of our compensation program for executives in relation to compensation paid by other public companies,
compensation data from Radford Global Life Sciences Survey, their historical review of all executive officer compensation, and recommendations from our Chief Executive Officer (other than for his own compensation). The compensation committee has the
sole authority to select, compensate and terminate its external advisors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation committee utilizes the following components of
compensation (described further below) to strike an appropriate balance between promoting sustainable and excellent performance and discouraging any excessive risk-taking behavior: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Base salary; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual bonuses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual long-term equity compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Personal benefits and perquisites; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Acceleration and severance agreements tied to changes in control of the Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Base Salaries </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the Company&#146;s
2022 fiscal year, the annual base salaries for Dr.&nbsp;Hedrick, Mr.&nbsp;Sims and Dr.&nbsp;LaFrance were $535,000, $305,000 and $440,000, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Annual Bonuses </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Target bonuses are
reviewed annually and established as a percentage of the executives&#146; base salaries, generally based upon seniority of the officer and targeted at or near the median of the peer group (with reference to our corporate compensation philosophy) and
relevant survey data (including the Radford Global Life Sciences Survey). Each year, the compensation committee establishes corporate objectives related to the Company&#146;s clinical, financial and operational goals and sets each executive&#146;s
respective bonus target percentages, taking into account recommendations from our Chief Executive Officer as it relates to individual objectives for executive positions other than the Chief Executive Officer. Our Chief Executive Officer&#146;s
target bonus is set by the compensation committee to align entirely with our overall corporate objectives. Our other NEOs have additional individual goals the attainment of which comprises a specified percentage of their total bonus compensation.
After each fiscal <FONT STYLE="white-space:nowrap">year-end,</FONT> our Chief Executive Officer provides the compensation committee with a written evaluation showing actual performance as compared to corporate and/or individual objectives, and the
compensation committee uses that information, along with the overall corporate performance, to determine what percentage of each executive&#146;s bonus target will be paid out as a bonus for that year. Overall, the compensation committee seeks to
establish the corporate and individual functional goals to be challenging yet attainable, and stretch goals that are highly challenging. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Hedrick&#146;s target bonus for the Company&#146;s 2022 and 2021 fiscal years as a
percentage of base salary was 55%. Mr.&nbsp;Sims&#146; and Dr.&nbsp;LaFrance&#146;s target bonus for the Company&#146;s 2022 and 2021 fiscal years as a percentage of base salary was 35%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the Company&#146;s 2022 fiscal year, the corporate goals approved by the Board (upon recommendation of the compensation committee for
purposes of executive compensation) were determined by the compensation committee to have been achieved at a level of 123%. As our Chief Executive Officer&#146;s bonus is based exclusively on attainment of our corporate goals, Dr.&nbsp;Hedrick
received $361,928 or 123% of his target cash bonus. Based upon the attainment of 123% of the corporate goals, and (i)&nbsp;upon an attainment of 100% of his individual goals, our Chief Financial Officer, Mr.&nbsp;Sims, received $125,164, or 117% of
his target cash bonus; and (ii)&nbsp;upon an attainment of 75% of his individual goals, our Chief Medical Officer, Dr.&nbsp;LaFrance, received $152,460, or 99% of his target cash bonus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Long-Term Equity Compensation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
designed our long-term equity grant program to further align the interests of our executives with those of our stockholders and to reward the executives&#146; longer-term performance. Historically, the compensation committee has granted stock
options, although from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time,</FONT></FONT> to further increase the emphasis on compensation tied to performance, the compensation committee may grant other equity awards as
allowed by the 2020 Stock Incentive Plan based on its judgment as to whether the complete compensation packages to our executives, including prior equity awards, are appropriate and sufficient to retain and incentivize the executives and whether the
grants balance long-term versus short-term compensation. The compensation committee also considers our overall performance as well as the individual performance of each of our NEOs, the potential dilutive effect of restricted stock awards, the
dilutive and overhang effect of the equity awards, and recommendations from the Chief Executive Officer (other than with respect to his own equity awards). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock options are granted with an exercise price equal to the fair market value of our common stock on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no new stock options awarded to our NEOs in 2022. For the year ended December&nbsp;31, 2021, our Chief Executive Officer was
awarded stock options covering a total of 289,085 shares, our Chief Financial Officer was awarded stock options covering a total of 166,822 shares and our Chief Medical Officer was issued a stock option covering 120,000 shares. You can find more
information on the stock options granted to our Named Executive Officers below under &#147;Outstanding Equity Awards at December&nbsp;31, 2022.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Personal Benefits and Perquisites </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of
our executives are eligible to participate in our employee benefit plans, including medical, dental, vision, life insurance, short-term and long-term disability insurance, flexible spending accounts and 401(k). These plans are available to all
full-time employees. In keeping with our philosophy to provide total compensation that is competitive within our industry, we offer limited personal benefits and perquisites to executive officers. You can find more information on the amounts paid
for these perquisites to or on behalf of our NEOs in our 2022 Summary Compensation Table. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at December&nbsp;31, 2022 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding outstanding equity awards held by our NEOs as of December&nbsp;31, 2022. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Grant</B><br><B>Date</B><br><B><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B><br><B>of Securities</B><br><B>Underlying</B><br><B>Unexercised</B><br><B>Options</B><br><B>(#)</B><br><B>Exercisable<SUP
STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B><br><B>of<BR>Securities</B><br><B>Underlying</B><br><B>Unexercised</B><br><B>Options</B><br><B>(#) Un-</B><br><B>Exercisable</B><br><B><SUP
STYLE="font-size:75%; vertical-align:top">(2)(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Exercise</B><br><B>Price</B><br><B>($)<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Expiration</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc H. Hedrick, M.D.,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/31/2013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/31/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/31/2013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/31/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/11/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/11/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/21/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/21/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/30/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/30/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/04/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/04/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/08/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/08/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/25/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/25/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/16/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/16/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/25/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/25/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Sims,<BR><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/06/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/06/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/16/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/16/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/25/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/25/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Norman LaFrance, M.D.<BR><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/11/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/11/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For a better understanding of this table, we have included an additional column showing the grant date of the
stock options. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise provided, unvested stock options are subject to four-year vesting (from the grant date), and
all stock options have a contractual term of 10 years from the date of grant. Awards presented in this table contain one of the following two vesting provisions: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">With respect to an initial stock option grant to an employee,
1/4<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> of the shares subject to the award vest on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the vesting start date, while an additional 1/36th of the remaining option
shares vest at the end of each month thereafter for 36 consecutive months, or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">With respect to stock option grants made to an employee after one full year of employment, 1/48th of the shares
subject to the award vest at the end of each month over a four-year period, as measured from the vesting start date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We consummated a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-15</FONT></FONT>
reverse stock split in May 2016, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-10</FONT></FONT> reverse stock split in May 2018 and a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-50</FONT></FONT> reverse stock split in August 2019. The amounts set forth in this column reflect these three reverse stock splits </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Narrative Disclosure: Termination-Based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Executive Employment Agreements, if one of our NEOs is terminated without &#147;cause&#148; or resigns for
&#147;good reason,&#148; (a &#147;Severance Termination&#148;), then such NEO will be eligible to receive: (i)&nbsp;an amount equal to twelve months of his base salary; (ii)&nbsp;an amount equal to his target bonus for the year in which such
Severance Termination occurs; (iii)&nbsp;the annual bonus earned for the prior calendar year if not yet paid as of the date of such Severance Termination; (iv)&nbsp;an amount equal to twelve months of the premiums such NEO is required to pay under
the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#147;COBRA&#148;) to continue coverage for him and his eligible dependents under our group health plans; and (v)&nbsp;the accelerated vesting of such NEO&#146;s unvested equity
incentive awards that would have vested during the period beginning on the date of such Severance Termination and ending on (1)&nbsp;in case of a Severance Termination of Dr.&nbsp;Hedrick and LaFrance, twelve months thereafter, or (ii)&nbsp;in the
case of a Severance Termination of Mr.&nbsp;Sims, nine months thereafter. In order to be eligible for the benefits set forth above, such NEO must sign (and not revoke) a general release of claims in favor of the Company as of the date of the
Severance Termination, as applicable (a &#147;Release&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a Severance Termination occurs within the period beginning on the date
the Company and an acquiror formally or informally agree on the terms of a transaction which, if consummated, would constitute a &#147;change in control&#148; and ending on the closing date of the change in control, or within twelve months following
a change in control, upon signing a Release (a &#147;CoC Termination&#148;), such NEO will be eligible to receive: (i)&nbsp;those items listed in the above paragraph under subclauses (ii)&nbsp;and (iii); (ii) an amount equal to (1)&nbsp;in the case
of a CoC Termination of Dr.&nbsp;Hedrick or Dr.&nbsp;LaFrance, 18 months of the greater of his base salary in effect immediately prior to the date of such CoC Termination and his base salary in effect on the date the terms of a transaction that
results in a change in control are agreed to, or (2)&nbsp;in the case of a CoC Termination of Mr.&nbsp;Sims, 12 months of the greater of his base salary in effect immediately prior to the CoC Termination and his base salary in effect on the date the
terms of a transaction that results in a change in control; (iii)&nbsp;the amounts listed in the above paragraph under subclause (iv)&nbsp;except that, if the CoC Termination is for Dr.&nbsp;Hedrick or Dr.&nbsp;LaFrance, the amount of the COBRA
payment will be increased to 18 months; (iv)&nbsp;the acceleration of such NEO&#146;s remaining unvested equity incentive awards effective on the later of the CoC Termination and the date of the change in control; and (v)&nbsp;the right to exercise
the equity incentive awards granted to him on or after the date of his Executive Employment Agreement until the later of (1)&nbsp;three months after the CoC Termination, (2)&nbsp;three months following the change in control with respect to any
equity incentive awards that become exercisable upon a change in control due to this acceleration in connection with the change in control, and (3)&nbsp;any period specified in such NEO&#146;s award agreements (but not beyond the original expiration
date of any equity incentive award). Further, even if a CoC Termination does not occur, if any of our NEOs remain employed by the Company as of the closing of such change in control, all of such NEO&#146;s outstanding unvested incentive stock awards
shall automatically accelerate on the date of such change of control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Executive Employment Agreements, the term
&#147;cause&#148; generally refers to the occurrence of certain events including (i)&nbsp;the employee&#146;s extended disability, (ii)&nbsp;employee&#146;s repudiation of his employment or his Executive Employment Agreement, (iii)&nbsp;the
employee&#146;s conviction of a felony or certain misdemeanors, (iv)&nbsp;employee&#146;s demonstrable and documented fraud, (v)&nbsp;intentional, reckless or grossly negligent action which causes material harm to the Company, (vi)&nbsp;intentional
failure to substantially perform material employment duties or directives, and (vii)&nbsp;chronic absence from work for reasons other than illness, permitted vacation or resignation for good reason. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Executive Employment Agreements, the term &#147;good reason&#148; generally refers
to: (i)&nbsp;the Company&#146;s material breach of its obligation to pay employee the compensation earned for any past service (at the rate which had been stated to be in effect for such period of service); (ii) a change in employee&#146;s position
with the Company which materially reduces the employee&#146;s duties or stature in the business conducted by the Company; and (iii)&nbsp;a reduction in the employee&#146;s level of compensation, provided, however, that a Company-wide reduction of
compensation of not more than fifteen percent (15%) that is also applicable to all of the senior management team of the Company and which continues for less than three (3)&nbsp;months, shall not constitute Good Reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Executive Employment Agreements, the term &#147;change of control&#148; generally refers to (i)&nbsp;a change in the composition of
the Board, as a result of which fewer <FONT STYLE="white-space:nowrap">than&nbsp;one-half&nbsp;of</FONT> the incumbent directors are directors who either: (A)&nbsp;had been directors of the Company; or (B)&nbsp;were elected, or nominated for
election, to the Board with the affirmative votes of at least a majority of the aggregate of the original directors who were still in office at the time of the election or nomination and the directors whose election or nomination was previously so
approved; (ii)&nbsp;any &#147;person&#148; who by the acquisition or aggregation of securities, is or becomes the &#147;beneficial owner&#148; (as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;13d-3&nbsp;under</FONT> the Exchange Act),
directly or indirectly, of securities of the Company representing 50% or more of the combined voting power of the Company&#146;s then outstanding securities ordinarily having the right to vote at elections of directors (the &#147;Base Capital
Stock&#148;); except that any change in the relative beneficial ownership of the Company&#146;s securities by any person resulting solely from a reduction in the aggregate number of outstanding shares of Base Capital Stock, and any decrease
thereafter in such person&#146;s ownership of securities, shall be disregarded until such person increases in any manner, directly or indirectly, such person&#146;s beneficial ownership of any securities of the Company; (iii)&nbsp;the consummation
of a merger or consolidation of the Company with or into another entity or any other corporate reorganization, if persons who were not stockholders of the Company immediately prior to such merger, consolidation or other reorganization own
immediately after such merger, consolidation or other reorganization 50% or more of the voting power of the outstanding securities of each of (A)&nbsp;the continuing or surviving entity and (B)&nbsp;any direct or indirect parent corporation of such
continuing or surviving entity; or (iv)&nbsp;
the sale, transfer or other disposition of all or substantially all of the Company&#146;s assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx417044_4"></A>PAY VERSUS PERFORMANCE
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As required by Section&nbsp;953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(v) of Regulation <FONT
STYLE="white-space:nowrap">S-K,</FONT> we are providing the following information about the relationship between executive compensation and certain financial performance of our Company. The disclosure included in this section is prescribed by SEC
rules and does not necessarily align with how the Company or the compensation committee view the link between the Company&#146;s performance and its NEOs pay. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pay Versus Performance Table </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
table below presents information on the compensation of our chief executive officer and our other NEOs in comparison to certain performance metrics for 2022 and 2021. The metrics are not those that the compensation committee uses when setting
executive compensation. The use of the term &#147;compensation actually paid&#148; (&#147;CAP&#148;) is required by the SEC&#146;s rules. Neither CAP nor the total amount reported in the Summary Compensation Table reflect the amount of compensation
actually paid, earned or received during the applicable year. Per SEC rules, CAP was calculated by adjusting the Summary Compensation Table Total values for the applicable year as described in the footnotes to the table. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Summary<BR>Compensation<BR>Table&nbsp;Total&nbsp;for<BR>CEO&nbsp;(1)&nbsp;(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Compensation<BR>Actually Paid<BR>to CEO (1) (3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR>Summary<BR>Compensation<BR>Table&nbsp;Total&nbsp;for<BR><FONT STYLE="white-space:nowrap">Non-CEO</FONT><BR>NEOs (1) (2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR>Compensation<BR>Actually Paid<BR>to <FONT STYLE="white-space:nowrap">Non-CEO</FONT><BR>NEOs (1) (3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value of<BR>initial fixed<BR>$100<BR>investment<BR>based on<BR>total<BR>shareholder<BR>return<BR>(TSR):</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net Loss<BR>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">954,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,640,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">541,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">805,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,275,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,667,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,728,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">568,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">530,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,399,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For each year shown, the CEO was Marc H. Hendrick, M.D. and the other NEOs were Andrew Sims and Norman
LaFrance. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts in this column represent the &#147;Total&#148; column set forth in the Summary Compensation Table
(&#147;SCT&#148;) on page 25. See the footnotes to the SCT for further detail regarding the amounts in these columns. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The dollar amounts reported in these columns represent the amounts of &#147;compensation actually paid.&#148;
The Amounts are computed in accordance with Item 402(v) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> by deducting and adding the following amounts from the &#147;Total&#148; column of the SCT (pursuant to SEC rules, fair value at each
measurement date is computed in a manner consistent with the fair value methodology used to account for share-based payments in our financial statements under GAAP): </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>CEO</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-CEO&nbsp;NEOs</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SCT Total Compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">954,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,083,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Add Change in Fair Value of Awards Granted in Prior Years Unvested as of 12/31/22</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">449,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">359,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Add Change in Fair Value of Awards Granted in Prior Years that Vested during 2022 as of the
Vesting Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">236,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">167,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Compensation Actually Paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,640,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,610,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>CEO</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-CEO&nbsp;NEOs</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SCT Total Compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,667,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,137,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deduct amounts reported under the &#147;Stock Awards&#148; and &#147;Option Awards&#148; column of
the SCT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">773,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">673,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Add Fair Value of Awards Granted in 2021 Unvested as of 12/31/21</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">498,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Add Change in Fair Value of Awards Granted in Prior Years Unvested as of 12/31/21</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">450,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Add Fair Value of Awards Granted and Vested in 2021 as of the Vesting Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Add Change in Fair Value of Awards Granted in Prior Years that Vested during 2021 as of the
Vesting Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Compensation Actually Paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,728,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,060,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pay Versus Performance Narrative Disclosure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with Item 402(v) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> we are providing the following descriptions of the
relationships between information presented in the Pay Versus Performance table on CAP and each of total shareholder return (&#147;TSR&#148;) and net loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not utilize TSR and net loss in our executive compensation program. However, we do utilize several other performance measures to align
executive compensation with our performance. As described in more detail above in the section &#147;Employment Agreements &#150; Executive Compensation &#150; Annual Bonuses,&#148; part of the compensation our NEOs are eligible to receive consists
of annual performance-based cash bonuses that are designed to provide appropriate incentives to our executives to achieve defined annual corporate goals and to reward our executives for individual achievement towards these
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
goals, subject to certain employment criteria. Additionally, we view stock options, which are an integral part of our executive compensation program, as related to company performance although
not directly tied to TSR, because they provide value only if the market price of our common stock increases, and if the executive officer continues in our employment over the vesting period. These stock option awards strongly align our executive
officers&#146; interests with those of our stockholders by providing a continuing financial incentive to maximize long-term value for our stockholders and by encouraging our executive officers to continue in our employment for the <FONT
STYLE="white-space:nowrap">long-term.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to net income, specifically, because we are not a commercial-stage company, we
did not have any revenue during the periods presented, other than revenue associated with grants. Consequently, our company does not consider net loss as a performance measure for our executive compensation program. In 2022, our net loss increased
from 2021, which was primarily due to increases in research and development expenses and costs associated with the settlement of litigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following graphs illustrates the relationship during 2021-2022 of the CAP for our CEO and other NEOs as calculated pursuant to SEC rules
to our TSR. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; text-indent:9%" ALIGN="center">


<IMG SRC="g417044g0224071628329.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following graph illustrates the relationship during 2021-2022 of the CAP for our CEO and
other NEOs as calculated pursuant to SEC rules to our net loss. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; text-indent:9%" ALIGN="center">


<IMG SRC="g417044g0224071628626.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Compensation Plan Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table gives information as of&nbsp;December 31, 2022 about shares of our common stock that may be issued upon the exercise of
outstanding options, and shares remaining available for issuance under all of our equity compensation plans: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Plan Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;securities&nbsp;to&nbsp;be&nbsp;issued</B><br><B>upon exercise of outstanding</B><br><B>options and rights</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>average&nbsp;exercise&nbsp;price</B><br><B>of&nbsp;outstanding&nbsp;options<BR>and rights</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of securities remaining</B><br><B>available for future issuance under</B><br><B>equity
compensation</B><br><B>plans&nbsp;(excluding&nbsp;securities&nbsp;reflected</B><br><B>in column(a))</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(a)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(b)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(c)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by security</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">holders (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">160,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">approved by security</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">holders (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,014,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,635,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,175,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,726,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i)&nbsp;options outstanding that were issued under the 2004 Stock Option and Stock Purchase Plan
which expired in August 2004 and (ii)&nbsp;the 2015 New Employee Incentive Plan. For more information, see &#147;Material Features of the Amended and Restated 2015 New Employee Incentive Plan and the 2020 Stock Incentive Plan&#148; provided in our
annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;23, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Notes to the Consolidated Financial Statements included with our annual report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;23, 2023 for a description of the 2020 Stock Incentive Plan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx417044_5"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding ownership of our common stock as of February&nbsp;23, 2023 (or earlier date for
information based on filings with the SEC) by (a)&nbsp;each person known to us to own more than 5% of the outstanding shares of our common stock, (b)&nbsp;each director, (c)&nbsp;our named executive officers and (e)&nbsp;all current directors and
executive officers as a group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe, based on information provided to us or based on filings with the SEC, that each of the
stockholders listed below has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable. A total of 35,414,158 shares of our common
stock were issued and outstanding as of February&nbsp;23, 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address of Beneficial Owner <SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares of</B><br><B>Common<BR>Stock</B><br><B>Owned<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of Shares</B><br><B>of Common Stock</B><br><B>Subject to</B><br><B>Awards/Warrants</B><br><B>Exercisable<BR>Within</B><br><B>60 Days
of<BR>February&nbsp;23,<BR>2023<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Number<BR>of</B><br><B>Shares
of</B><br><B>Common<BR>Stock</B><br><B>Beneficially</B><br><B>Owned<SUP STYLE="font-size:75%; vertical-align:top">(4)(5)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B><br><B>Ownership</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Greater than 5% Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#151;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Named Executive Officers and Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc H. Hedrick, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">256,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">290,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.82</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Sims</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.35</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Norman LaFrance, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Howard Clowes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.19</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">An van <FONT STYLE="white-space:nowrap">Es-Johansson</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,7000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.14</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard J. Hawkins</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greg Petersen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.32</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert P. Lenk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All current executive officers and directors as a group (8 persons)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">134827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">687,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">822,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.32</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than one percent (1%) of the outstanding shares as of February&nbsp;23,
2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise indicated, the address of each of the individuals is c/o Plus Therapeutics, Inc., 4200
Marathon Blvd. Suite 200, Austin, TX 78756. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise indicated, represents shares of outstanding common stock owned by the named parties as of
February&nbsp;23, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares of common stock subject to stock options or warrants currently exercisable or exercisable within 60 days
of February&nbsp;23, 2023 are deemed to be outstanding for computing the percentage ownership of the person holding such options or warrants and the percentage ownership of any group of which the holder is a member, but are not deemed outstanding
for computing the percentage of any other person or group. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts and percentages of common stock beneficially owned are reported on the basis of regulations of the
SEC governing the determination of beneficial ownership of securities. Under the rules of the SEC, a person is deemed to be a &#147;beneficial owner&#148; of a security if that person has or shares &#147;voting power,&#148; which includes the power
to vote or to direct the voting of such security, or &#147;investment power,&#148; which includes the power to dispose of or to direct the disposition of such security. A person is also deemed to be a beneficial owner of any securities for which
that person has a right to acquire beneficial ownership within 60 days. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Richard J. Hawkins, the Chairman of our Board, purchased one (1)&nbsp;share of Series F Preferred Stock on
March 3, 2023. The holder of the Series F Preferred Stock is only permitted to vote with the holders of our common stock on proposals related to the reverse stock split and will automatically, without any action of the holder, vote the share of
Series F Preferred Stock in a manner that &#147;mirrors&#148; the proportions of &#147;For&#148; and &#147;Against&#148; votes cast by the holders of the our common stock are voted on the reverse stock split proposal (excluding, for the avoidance of
doubt, any shares of common stock that are not voted). </P></TD></TR></TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx417044_6"></A>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Party Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have adopted a written Related Person Transactions Policy that sets forth our policies and procedures regarding the identification, review, consideration, and oversight of &#147;related person transactions.&#148; For purposes of our policy only, a
&#147;related person transaction&#148; is a transaction, arrangement, or relationship (or any series of similar transactions, arrangements or relationships) in which we or any of our subsidiaries are participants involving an amount that exceeds
$120,000, in which any &#147;related person&#148; has a material interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Transactions involving compensation for services provided to
us as an employee, consultant, or director are not considered related person transactions under this policy. A related person is any executive officer, director, nominee to become a director or a holder of more than 5% of any class of our voting
securities (including our common stock), including any of their immediate family members and affiliates, including entities owned or controlled by such persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the policy, the related person in question or, in the case of transactions with a holder of more than 5% of any class of our voting
securities, an officer with knowledge of the proposed transaction, must present information regarding the proposed related person transaction to our audit committee (or, where review by our audit committee would be inappropriate, to another
independent body of our Board) for review. To identify related person transactions in advance, we rely on information supplied by our executive officers, directors, and certain significant stockholders. In considering related person transactions,
our audit committee considers the relevant available facts and circumstances, which may include, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risks, costs, and benefits to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact on a director&#146;s independence in the event the related person is a director, immediate family
member of a director or an entity with which a director is affiliated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the transaction; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of other sources for comparable services or products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms available to or from, as the case may be, unrelated third parties. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit committee will approve only those transactions that it determines are fair to us
and in our best interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following includes a summary of any related party transactions since January&nbsp;1, 2021 to which we have
been a party.&nbsp;We also describe below certain other transactions with our directors, executive officers and 5% stockholders. We believe the terms obtained or consideration that we paid or received, as applicable, in connection with the
transactions described below were comparable to terms available or the amounts that would be paid or received, as applicable, from unaffiliated third parties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director and Officer Indemnification </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation, as amended, and our amended and restated bylaws, as amended, provide that we will
indemnify each of our directors and officers to the fullest extent permitted by the Delaware General Corporation Law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option Grants to
Executive Officers and Directors </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into employment agreements with our executive officers pursuant to which we pay
our executive officers annual salaries and bonuses as more fully described above under &#147;Executive Compensation.&#148; Further, we have granted stock options to our executive officers and <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors as more fully described above under &#147;Director Compensation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information under the heading &#147;Board
Independence&#148; in this Proxy Statement is incorporated herein by reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx417044_7"></A>AUDIT MATTERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Report of the Audit Committee </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following report of
the audit committee does not constitute soliciting material and shall not be deemed filed or incorporated by reference into any other filing by Plus Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Exchange Act, whether made
before or after the date hereof and irrespective of any general incorporation language in any such filing. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee is a
committee of the Board comprised solely of independent directors as required by the listing standards of Nasdaq and rules and regulations of the SEC. The audit committee provides assistance to the Board in fulfilling its legal and fiduciary
obligations in matters involving the Company&#146;s accounting, auditing, financial reporting, internal control and legal compliance functions by approving the services performed by the Company&#146;s independent registered public accountants and
reviewing their reports regarding the Company&#146;s accounting practices and systems of internal accounting controls as set forth in a written charter adopted by the Board, which is available on the Company&#146;s website at
<I>www.plustherapeutics.com</I>. The composition and responsibilities of the audit committee, as reflected in its charter, are intended to be in accordance with applicable requirements. The audit committee reviews and assesses the adequacy of its
charter and the audit committee&#146;s performance on an annual basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s management is responsible for preparing the
Company&#146;s financial statements and the independent registered public accountants are responsible for auditing those financial statements. The audit committee is responsible for overseeing the conduct of these activities by the Company&#146;s
management and the independent registered public accountants. In this context, the audit committee has met and held discussions with management and the independent registered public accountants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Management represented to the audit committee that the Company&#146;s consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles, and the
audit committee has reviewed and discussed the consolidated financial statements with management and the independent registered public accountants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee has discussed with the independent registered public accountants matters required to be discussed by Auditing Standard
No.&nbsp;1301, as adopted by the Public Company Accounting Oversight Board (&#147;PCAOB&#148;) and approved by the SEC. In addition, the independent registered public accountants provided to the audit committee the written disclosures and letter
from such accountants as required by applicable requirements of the PCAOB regarding such accountants&#146; communications with the audit committee concerning independence and the audit committee has discussed with such accountants such
accountants&#146; independence from the Company and its management. The audit committee has discussed with management and the independent registered public accounts the procedures for selection of consultants, fully considered whether those services
provided by the independent registered public accountants are compatible with maintaining such accountants&#146; independence and has determined that the <FONT STYLE="white-space:nowrap">non-audit</FONT> services performed by such accountants are
compatible with maintaining their independence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee has discussed with the Company&#146;s management and its independent
registered public accountants, with and without management present, their evaluations of the Company&#146;s internal accounting controls and the overall quality of the Company&#146;s financial reporting. In reliance on the reviews and discussions
with management and the independent registered public accountants referred to above, the audit committee recommended to the Board, and the Board has approved, the inclusion of the audited financial statements in the Company&#146;s Annual Report on
Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2022, for filing with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
the audit committee has selected BDO USA, LLP as independent registered public accountants to audit the books, records and accounts of the Company and its subsidiaries for the fiscal year ending December&nbsp;31, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Respectfully submitted, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Greg Petersen, Chairman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Howard Clowes </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An van
<FONT STYLE="white-space:nowrap">Es-Johansson</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx417044_8"></A>PROPOSAL #1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ELECTION OF DIRECTORS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board
currently consists of six (6)&nbsp;persons. The Board, upon the recommendation of our governance and nominating committee, has nominated the following persons for election as directors: Howard Clowes, An van
<FONT STYLE="white-space:nowrap">Es-Johansson,</FONT> M.D., Richard J. Hawkins, Marc H. Hedrick, M.D., Robert Lenk, PhD, and Greg Petersen. All of the nominees are currently serving as members of our Board. All directors are elected annually and
serve <FONT STYLE="white-space:nowrap">one-year</FONT> terms until the next Annual Meeting, or until they resign, are removed, or their respective successors are duly elected and qualified. If any nominee should decline or be unable to accept such
nomination or to serve as a director, or for good cause will not serve as a director, an event which our Board does not currently anticipate, our Board reserves the right to nominate another person or to vote to reduce the size of our Board. The
designated proxy holders will have the express discretionary authority to vote for a replacement nominee and proxies will be voted for any nominee designated by our Board to fill the vacancy. If another person is nominated, the proxy holders intend
to vote the shares to which the proxy relates for the election of the persons nominated by our Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors and Nominees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biographical information and the attributes, skills and experience of each nominee that led our governance and nominating committee and Board
to determine that such nominee should serve as a director are discussed in the &#147;Directors and Executive Officers&#148; section of this proxy statement and is incorporated into this section by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Required Vote </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominees will be
elected by a plurality vote, which means that the six nominees receiving the most affirmative votes will be elected. Only votes &#147;FOR&#148; or &#147;WITHHELD&#148; will affect the outcome. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT>
will have no effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>YOUR BOARD UNANIMOUSLY RECOMMENDS A VOTE &#147;FOR&#148; THE NOMINEES TO THE BOARD NAMED ABOVE. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx417044_9"></A>PROPOSAL #2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit committee has selected BDO USA, LLP (&#147;BDO&#148;), as our independent registered public accounting firm for the fiscal year
ending December&nbsp;31, 2023 and has further directed that we submit the selection of the independent registered public accounting firm for ratification by our stockholders at the Annual Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BDO has served as our independent registered public accounting firm since July 2016. The selection of the independent registered public
accounting firm is not required to be submitted for stockholder approval. However, if the stockholders do not ratify this selection, the audit committee will reconsider its selection of BDO. Even if the selection is ratified, our audit committee may
direct the appointment of a different independent accounting firm at any time during the year if the audit committee determines that the change would be in the Company&#146;s best interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Representatives of BDO will be available at the Annual Meeting and will have an opportunity to make a statement if they desire to do so and
will be available to respond to appropriate questions from stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional information concerning the audit committee and BDO
can be found in the &#147;Audit Matters&#148; section of this Proxy Statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Principal Accountant Fees and Services </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The decision to engage BDO as our independent registered public accounting firm for the year ended December&nbsp;31, 2023 was approved by the
audit committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our policies require the audit committee to <FONT STYLE="white-space:nowrap">pre-approve</FONT> all audit and permitted <FONT
STYLE="white-space:nowrap">non-audit</FONT> services provided by the independent registered public accounting firm, including engagement fees and terms. The audit committee may delegate <FONT STYLE="white-space:nowrap">pre-approval</FONT> authority
to one or more of its members, who will report any <FONT STYLE="white-space:nowrap">pre-approval</FONT> decisions to the full committee at its next scheduled meeting but may not delegate <FONT STYLE="white-space:nowrap">pre-approval</FONT> authority
to members of management. The audit committee may approve only those <FONT STYLE="white-space:nowrap">non-audit</FONT> services classified as &#147;all other services&#148; that it believes to be routine and recurring services, to be consistent with
SEC rules and to not impair the auditor&#146;s independence with respect to us. The audit committee reviewed and <FONT STYLE="white-space:nowrap">pre-approved</FONT> all audit services and permitted <FONT STYLE="white-space:nowrap">non-audit</FONT>
services performed during the years ended December&nbsp;31, 2022 and 2021. The following table shows the aggregate fees paid or accrued by us for the audit and other services provided by BDO for fiscal years ended December&nbsp;31, 2022 and 2021.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fiscal Year Ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Fees<SUP STYLE="font-size:75%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">343,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">319,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Related Fees<SUP STYLE="font-size:75%; vertical-align:top"> (2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax Fees<SUP STYLE="font-size:75%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">382,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">354,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Audit fees consist of fees for professional services performed by BDO for the audit of the financial statements
included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and review of the financial statements included in our quarterly Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filings, reviews of registration statements and
issuances of consents, and services that are normally provided in connection with statutory and regulatory filings or engagements. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Audit related fees consist of fees for assurance and related services, performed by BDO that are reasonably
related to the performance of the audit or review of our financial statements. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tax fees consist of fees for professional services performed by BDO with respect to tax compliance, tax advice,
tax consulting and tax planning. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Required Vote </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proposal to ratify the appointment of BDO requires the affirmative vote of a majority of the common stock having voting power present in
person virtually or represented by proxy at the Annual Meeting. Abstentions are considered present and entitled to vote with respect to this proposal and will, therefore, be treated as votes against this proposal. Because brokers have discretionary
authority to vote on this proposal, we do not expect any broker <FONT STYLE="white-space:nowrap">non-votes</FONT> in connection with this proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>YOUR BOARD UNANIMOUSLY RECOMMENDS A VOTE &#147;FOR&#148; THE RATIFICATION OF THE APPOINTMENT OF BDO USA, LLP AS OUR INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM FOR FISCAL YEAR 2023. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx417044_10"></A>PROPOSAL #3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">NON-BINDING</FONT> ADVISORY VOTE ON EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act, enacted in July 2010, and related SEC regulations, we are providing
our stockholders with the opportunity to cast an advisory vote on the compensation of our named executive officers as disclosed in this Proxy Statement in accordance with the compensation disclosure rules of the SEC. Our stockholders previously
expressed a preference that we hold advisory votes on executive compensation on an annual basis, and our board of directors accordingly determined to hold such votes every year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our executive compensation programs are designed to reward our named executive officers for the achievement of short-term and long-term
strategic and operational goals, while at the same time avoiding the encouragement of unnecessary or excessive risk taking. Stockholders are encouraged to read the Executive Compensation section of this Proxy Statement for a more detailed discussion
of how our compensation programs reflect our objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board believes the Company&#146;s executive compensation programs use
appropriate structures and sound pay practices that are effective in achieving our core objectives. Accordingly, the Board recommends that you vote in favor of the following resolution: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;RESOLVED, that the Company&#146;s stockholders approve, on an advisory basis, the compensation of the named executive officers, as
described in the Company&#146;s proxy statement for the Annual Meeting of Stockholders pursuant to Item 402 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> and other compensation disclosure rules of the Securities and Exchange
Commission.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The vote on this proposal is advisory and therefore not binding on us or our Board. Although the vote is <FONT
STYLE="white-space:nowrap">non-binding,</FONT> the Board will review the voting results, seek to determine the cause or causes of any significant negative voting, and take them into consideration when making future decisions regarding executive
compensation programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Required Vote </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proposal to approve, on an advisory basis, the compensation of our named executive officers requires the affirmative vote of a majority of
the common stock having voting power present in person virtually or represented by proxy at the Annual Meeting. Abstentions are considered present and entitled to vote with respect to this proposal and will, therefore, be treated as votes
&#147;against&#148; this proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>OUR BOARD UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE &#147;FOR&#148; THE APPROVAL, ON AN
ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx417044_11"></A>PROPOSAL #4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">NON-BINDING</FONT> ADVISORY VOTE REGARDING FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act, enacted in July 2010, and related SEC regulations, we are
required to provide our stockholders not less than once every six years with the opportunity to cast an advisory vote on the frequency at which future advisory
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-pay&#148;</FONT></FONT> votes on executive compensation will be proposed to our stockholders.&nbsp;We last provided our stockholders with the opportunity to vote on the
frequency of future advisory &#147;say on pay&#148; votes on executive compensation at our 2017 annual meeting, at which time our stockholders voted that advisory &#147;say on pay&#148; votes on executive compensation would take place every
year.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are again asking stockholders to vote on whether future <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-pay&#148;</FONT></FONT> votes on executive compensation should occur every year, every two years or every three years. After careful consideration of this proposal, our Board
has determined that an advisory vote on executive officer compensation that occurs every year is the most appropriate alternative for us, and therefore our Board recommends that you vote for an advisory vote on executive compensation to occur every
year. Even though our executive compensation programs stress long-term value creation and look at long-term performance, we still believe a <FONT STYLE="white-space:nowrap">one-year</FONT> interval for the advisory vote on executive compensation is
most appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proposal gives you the opportunity to express your views on the frequency of stockholder advisory votes regarding
our executive officer compensation.&nbsp;The advisory vote by the stockholders on frequency is distinct from the advisory vote on the compensation of our executive officers; this proposal deals with the issue of how frequently such a vote on such
compensation should be presented to our stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may vote for one of these three alternatives or you may abstain from making a
choice. The vote on this proposal is advisory and therefore not binding on us or our Board.&nbsp;However, we value your opinions and to the extent there is any significant vote in favor of one frequency over the other options, the Board will take
this into account when considering how frequently we should conduct future advisory votes on the compensation of our executive officers.&nbsp;The Board may, however, decide that it is in the best interest of the Company and the stockholders to hold
future advisory votes on executive compensation more or less frequently than the option that has been selected by a plurality of the stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Required Vote and Board Recommendation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The option of every year, every two years or every three years that receives the affirmative vote of holders of a plurality of shares present
in person virtually or by proxy and entitled to vote on the proposal will be the frequency recommended by stockholders for the advisory vote on the compensation of our executive officers, unless none of the frequency options receives a majority
vote, in which case the option that receives the highest number of votes will be considered to be the frequency recommended by stockholders. Abstentions have the same effect as a vote against each of the frequency options. Broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> are not counted for any purpose in determining which frequency option has been recommended by stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE BOARD RECOMMENDS THAT THE STOCKHOLDERS VOTE FOR A FREQUENCY OF &#147;EVERY YEAR&#148; FOR FUTURE
<FONT STYLE="white-space:nowrap">NON-BINDING</FONT> ADVISORY VOTES ON EXECUTIVE COMPENSATION. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx417044_12"></A>PROPOSAL #5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE REVERSE STOCK SPLIT PROPOSAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPROVAL OF AN AMENDMENT TO THE COMPANY&#146;S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF THE
OUTSTANDING SHARES OF THE COMPANY&#146;S COMMON STOCK, AT A RATIO OF NOT LESS THAN <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-FOR-3</FONT></FONT> AND NOT GREATER THAN <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-FOR-15,</FONT></FONT> WITH THE EXACT RATIO AND EFFECTIVE TIME OF THE REVERSE STOCK SPLIT TO BE DETERMINED BY THE BOARD OF DIRECTORS. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board has unanimously
approved, and recommended that our stockholders approve, an amendment to our Charter (the &#147;Certificate of Amendment&#148;), to effect a reverse stock split at a ratio of not less than <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-for-3</FONT></FONT> and not greater than <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-15</FONT></FONT> (the &#147;Reverse Stock Split&#148;), with the final decision of whether to proceed with
the Reverse Stock Split, the effective time of the Reverse Stock Split, and the exact ratio of the Reverse Stock Split to be determined by the Board, in its sole discretion and without further action by the stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the stockholders approve the Reverse Stock Split, and the Board decides to implement it, the Reverse Stock Split will become effective as
of a date and time to be determined by the Board<B><I> </I></B>that will be specified in the Charter Amendment (the &#147;Effective Time&#148;). If the Board does not decide to implement the Reverse Stock Split within twelve months from the date of
the Annual Meeting, the authority granted in this proposal to implement the Reverse Stock Split will terminate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Reverse Stock Split
will be realized simultaneously for all outstanding shares of common stock. The Reverse Stock Split will affect all holders of shares of common stock uniformly and each stockholder will hold the same percentage of common stock outstanding
immediately following the Reverse Stock Split as that stockholder held immediately prior to the Reverse Stock Split, except for immaterial adjustments that may result from the treatment of fractional shares as described below. The Reverse Stock
Split will not change the par value of our common stock and will not reduce the number of authorized shares of common stock. The Reverse Stock Split will also affect outstanding equity awards and warrants, as described in &#147;Principal Effects of
Reverse Stock Split on Outstanding Equity Awards, Warrants, and Equity Plans&#148; below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Purpose and Rationale for the Reverse Split </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Avoid Delisting from the Nasdaq.</I> As we have previously reported, on May&nbsp;24, 2022, we received written notice (the
&#147;Notification Letter&#148;) from the Listings Qualifications Department of Nasdaq that because the closing bid price for our common stock had fallen below $1.00 per share for 30 consecutive business days, we no longer complied with the minimum
bid price requirement pursuant to Nasdaq Listing Rule&nbsp;5550(a)(2) (the &#147;Minimum Bid Requirement&#148;). The Notification Letter stated that we had 180&nbsp;days, or until November&nbsp;21, 2022, to demonstrate compliance with the Minimum
Bid Requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;22, 2022, we received a second later from Nasdaq advising that we had been granted an additional 180
calendar days, or to May&nbsp;22, 2023, to regain compliance with the Minimum Bid Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to regain compliance with the Minimum Bid Requirement, our common stock must
maintain a minimum closing bid price of $1.00 for at least ten consecutive business&nbsp;days during the compliance period. We believe that the Reverse Stock Split is our best option to meet the criteria to satisfy the Minimum Bid Requirement for
continued listing on the Nasdaq Capital Market. A decrease in the number of outstanding shares of our common stock resulting from the Reverse Stock Split should, absent other factors, assist in ensuring that the per share market price of our common
stock remains above the requisite price for continued listing. However, we cannot provide any assurance that our minimum bid price would remain over the minimum bid price requirement of the Nasdaq Capital Market following the Reverse Stock Split.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to approve the Reverse Stock Split may potentially have serious, adverse effects on us and our stockholders. Our common stock
could be delisted from The Nasdaq Capital Market. Our shares may then trade on the OTC Bulletin Board or other small trading markets, such as the pink sheets. In that event, our common stock could trade thinly as a microcap or penny stock, adversely
decrease to nominal levels of trading and may be avoided by retail and institutional investors, resulting in the impaired liquidity of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&nbsp;23, 2023, our common stock closed at $0.3920 per share on The Nasdaq Capital Market. The Reverse Split, if effected, would
likely have the immediate effect of increasing the price of our common stock as reported on The Nasdaq Capital Market, therefore reducing the risk that our common stock could be delisted from The Nasdaq Capital Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the volatility and fluctuations in the capital markets, and if our share price does not appreciate prior to these deadlines, we believe
that our best option to meet Nasdaq&#146;s $1.00 minimum bid price requirement under the Minimum Bid Price Rule would be to effect the Reverse Stock Split to increase the <FONT STYLE="white-space:nowrap">per-share</FONT> trading price of our common
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we believe that the low per share market price of our common stock impairs our marketability to and acceptance by
institutional investors and other members of the investing public and creates a negative impression of the Company. We believe that many investors, brokerage firms and market makers consider <FONT STYLE="white-space:nowrap">low-priced</FONT> stocks
as unduly speculative in nature and, as a matter of policy, avoid investment and trading in such stocks. Moreover, the analysts at many brokerage firms do not monitor the trading activity or otherwise provide coverage of lower priced stocks. The
presence of these factors may be adversely affecting, and may continue to adversely affect, not only the pricing of our common stock but also its trading liquidity. In addition, these factors may affect our ability to raise additional capital
through the sale of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, we believe that a higher stock price could help us attract and retain employees and other
service providers. We believe that some potential employees and service providers are less likely to work for a company with a low stock price, regardless of the size of the company&#146;s market capitalization. If the Reverse Stock Split
successfully increases the per share price of our common stock, we believe this increase will enhance our ability to attract and retain employees and other service providers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hope that the decrease in the number of shares of our outstanding common stock as a consequence of the Reverse Stock Split, and the
anticipated increase in the price per share, will encourage greater interest in our common stock by the financial community, business development partners and the investing public, help us attract and retain employees and other service providers,
help us raise additional capital through the sale of our common stock in the future if needed, and possibly promote greater liquidity for our stockholders with respect to those shares presently held by them. However, liquidity of our common stock
may very well be adversely affected by the reduced number of shares that would be outstanding if the Reverse Stock Split is effected, particularly if the price per share of our common stock begins a declining trend after the Reverse Stock Split is
effected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The voting power of stockholders that gives brokers directions to vote at our recent
meetings of stockholders raises questions about how difficult it would be to garner the stockholder participation that would be necessary to achieve the voting standard of approval by a majority of the voting power of our outstanding capital stock
needed to approve an amendment to our Charter to effect the Reverse Stock Split. In order to attempt to procure the vote necessary to effect the Reverse Stock Split, on March 3, 2023, we issued one (1)&nbsp;share of our Series F Preferred Stock to
our Chairman of the Board, Richard J. Hawkins. The terms of the Series F Preferred Stock are set forth in a Certificate of Designation of Series F Preferred Stock, filed with the Secretary of State of the State of Delaware, and effective on March 3,
2023. The Series F Preferred Stock does not have any voting rights except with respect to a reverse stock split proposal, including the Reverse Stock Split proposal presented at the Annual Meeting, or otherwise as required by law. With respect to
the Reverse Stock Split proposal, the outstanding share of Series F Preferred Stock is entitled to 50,000,000 votes on such proposal, which is referred to as supermajority voting; however the votes by the holder of Series F Preferred Stock will
automatically, without action by the holder, be counted in the same &#147;mirrored&#148; proportion as the aggregate votes cast by the holders of common stock who vote on this proposal. For example, if 50.5% of the shares of common stock voted in
person virtually or by proxy at the Annual Meeting are voted FOR the Reverse Stock Split proposal, then we will count 50.5% of the votes cast (or votes) by the holder of the Series F Preferred Stock as votes FOR the Reverse Stock Split proposal.
Holders of common stock and Series F Preferred Stock will vote on the Reverse Stock Split proposal as a single class. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board
determined that it was in the best interests of the Company to provide for supermajority voting of the Series F Preferred Stock in order to obtain sufficient votes for the Reverse Stock Split proposal and thereby to attempt to avoid delisting by
Nasdaq of our common stock. Due to the required proportional voting structure of the Series F Preferred Stock that mirrors the actual voting by holders of the common stock, the supermajority voting will serve to reflect the voting preference of the
holders of shares of our common stock that actually vote on the matter, whether for or against the proposal, and therefore will not override the stated preference of the holders of shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Reverse Stock Split proposal is approved, the outstanding share of Series F Preferred Stock will be automatically redeemed upon the
effectiveness of the amendment to the Charter implementing the Reverse Stock Split. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board believes that stockholder adoption of a
range of reverse stock split ratios (as opposed to adoption of a single reverse stock split ratio or a set of fixed ratios) provides maximum flexibility to achieve the purposes of a reverse stock split and, therefore, is in the best interests of the
Company. In determining a ratio following the receipt of stockholder adoption, the Board (or any authorized committee of the Board) may consider, among other things, factors such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the historical trading price and trading volume of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of shares of our common stock outstanding; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the then-prevailing trading price and trading volume of our common stock and the anticipated impact of the
Reverse Stock Split on the trading market for our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the anticipated impact of a particular ratio on our ability to reduce administrative and transactional costs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the continued listing requirements of Nasdaq; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">prevailing general market and economic conditions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board reserves the right to elect to abandon the Reverse Stock Split, notwithstanding
stockholder adoption thereof, if it determines, in its sole discretion, that the Reverse Stock Split is no longer needed to regain compliance with Nasdaq&#146;s listing requirements or is no longer in the best interests of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reverse Stock Split Amendment to the Charter </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Reverse Stock Split is approved and implemented, Article IV.A. of the Charter shall be amended and restated in its entirety as follows:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Authorized Shares. The total number of shares of stock which the Corporation shall have authority to issue is 105,000,000 shares,
consisting of 100,000,000 shares of Common Stock, par value $0.001 per share (&#147;Common Stock&#148;) and 5,000,000 shares of Preferred Stock, par value $0.001 per share (&#147;Preferred Stock&#148;). Upon the effectiveness of this Certificate of
Amendment to the Amended and Restated Certificate of Incorporation of the Corporation, each whole number of shares, as determined by the Board, of Common Stock issued and outstanding at such time shall, automatically and without any further action
on the part of the Corporation or the holder thereof, be combined into one (1)&nbsp;validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> share of Common Stock (the &#147;Reverse Stock Split&#148;). The par value of
the Common Stock following the Reverse Stock Split shall remain $0.001 per share. No fractional shares shall be issued, and, in lieu thereof, the Corporation shall pay cash equal to such fraction multiplied by the fair market value of a share of
Common Stock, as determined by the Board of Directors. Each certificate that immediately prior to the Effective Time represented shares of Common Stock (an &#147;Old Certificate&#148;) shall thereafter represent that number of shares of Common Stock
into which the shares of Common Stock represented by the Old Certificate shall have been combined, subject to the elimination of fractional share interests as described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Amendment attached hereto as Appendix A reflects the changes that will be implemented to our Charter if the Reverse Stock
Split is approved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Principal Effects of the Reverse Stock Split </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the stockholders approve the proposal to authorize the Board to implement the Reverse Stock Split and the Board implements the Reverse Stock
Split, we will amend the existing provision of Article IV.A. of our Charter in the manner set forth above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By approving this amendment,
stockholders will approve the combination of any whole number of shares of common stock between and including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-3</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-for-15,</FONT></FONT> with the exact number to be determined by the Board, into one (1)&nbsp;share. The Certificate of Amendment to be filed with the Secretary of State of the State of Delaware will include only that
number determined by the Board to be in the best interests of the Company and its stockholders. In accordance with these resolutions, the Board will not implement any amendment providing for a different split ratio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As explained above, the Reverse Stock Split will be effected simultaneously for all issued and outstanding shares of common stock and the
reverse stock split ratio will be the same for all issued and outstanding shares of common stock. The Reverse Stock Split will affect all of our stockholders uniformly and will not affect any stockholder&#146;s percentage ownership interests in the
Company, except to the extent that the Reverse Stock Split results in any of our stockholders receiving a cash payment in lieu of owning a fractional share, as described in the section titled &#147;Fractional Shares&#148; below. The shares of our
common stock will remain fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> after giving effect to the Reverse Stock Split. The Reverse Stock Split will not affect our continuing obligations under the periodic reporting
requirements of the Exchange Act. Following the Reverse Stock Split, our common stock will continue to be listed on The Nasdaq Capital Market, under the symbol &#147;PSTV,&#148; although it would receive a new CUSIP number. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon effectiveness of the Reverse Stock Split, the number of authorized shares of common
stock that are not issued or outstanding will increase substantially, because the proposed amendment will not reduce the number of authorized shares, while it will reduce the number of outstanding shares by a factor of between and including <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-3</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-15,</FONT></FONT> depending on the reverse stock split ratio selected by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares that are authorized but unissued after the Reverse Stock Split will be available for issuance, and, if we issue these shares, the
ownership interest of holders of our common stock may be diluted. We may issue such shares to raise capital and/or as consideration in acquiring other businesses or establishing strategic relationships with other companies. Such acquisitions or
strategic relationships may be effected using shares of our common stock or other securities convertible into shares of our common stock and/or by using capital that may need to be raised by selling such securities. We do not have any agreement,
arrangement or understanding at this time with respect to any specific transaction or acquisition for which the newly unissued authorized shares would be issued. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Procedure for Effecting Reverse Stock Split and Exchange of Stock Certificates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Reverse Stock Split is approved by our stockholders, and if at such time the Board still believes that a reverse stock split is in the
best interests of the Company and its stockholders, the Board will determine the ratio of the Reverse Stock Split to be implemented. The Reverse Stock Split will become effective as of the Effective Time. The Board will determine the exact timing of
the filing of the Certificate of Amendment based on its evaluation as to when the filing would be the most advantageous to the Company and its stockholders. If the Board does not decide to implement the Reverse Stock Split within twelve months from
the date of the Annual Meeting, the authority granted in this proposal to implement the Reverse Stock Split will terminate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as
described below under the section titled &#147;Fractional Shares,&#148; at the Effective Time, each whole number of issued and outstanding <FONT STYLE="white-space:nowrap">pre-Reverse</FONT> Stock Split shares that the Board has determined will be
combined into one (1)&nbsp;post-Reverse Stock Split share, will, automatically and without any further action on the part of our stockholders, be combined into and become one (1)&nbsp;share of common stock, and each certificate which, immediately
prior to the Effective Time represented <FONT STYLE="white-space:nowrap">pre-Reverse</FONT> Stock Split shares, will be deemed for all corporate purposes to evidence ownership of post-Reverse Stock Split shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fractional Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares
will be issued in connection with the Reverse Stock Split. Stockholders of record at the Effective Time of the Reverse Stock Split who otherwise would be entitled to receive fractional shares because they hold a number of <FONT
STYLE="white-space:nowrap">pre-Reverse</FONT> Stock Split shares not evenly divisible by the number of <FONT STYLE="white-space:nowrap">pre-Reverse</FONT> Stock Split shares for which each post-Reverse Stock Split share is to be exchanged, will, in
lieu of a fractional share, be entitled, upon surrender to the exchange agent of certificate(s) representing such <FONT STYLE="white-space:nowrap">pre-Reverse</FONT> Stock Split shares, to a cash payment in lieu thereof. The cash payment will equal
the fraction to which the stockholder would otherwise be entitled multiplied by the average of the closing prices (as adjusted to reflect the Reverse Stock Split) of our common stock, as reported by Bloomberg L.P., during the ten consecutive trading
days ending on the trading day that is the second day immediately prior to the date on which the Reverse Stock Split becomes effective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders should be aware that, under the escheat laws of the various jurisdictions where
stockholders reside, sums due for fractional interests that are not timely claimed after the Effective Time may be required to be paid to the designated agent for each such jurisdiction. Thereafter, stockholders otherwise entitled to receive such
funds may have to seek to obtain them directly from the state to which they were paid. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with the Reverse Stock Split </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict whether the Reverse Stock Split will increase the market price for our common stock. Additionally, the market price of our
common stock will also be based on our performance and other factors, some of which are unrelated to the number of shares outstanding. Further, there are a number of risks associated with the Reverse Stock Split, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The market price per share of our shares of common stock post-Reverse Stock Split may not remain in excess of
the $1.00 minimum bid price per share as required by Nasdaq, or we may fail to meet the other requirements for continued listing on Nasdaq, including the minimum value of listed securities, as described above, resulting in the delisting of our
common stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Although the Board believes that a higher stock price may help generate the interest of new investors, the
Reverse Stock Split may not result in a <FONT STYLE="white-space:nowrap">per-share</FONT> price that will successfully attract certain types of investors and such resulting share price may not satisfy the investing guidelines of institutional
investors or investment funds. Further, other factors, such as our development programs, financial results, market conditions and the market perception of our business, may adversely affect the interest of new investors in the shares of our common
stock. As a result, the trading liquidity of the shares of our common stock may not improve as a result of the Reverse Stock Split and there can be no assurance that the Reverse Stock Split, if completed, will result in the intended benefits
described above. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Reverse Stock Split could be viewed negatively by the market and other factors, such as those described
above, may adversely affect the market price of the shares of our common stock. Consequently, the market price per post-Reverse Stock Split shares may not increase in proportion to the reduction of the number of shares of our common stock
outstanding before the implementation of the Reverse Stock Split. Accordingly, the total market capitalization of our shares of common stock after the Reverse Stock Split may be lower than the total market capitalization before the Reverse Stock
Split. Any reduction in total market capitalization as the result of the Reverse Stock Split may make it more difficult for us to meet the Nasdaq Listing Rule regarding minimum value of listed securities, which could result in our shares of common
stock being delisted from The Nasdaq Capital Market. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Reverse Stock Split may result in some stockholders owning &#147;odd lots&#148; of less than 100 shares of
common stock. Odd lot shares may be more difficult to sell, and brokerage commissions and other costs of transactions in odd lots are generally somewhat higher than the costs of transactions in &#147;round lots&#148; of even multiples of 100 shares.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Reverse Stock Split is effected, stockholders who hold uncertificated shares (i.e., shares held in book-entry form and not represented
by a physical stock certificate), either as direct or beneficial owners, will have their holdings electronically adjusted automatically by our transfer agent (and, for beneficial owners, by their brokers or banks that hold in &#147;street name&#148;
for their benefit, as the case may be) to give effect to the Reverse Stock Split. Stockholders who hold uncertificated shares as direct owners will be sent a statement of holding from our transfer agent that indicates the number of post-Reverse
Stock Split shares of our common stock owned in book-entry form. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certificated Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As soon as practicable after the Effective Time of the Reverse Stock Split, stockholders will be notified that the Reverse Stock Split has been
effected. We expect that our transfer agent will act as exchange agent for purposes of implementing the exchange of stock certificates. Holders of <FONT STYLE="white-space:nowrap">pre-Reverse</FONT> Stock Split shares will be asked to surrender to
the exchange agent certificates representing <FONT STYLE="white-space:nowrap">pre-Reverse</FONT> Stock Split shares in exchange for the appropriate number of shares representing post-Reverse Stock Split shares electronically in book-entry form and
provide the stockholder with a statement reflecting the number of shares registered in the stockholder&#146;s account. Until surrendered, we will deem such stockholder&#146;s outstanding certificate(s) held by stockholders to be cancelled and only
to represent the number of shares of post-Reverse Stock Split shares to which these stockholders are entitled. Any <FONT STYLE="white-space:nowrap">pre-Reverse</FONT> Stock Split shares submitted for transfer, whether pursuant to a sale or other
disposition, or otherwise, will automatically be exchanged for post-Reverse Stock Split shares. STOCKHOLDERS SHOULD NOT DESTROY ANY STOCK CERTIFICATE(S) AND SHOULD NOT SUBMIT ANY CERTIFICATE(S) UNTIL REQUESTED TO DO SO. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Principal Effects of Reverse Stock Split on Outstanding Equity Awards, Warrants, and Equity Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&nbsp;23, 2023, there were: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">outstanding stock options to purchase an aggregate of 2,014,246 shares of our common stock with a weighted
average exercise price of $2.33 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">outstanding restricted stock units to receive an aggregate of 684,201 shares of our common stock; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">warrants to purchase an aggregate of 2,141,000 shares of our common stock with a weighted average exercise
price of $2.73 per share. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When the Reverse Stock Split becomes effective, the number of shares of common stock covered
by such rights will be reduced to between and including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-3</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-15</FONT></FONT> the number
currently covered, and the exercise price per share will be increased to between and including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-3</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-for-15</FONT></FONT> times the current exercise price, resulting in the same aggregate price being required to be paid therefor upon exercise thereof as was required immediately preceding the Reverse Stock Split. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the number of shares of common stock and number of shares of common stock subject to stock options or similar rights authorized
under our equity incentive plan and employee stock purchase plan will automatically be proportionately adjusted for the reverse stock split ratio, such that fewer shares will be subject to such plans. Further, the per share exercise price under such
plans will automatically be proportionately adjusted for the Reverse Stock Split. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Reverse Stock Split will not affect the common stock capital account on our balance sheet. However, because the par value of our common
stock will remain unchanged at the effective time of the split, the components that make up the common stock capital account will change by offsetting amounts. Depending on the size of the Reverse Stock Split the Board decides to implement, the
stated capital component will be reduced proportionately based upon the Reverse Stock Split and the additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital component will be increased with the amount by which the stated capital is
reduced. Immediately after the Reverse Stock Split, the per share net income or loss and net book value of our common stock will be increased because there will be fewer shares of common stock outstanding. All historic share and per share amounts in
our financial statements and related footnotes will be adjusted accordingly for the Reverse Stock Split. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Effect on Par Value </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proposed amendment to our Charter will not affect the par value of our common stock, which will remain at $0.001 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Going Private Transaction </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the decrease in the number of outstanding shares following the proposed Reverse Stock Split, our Board does not intend for this
transaction to be the first step in a &#147;going private transaction&#148; within the meaning of Rule <FONT STYLE="white-space:nowrap">13e-3</FONT> of the Exchange Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Potential Anti-Takeover Effect </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although
the increased proportion of unissued authorized shares to issued shares could, under certain circumstances, have an anti-takeover effect (for example, by permitting issuances that would dilute the stock ownership of a person seeking to effect a
change in the composition of the Board or contemplating a tender offer or other transaction for the combination of the Company with another company), the Reverse Stock Split proposal is not being proposed in response to any effort of which we are
aware to accumulate shares of our common stock or obtain control of the Company, nor is it part of a plan by management to recommend a series of similar amendments to the Board and stockholders. Other than the Reverse Stock Split proposal, the Board
does not currently contemplate recommending the adoption of any other actions that could be construed to affect the ability of third parties to take over or change control of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Dissenters&#146; Appraisal Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Delaware General Corporation Law, our stockholders are not entitled to dissenters&#146; appraisal rights with respect to the Reverse
Stock Split, and we will not independently provide stockholders with any such right. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material United States Federal Income Tax Consequences of the
Reverse Stock Split </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is not intended as tax or legal advice. Each holder should seek advice based on his, her or its
particular circumstances from an independent tax advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of certain United States federal income tax
consequences of the Reverse Stock Split generally applicable to beneficial holders of shares of our common stock. This summary addresses only such stockholders who hold their <FONT STYLE="white-space:nowrap">pre-Reverse</FONT> Stock Split shares as
capital assets and will hold the post-Reverse Stock Split shares as capital assets. This discussion does not address all United States federal income tax considerations that may be relevant to particular stockholders in light of their individual
circumstances or to stockholders that are subject to special rules, such as financial institutions, <FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations, insurance companies, dealers in securities, and foreign stockholders. The following
summary is based upon the provisions of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), applicable Treasury Regulations thereunder, judicial decisions and current administrative rulings, as of the date hereof, all of which are
subject to change, possibly on a retroactive basis. Tax consequences under state, local, foreign, and other laws are not addressed herein. Each stockholder should consult its tax advisor as to the particular facts and circumstances which may be
unique to such stockholder and also as to any estate, gift, state, local or foreign tax considerations arising out of the Reverse Stock Split. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exchange Pursuant to Reverse Stock Split </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No gain or loss will be recognized by a stockholder upon such stockholder&#146;s exchange of
<FONT STYLE="white-space:nowrap">pre-Reverse</FONT> Stock Split shares for post-Reverse Stock Split shares pursuant to the Reverse Stock Split, except to the extent of cash, if any, received in lieu of fractional shares, further described in
&#147;Cash in Lieu of Fractional Shares&#148; below. The aggregate tax basis of the post-Reverse Stock Split shares received in the Reverse Stock Split, including any fractional share deemed to have been received, will be equal to the aggregate tax
basis of the <FONT STYLE="white-space:nowrap">pre-Reverse</FONT> Stock Split shares exchanged therefor, and the holding period of the post-Reverse Stock Split shares will include the holding period of the
<FONT STYLE="white-space:nowrap">pre-Reverse</FONT> Stock Split shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash in Lieu of Fractional Shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of <FONT STYLE="white-space:nowrap">pre-Reverse</FONT> Stock Split shares that receives cash in lieu of a fractional share of
post-Reverse Stock Split shares should generally be treated as having received such fractional share pursuant to the Reverse Stock Split and then as having exchanged such fractional share for cash in a redemption by us. The amount of any gain or
loss should be equal to the difference between the ratable portion of the tax basis of the <FONT STYLE="white-space:nowrap">pre-Reverse</FONT> Stock Split shares exchanged in the Reverse Stock Split that is allocated to such fractional share and the
cash received in lieu thereof. In general, any such gain or loss will constitute a long-term capital gain or loss if the holder&#146;s holding period for such <FONT STYLE="white-space:nowrap">pre-Reverse</FONT> Stock Split shares exceeds one year at
the time of the Reverse Stock Split. Deductibility of capital losses by holders is subject to limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interests of Directors and Executive
Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors and executive officers have no substantial interests, directly or indirectly, in the matters set forth in this
proposal except to the extent of their ownership of shares of our common stock and Series F Preferred Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reservation of Right to Abandon Reverse
Stock Split </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We reserve the right to not file the Certificate of Amendment and to abandon any Reverse Stock Split without further
action by our stockholders at any time before the effectiveness of the filing with the Secretary of the State of Delaware of the Certificate of Amendment, even if the authority to effect these amendments is approved by our stockholders at the Annual
Meeting. By voting in favor of the Reverse Stock Split, you are expressly also authorizing the Board to delay, not proceed with, and abandon, the Reverse Stock Split and the Certificate of Amendment if it should so decide, in its sole discretion,
that such actions are in the best interests of our stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recommendation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board recommends a vote &#147;FOR&#148; the approval of the Certificate of Amendment so as to effect the Reverse Stock Split. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote, in
person virtually or by proxy, by the holders on the Record Date of a majority of the voting power of the outstanding shares of our common stock and Series F Preferred Stock, voting together as a single class, is required to approve the Certificate
of Amendment to our Charter to effect the Reverse Stock Split of our common stock. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes,</FONT> if any, will thus count as votes AGAINST the Reverse Stock Split. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of proxies solicited by this Proxy Statement will vote the proxies received by them as directed on the proxy card or, if no direction
is made, then FOR the Reverse Stock Split. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OUR BOARD RECOMMENDS A VOTE &#147;FOR&#148; APPROVAL OF AN AMENDMENT TO OUR CHARTER TO
EFFECT A REVERSE STOCK SPLIT. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx417044_13"></A>PROPOSAL #6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROPOSAL TO APPROVE THE THIRD AMENDMENT AND RESTATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF THE 2020 STOCK INCENTIVE PLAN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;24, 2023, our Board approved the third amendment and restatement of our 2020 Stock Incentive Plan (the &#147;Third Amended
Plan&#148;), subject to the approval of our stockholders at the Annual Meeting. The 2020 Stock Incentive Plan that was approved by our stockholders at our 2020 annual meeting of stockholders, the amended and restated 2020 Stock Incentive Plan that
was approved by our stockholders at our 2021 annual meeting of stockholders and the second amended and restated 2020 Stock Incentive Plan that was approved by our stockholders at our 2022 annual meeting of stockholders are collectively referred to
as the &#147;Plan&#148; in this proposal. The Board is requesting stockholder approval of the Third Amended Plan. Unless provided otherwise, all numerical share numbers referenced in this proposal are measured on a current, <FONT
STYLE="white-space:nowrap">pre-Reverse</FONT> Stock Split basis. If the Reverse Stock Split contemplated herein is implemented, all of the amounts set forth in the preceding sentence would be adjusted proportionately. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board believes that equity awards are a key element underlying its ability to retain, recruit and motivate key personnel who are critical
to our ability to execute successfully and implement our growth plans. After reviewing the Plan, the Board has determined that the share reserve available for awards under the Plan post-Reverse Stock Split will be insufficient and limits the
Board&#146;s ability to provide equity incentives that align the interests of our directors, executives and employees with those of our stockholders and limits our ability to attract and retain talented personnel. Approval of the Third Amended Plan
by our stockholders will allow us to grant stock options, restricted stock unit awards and other awards at levels determined appropriate by our Board or compensation committee. The Third Amended Plan contains the following material changes from the
Plan: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Subject to adjustment for certain changes in our capitalization, the maximum aggregate number of shares of our
common stock that may be issued under the Third Amended Plan is increased by 1,000,000 shares.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Subject to adjustment for certain changes in our capitalization, the number of shares of our common stock
issuable under the Third Amended Plan as incentive stock options (&#147;ISOs&#148;) has been increased to 4,550,000 shares. </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Third Amended Plan extends the period during which ISOs can be granted through 10 years following the date
the Third Amended Plan was approved by the Board. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary of the principal features of the Third Amended
Plan is qualified by reference to the terms of the Third Amended Plan, a copy of which is attached to this Proxy Statement as Appendix A. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation
and Governance Best Practices </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Third Amended Plan approved by our Board and submitted for stockholder approval includes an increase
in the number of shares available for issuance of equity incentive awards by the Company by 1,000,000 shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Third Amended Plan contains the following important compensation and governance best
practices: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>No single trigger accelerated vesting upon change in control</I>. The Third Amended Plan does not provide for
automatic vesting of awards upon a change in control. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>No liberal change in control definition</I>. The change in control definition in the Third Amended Plan is not
a &#147;liberal&#148; definition. A change in control transaction must actually occur in order for the change in control provisions in the Third Amended Plan to be triggered. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>No discounted stock options or stock appreciation rights</I>. All stock options and stock appreciation rights
granted under the Third Amended Plan must have an exercise or strike price equal to or greater than the fair market value of a share of our common stock on the date the stock option or stock appreciation right is granted. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Administration by independent committee</I>. The Third Amended Plan will be administered by the members of the
compensation committee, all of whom are <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> directors&#148; within the meaning of Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> under the Exchange Act and &#147;independent&#148; within the
meaning of the Nasdaq listing standards. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Material amendments require stockholder approval</I>. Consistent with Nasdaq rules and regulations, the Third
Amended Plan requires stockholder approval of any material revisions to the Third Amended Plan. In addition, certain other amendments to the Third Amended Plan require stockholder approval. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Repricing not permitted</I>. Repricing of stock options or stock appreciation rights and the cancellation of
stock options or stock appreciation rights with an exercise price greater than the current fair market value of a share in return for cash or the grant of new stock options or stock appreciation rights with a lower exercise price or the grant of
other awards is prohibited without stockholder approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>No liberal share recycling</I>. Liberal share recycling is not allowed.<B> </B>Shares withheld to pay the
grant price or exercise price or to satisfy a tax withholding obligation related to an award will not again become available for awards under the Third Amended Plan. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Limitations on dividends and dividend equivalents</I>. Dividends and dividend equivalents on shares and awards
that have not vested and accrued dividends are not paid under the Third Amended Plan until the underlying shares vest. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Awards subject to claw back</I>. There is a robust claw back provision under the Third Amended Plan.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Limit on <FONT STYLE="white-space:nowrap">non-employee</FONT> director awards and other awards</I>. The sum of
any cash compensation and the value of awards (calculating the value of any such stock awards based on the grant date fair value of such stock awards for financial reporting purposes) granted to any of our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors as compensation for services during any calendar year may not exceed $500,000, or $700,000 in the calendar year of the <FONT STYLE="white-space:nowrap">non-employee</FONT>
director&#146;s initial service as a director). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Why We Are Asking Our Stockholders to Approve the Third Amended Plan </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Equity incentives are key to retaining key talent to drive our business forward. </I>The Board believes that
equity awards are a key element underlying our ability to retain, recruit and motivate key personnel who are critical to our ability to execute successfully through this time of transition for our Company and implement our business plan to develop
our pipeline of therapeutics. Equity awards align the interests of our key personnel with those of our stockholders and are a substantial contributing factor to our success and the future growth of our business. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Current shares available for awards are inadequate. </I>We believe that the shares currently available for
grant under the Plan will be insufficient to meet our anticipated retention and recruiting needs.&nbsp;As of February&nbsp;23, 2023, there were 1,886,839 shares available for future grant under the Plan. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information regarding Equity Incentive Program, Dilution and Overhang </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides certain information regarding our equity incentive program: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As of<BR>February&nbsp;23,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total number of shares of common stock subject to outstanding stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,014,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average exercise price of outstanding stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average remaining term of outstanding stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.762 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total number of shares of common stock subject to outstanding full value awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total number of shares of common stock available for grant under the 2020 Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,796,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total number of shares of common stock available for grant under the 2015 New Employee Incentive
Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total number of shares of common stock outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,414,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Per-share</FONT> closing price of common stock as reported on the
Nasdaq Capital Market</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.3920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To provide the Company the flexibility to responsibly address our future equity compensation needs, we are
requesting that stockholders approve the Third Amended Plan to make an additional 1,000,000 shares available for grant. Grant levels for the preceding three fiscal years have averaged 510,831 shares per year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows our key dilution metrics over the last three years: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Key Equity Metrics</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Year</B><br><B>Average</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Equity Burn Rate<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.29</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.96</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.31</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.55</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.87</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Overhang<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.04</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.40</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.92</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.79</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Net Equity Burn Rate is calculated by dividing the number of shares subject to equity awards granted during the
year, minus shares subject to awards that were cancelled or forfeited during the year, by the weighted average number of shares outstanding during the year. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dilution is calculated by dividing the number of shares subject to equity awards outstanding at the end of the
year by the number of shares outstanding at the end of the year. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Overhang is calculated by dividing (a)&nbsp;the sum of (i)&nbsp;the number of shares subject to equity awards
outstanding at the end of the year and (ii)&nbsp;the number of shares available for future grants by (b)&nbsp;the sum of (i)&nbsp;the number of shares outstanding at the end of the year and (ii)&nbsp;the number of shares subject to equity awards
outstanding at the end of the year and (iii)&nbsp;the number of shares available for future grants. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When considering
the number of shares authorized for issuance under the Third Amended Plan, the compensation committee reviewed, among other things, the potential dilution to the Company&#146;s current stockholders as measured by burn rate, dilution and overhang,
projected future share usage and projected future forfeitures. The projected future usage of shares for long-term incentive awards under the Third Amended Plan was reviewed under scenarios based on a variety of assumptions. The compensation
committee is committed to effectively managing the number of shares reserved for issuance under the Third Amended Plan while minimizing stockholder dilution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of the 2020 Stock Incentive Plan, as amended and restated </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Purpose </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the Third
Amended Plan is to assist management in the recruitment, retention and motivation of employees, outside directors and consultants who are in a position to make material contributions to our <FONT STYLE="white-space:nowrap">long-term</FONT> success
and the creation of stockholder value. The Third Amended Plan offers a significant incentive to encourage our employees, outside directors and consultants by enabling those individuals to acquire shares of our common stock, thereby increasing their
proprietary interest in the growth and success of our Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Types of Awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Third Amended Plan provides for the direct award or sale of shares of common stock (including restricted stock), the award of stock units
and stock appreciation rights, and the grant of both incentive stock options to purchase common stock intended to qualify for preferential tax treatment under Section&nbsp;422 of the Code and nonstatutory stock options to purchase common stock that
do not qualify for such treatment under the Code. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Eligibility </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All employees (including officers) and directors of the Company or any subsidiary and any consultant who performs services for the Company or a
subsidiary are eligible to purchase shares of common stock and to receive awards of shares or grants of nonstatutory stock options, stock units and stock appreciation rights. Only employees are eligible to receive grants of incentive stock options.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&nbsp;23, 2023, we (including our affiliates) had approximately 17 employees
and 5 <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, all of whom are eligible to receive awards under the Third Amended Plan. We also engage consultants from time to time who are eligible to receive awards under the Third Amended
Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Administration </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Third Amended Plan is administered by the compensation committee of our Board. Subject to the limitations set forth in the Third Amended Plan, the compensation committee has the authority to determine, among other things, to whom awards will be
granted, the number of shares subject to awards, the term during which an option, stock unit or stock appreciation right may be exercised and the rate at which the awards may vest or be earned, including any performance criteria to which they may be
subject. The compensation committee also has the authority to determine the consideration and methodology of payment for awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
compensation committee, our Board and any of their designees do not have the authority to: (i)&nbsp;amend the terms of an outstanding option or stock appreciation right to reduce its exercise price, or (ii)&nbsp;cancel outstanding options or stock
appreciation rights with an exercise price above the then-current fair market value per share in exchange for another option, stock appreciation right with a lower exercise price or for other award or for cash, unless the stockholders of the Company
have previously approved such an action or the action relates to a capitalization adjustment under the terms of the Third Amended Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shares
Available for Awards </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to adjustment for certain changes in our capitalization, the aggregate number of shares of our common
stock that may be issued under the Third Amended Plan will not exceed 4,659,286 shares, which is the sum of (i) 550,000 shares approved at the Company&#146;s 2020 annual meeting of stockholders, <I>plus</I> (ii) 1,000,000 shares approved at the
Company&#146;s 2021 annual meeting of stockholders, <I>plus</I> (iii) 2,000,000 shares approved at the Company&#146;s 2022 annual meeting of stockholders, <I>plus</I> (iv) 1,000,000 shares approved at the Company&#146;s 2023 annual meeting of
stockholders, <I>plus</I> (v)&nbsp;the number of unallocated shares remaining available for grant under the Plus Therapeutics, Inc. 2014 Equity Incentive Plan, as amended (the &#147;2014 Plan&#148;) as of the effective date of the Plan, plus
(vi)&nbsp;the Predecessor Plan&#146;s Returning Shares (as defined below), as such shares become available from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term
&#147;Predecessor Plan&#146;s Returning Shares&#148; refers to the following shares of our common stock subject to any outstanding stock award granted under the 2014 Plan: (i)&nbsp;any shares subject to such stock award that are not issued because
such stock award expires or otherwise terminates without all of the shares covered by such stock award having been issued, and (ii)&nbsp;any shares issued pursuant to such stock award that are forfeited back to us because of a failure to vest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares that may be delivered in the aggregate pursuant to the exercise of incentive stock options granted under the Third
Amended Plan will not exceed 4,550,000 shares plus, to the extent allowable under Section&nbsp;422 of the Code, any shares that become available for issuance under the Third Amended Plan discussed below as a result of forfeiture or termination of
awards. These limitations, and the terms of outstanding awards, shall be adjusted as appropriate and equitable in the event of a stock dividend, stock split, reclassification of stock or similar events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If stock units, options, or stock appreciation rights are forfeited or terminate for any other reason before being settled or exercised, or if
restricted shares are forfeited, then the corresponding shares will again become available for awards under the Third Amended Plan. If stock units are settled or stock appreciation rights are exercised, then only the number of shares settled or
exercised shall reduce the number of shares available under the Third Amended Plan.&nbsp;Shares withheld to satisfy the grant price or exercise price or tax withholding obligation pursuant to an award will not again become available for awards under
the Third Amended Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-employee</FONT> Director Compensation Limit </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Third Amended Plan, the sum of any cash compensation, or other compensation, and the value (determined as of the grant date in
accordance with Financial Accounting Standards Board Accounting Standards Codification of Topic 718, or any successor thereto) of awards granted to any of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors as compensation for
services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director during any calendar year may not exceed $500,000 (increased to $700,000 in the calendar year of his or her initial service). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of any
grants of stock options under the Third Amended Plan will be set forth in a stock option agreement to be entered into between the Company and the recipient. The compensation committee will determine the terms and conditions of such option grants,
which need not be identical. The compensation committee may modify, extend or renew outstanding options but the compensation committee may not modify outstanding options to lower the exercise price or cancel options in exchange for cash or for
options or stock appreciation rights with a lower exercise price or for another award, other than in connection with a corporate transaction, without stockholder approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price of each option will be set by the compensation committee, subject to the following limits. The exercise price of an
incentive stock option cannot be less than 100% of the fair market value of a share of common stock on the date the option is granted, and in the event an option recipient is deemed to be a 10% owner of our Company or one of our subsidiaries, the
exercise price of an incentive stock option cannot be less than 110% of the fair market value of a share of common stock on the date the option is granted. The exercise price of a nonstatutory stock option cannot be less than 100% of the fair market
value of a share of the Company&#146;s common stock on the date the option is granted. The maximum period in which an option may be exercised will be fixed by the compensation committee and included in each stock option agreement and cannot exceed
ten years in the case of an incentive stock option (and in the event an option recipient is deemed to be a 10% owner of our Company or one of our subsidiaries, the maximum period for an incentive stock option granted to that person cannot exceed
five years). In addition, no option recipient may be granted incentive stock options that are exercisable for the first time in any calendar year for our common stock having a total fair market value (determined as of the option grant) in excess of
$100,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price for the exercise of a stock option may be paid in cash or, to the extent that the stock option agreement so
provides, by surrendering shares of common stock, by a broker-assisted cashless exercise procedure, by a net exercise arrangement, by delivering a full-recourse promissory note, or in any other form that is consistent with applicable laws,
regulations and rules. Options generally will be nontransferable except in the event of the option recipient&#146;s death, but the compensation committee may allow the transfer of nonstatutory stock options through a gift or domestic relations order
to the option recipient&#146;s family members. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock options granted under the Third Amended Plan generally must be exercised by the
optionee before the earlier of the expiration of such option or 90 days after termination of the optionee&#146;s employment, except that the period may be extended on certain events including death and termination of employment due to disability.
Each stock option agreement will set forth the extent to which the option recipient will have the right to exercise the option following the termination of the recipient&#146;s service with us, and the right to exercise the option of any executors
or administrators of the award recipient&#146;s estate or any person who has acquired such options directly from the award recipient by bequest or inheritance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of any awards of restricted shares under the Third Amended Plan will be set forth in a restricted share agreement to be entered into
between the Company and the recipient. The compensation committee will determine the terms and conditions of the restricted share agreements, which need not be identical. A restricted share award may be subject to vesting requirements or transfer
restrictions or both. Restricted shares may be issued for such consideration as the compensation committee may determine, including cash, cash equivalents, <FONT STYLE="white-space:nowrap">full-recourse</FONT> promissory notes, past services and
future services. Award recipients who are granted restricted shares generally have all of the rights of a stockholder with respect to those shares.&nbsp;Holders of restricted shares must invest any cash dividends received in additional restricted
shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock Units </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of any awards of restricted stock units under the Amended Plan (referred to as &#147;stock units&#148; in the Third Amended Plan
document) will be set forth in a restricted stock unit agreement to be entered into between the Company and the recipient. The compensation committee will determine the terms and conditions of the restricted stock unit agreements, which need not be
identical. Restricted stock units give an award recipient the right to acquire a specified number of shares of common stock or, at the compensation committee&#146;s discretion, cash, or a combination of common stock and cash, at a future date upon
the satisfaction of certain vesting conditions based upon a vesting schedule or performance criteria established by the compensation committee. Restricted stock units may be granted in consideration of a reduction in the award recipient&#146;s other
compensation, but no cash consideration is typically required of the award recipient. Unlike restricted shares, the stock underlying restricted stock units will not be issued until the stock units have vested, and recipients of restricted stock
units generally will have no voting or dividend rights prior to the time of issuance of any common stock upon settlement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Appreciation Rights
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of any awards of stock appreciation rights under the Third Amended Plan will be set forth in an agreement to be entered
into between the Company and the recipient. The compensation committee will determine the terms, conditions and restrictions of any such agreements, which need not be identical. A stock appreciation right generally entitles the award recipient to
receive a payment upon exercise equal to the amount by which the fair market value of a share of common stock on the date of exercise exceeds the value of a share of common stock on the date of grant. The amount payable upon the exercise of a stock
appreciation right may be settled in cash or by the issuance of shares of common stock. The compensation committee may not modify outstanding stock appreciation rights to lower the exercise price or cancel stock appreciation rights in exchange for
cash or for options or stock appreciation rights with a lower exercise price or for another award, other than in connection with a corporate transaction, without stockholder approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Performance Criteria </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An award may
be made subject to the attainment of performance goals for a specified period of time relating to performance criteria including, but not limited to one or more of the following performance criteria, either individually, alternatively or in any
combination, applied to either us as a whole or to a business unit or subsidiary, either individually, alternatively or in any combination, and measured either annually or cumulatively over a period of years, on an absolute basis or relative to a <FONT
STYLE="white-space:nowrap">pre-established</FONT> target, to previous years&#146; results or to a designated comparison group or index, in each case as specified by the compensation committee in the award: (a)&nbsp;cash flow, (b)&nbsp;earnings per
share, (c)&nbsp;earnings before interest, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
taxes and amortization, (d)&nbsp;return on equity, (e)&nbsp;total stockholder return, (f)&nbsp;share price performance, (g)&nbsp;return on capital, (h)&nbsp;return on assets or net assets,
(i)&nbsp;revenue, (j) income or net income, (k)&nbsp;operating income or net operating income, (l)&nbsp;operating profit or net operating profit, (m)&nbsp;operating margin or profit margin, (n)&nbsp;return on operating revenue, (o)&nbsp;return on
invested capital, (p)&nbsp;market segment shares, (q)&nbsp;costs, (r) expenses, (s)&nbsp;achievement of target levels of discovery and/or development of products or services, including but not limited to research or regulatory achievements,
(t)&nbsp;third party coverage and/or reimbursement objectives, (u)&nbsp;test volume metrics, (v)&nbsp;objective customer indicators (including, without limitation, customer satisfaction), (w) improvements in productivity, (x)&nbsp;attainment of
objective operating goals, (y)&nbsp;objective employee metrics, or (z)&nbsp;any other measures of performance selected by the compensation committee. The compensation committee will appropriately adjust any evaluation of performance under a
qualifying performance criteria for a performance period: (i)&nbsp;to exclude asset <FONT STYLE="white-space:nowrap">write-downs,</FONT> (ii)&nbsp;to exclude litigation or claim judgments or settlements, (iii)&nbsp;to exclude the effect of changes
in tax law, accounting principles or other such laws or provisions affecting reported results, (iv)&nbsp;to exclude accruals for reorganization and restructuring programs, (v)&nbsp;to exclude any extraordinary nonrecurring items as determined under
generally accepted accounting principles and/or in managements&#146; discussion and analysis of financial condition and results of operations appearing in our annual report to stockholders for the applicable year, (vi)&nbsp;to exclude the dilutive
and/or accretive effects of acquisitions or joint ventures, (vii)&nbsp;to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a performance period following the divestiture,
(viii)&nbsp;to exclude the effect of any change in the outstanding shares of our common stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation,
<FONT STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other similar corporate change, or any distributions to our common stockholders other than regular cash dividends, (ix)&nbsp;to exclude the effects of stock based
compensation, (x)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles, and (xi)&nbsp;to make other appropriate adjustments selected
by the compensation committee.&nbsp;If applicable, the compensation committee will establish the goals before results are substantially certain and will determine and certify, for each award recipient, the extent to which the qualifying performance
criteria have been met. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment and Termination </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board may amend or terminate the Third Amended Plan at any time, but an amendment will not become effective without the approval of our
stockholders to the extent required by applicable laws, regulations or rules.&nbsp;No amendment or termination of the Third Amended Plan will affect an award recipient&#146;s rights under outstanding awards without the award recipient&#146;s
consent. No incentive stock options may be granted under the Third Amended Plan after the tenth anniversary of the date the Third Amended Plan is adopted by the Board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Forfeiture Events and Clawback/Recoupment Policy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation committee may specify in an award agreement that a participant&#146;s rights, payments, and benefits with respect to an award
will be subject to reduction, cancellation, forfeiture, or recoupment upon the occurrence of specified events, in addition to any otherwise applicable vesting or performance conditions of an award, including termination of service for cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that we are required to prepare restated financial results due to the material noncompliance of the Company, as a result of
misconduct, with any financial reporting requirement under the securities laws, at the discretion of the compensation committee any participant who knowingly or through gross negligence engaged in the misconduct, or who knowingly or through gross
negligence failed to prevent the misconduct, and any participant who is subject to automatic forfeiture under Section&nbsp;304 of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Sarbanes-Oxley Act of 2002, will reimburse the Company for (i)&nbsp;the amount of any payment in settlement of an award during the twelve month period following the first public issuance or
filing with the SEC of the financial document embodying the financial reporting requirement and (ii)&nbsp;any profits realized by the participation from the sale of securities of the Company during the twelve month period. In addition, to the extent
claw-back or similar provisions applicable to awards are required by applicable law, listing standards and/or policies adopted by the Company, awards granted under the Third Amended Plan shall be subject to such provisions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Effect of Certain Corporate Events </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a subdivision of the outstanding common stock or a combination or consolidation of the outstanding common stock (by
reclassification or otherwise) into a lesser number of shares, a recapitalization, a <FONT STYLE="white-space:nowrap">spin-off</FONT> or a similar occurrence, a declaration of a dividend payable in common stock or a declaration of a dividend payable
in a form other than shares in an amount that has a material effect on the price of the shares, the compensation committee will make appropriate adjustments in the number and class of shares covered by outstanding awards and the exercise price of
outstanding options and stock appreciation rights, the number and class of shares that may be issued pursuant to the exercise of incentive stock options, and the number and class of shares available under the Third Amended Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a merger or other reorganization, subject to any acceleration provisions in the agreement relating to an award, outstanding
awards will be treated in the manner provided in the agreement of merger or reorganization.&nbsp;That agreement may provide for the assumption of outstanding awards by the surviving corporation or its parent, for their continuation by the Company
(if the Company is the surviving corporation), for the substitution by the surviving corporation or its parent of its own awards, or for the acceleration of the exercisability of awards followed by the cancellation of those awards.&nbsp;The
agreement of merger or reorganization may also provide for the full exercisability or vesting and accelerated expiration of outstanding awards, cancellation of outstanding awards to the extent not vested or exercised prior to the effective time of
the merger or reorganization in exchange for such cash consideration, if any, as the compensation committee may consider appropriate, or settlement of the intrinsic value of the outstanding awards in cash or cash equivalents or equity, followed by
cancellation of the awards.&nbsp;The Company need not take the same action or actions with respect to all awards or portions thereof or with respect to all participants, and the Company may take different actions with respect to the vested and
unvested portions of an award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In its discretion, the compensation committee may provide in the award agreement governing an award or at
any other time may take any action as it deems appropriate to provide for acceleration of the exercisability, vesting and/or settlement in connection with a change in control of the Company of each or any outstanding award or portion thereof upon
such conditions, including termination of the participant&#146;s service prior to, upon or following the change in control. In the absence of such provision in an award agreement or any action taken by the compensation committee, no acceleration
will occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the Third Amended Plan, a change in control generally means the occurrence of any of the following events:
(i)&nbsp;a change in the composition of the Board occurs, as a result of which fewer than <FONT STYLE="white-space:nowrap">one-half</FONT> of the incumbent directors are directors who either had been directors on the date that is 24 months prior to
the date that the change in control could be deemed to occur, or were elected or nominated to the Board with the affirmative votes of at least a majority of the directors who had been directors on the date that was 24 months prior to the date the
change in control cold be deemed to occur and are still in office at the time of election or nomination, (ii)&nbsp;any person who, through the acquisition or aggregation of securities, becomes the beneficial owner of securities of the Company
representing 50% or more of the combined voting power of the Company&#146;s then outstanding securities ordinarily having the right to vote at </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
elections of directors (subject to certain exceptions set forth in the Third Amended Plan); (iii) the consummation of a merger or consolidation of the Company with or into another entity or any
other corporate reorganization, if persons who were not stockholders of the Company immediately prior to the merger, consolidation or other reorganization own immediately after the merger, consolidation or other reorganization 50% or more of the
voting power of the outstanding securities of each of the continuing or surviving entity and any direct or indirect parent corporation of such continuing or surviving entity; or (iv)&nbsp;the sale, transfer or other disposition of all or
substantially all of the Company&#146;s assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Federal Income Tax Aspects of Awards Under the Third Amended Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This is a brief summary of the federal income tax aspects of awards that may be made under the Third Amended Plan based on existing U.S.
federal income tax laws. This summary provides only the basic tax rules. It does not describe a number of special tax rules, including the alternative minimum tax and various elections that may be applicable under certain circumstances. It also does
not reflect provisions of the income tax laws of any municipality, state or foreign country in which a holder may reside, nor does it reflect the tax consequences of a holder&#146;s death. The tax consequences of awards under the Third Amended Plan
depend upon the type of award. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Incentive Stock Options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The recipient of an incentive stock option generally will not be taxed upon grant of the option. Federal income taxes are generally imposed
only when the shares of common stock from exercised incentive stock options are disposed of, by sale or otherwise. The amount by which the fair market value of the common stock on the date of exercise exceeds the exercise price is, however, included
in determining the option recipient&#146;s liability for the alternative minimum tax. If the incentive stock option recipient does not sell or dispose of the shares of common stock until more than one year after option exercise and two years after
the option was granted, then, upon sale or disposition of the shares, the difference between the exercise price and the market value of the shares of common stock as of the date of exercise will be treated as a capital gain, and not ordinary income.
If a recipient fails to hold the shares for the minimum required time the recipient will recognize ordinary income in the year of disposition generally in an amount equal to any excess of the market value of the common stock on the date of exercise
(or, if less, the amount realized or disposition of the shares) over the exercise price paid for the shares. Any further gain (or loss) realized by the recipient generally will be taxed as <FONT STYLE="white-space:nowrap">short-term</FONT> or <FONT
STYLE="white-space:nowrap">long-term</FONT> gain (or loss) depending on the holding period. Subject to the requirement of reasonableness, the provisions of Section&nbsp;162(m) of the Code and the satisfaction of our tax reporting obligation, we will
generally be entitled to a tax deduction at the same time and in the same amount as ordinary income is recognized by the option recipient. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nonstatutory Stock Options </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
recipient of stock options not qualifying as incentive stock options generally will not be taxed upon the grant of the option. Federal income taxes are generally due from a recipient of nonstatutory stock options when the stock options are
exercised. The excess of the fair market value of the common stock purchased on such date over the exercise price of the option is taxed as ordinary income. Thereafter, the tax basis for the acquired shares is equal to the amount paid for the shares
plus the amount of ordinary income recognized by the recipient. Subject to the requirement of reasonableness, the provisions of Section&nbsp;162(m) of the Code and the satisfaction of our tax reporting obligation, we will generally be entitled to a
tax deduction at the same time and in the same amount as ordinary income is recognized by the option recipient by reason of the exercise of the option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Recipients of restricted stock unit awards will generally recognize ordinary income when they receive shares upon settlement of the awards, in
an amount equal to the fair market value of the shares at that time.&nbsp;Recipients of restricted shares subject to a vesting requirement will generally recognize ordinary income at the time vesting occurs, in an amount equal to the fair market
value of the shares at that time minus the amount, if any, paid for the shares. However, a recipient of restricted shares which are not vested may, within 30 days of the date the shares are transferred, elect in accordance with Section&nbsp;83(b) of
the Code to recognize ordinary compensation income at the time of transfer of the shares rather than upon the vesting dates. Recipients of stock appreciation rights will generally recognize ordinary income upon exercise in an amount equal to the
excess of the fair market value of the underlying shares of common stock on the exercise date and cash received, if any, over the exercise price. Subject to the requirement of reasonableness, the provisions of Section&nbsp;162(m) of the Code and the
satisfaction of our tax reporting obligation, we will generally be entitled to a tax deduction at the same time and in the same amount as ordinary income is recognized by the recipient. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New Plan Benefits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No new grants have been made under the
Third Amended Plan requiring stockholder approval. With respect to future grants under the Third Amended Plan, it is not possible to determine specific amounts and types of awards that may be awarded in the future under the Third Amended Plan,
because the grant and actual settlement of awards will be discretionary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aggregate Past Grants Under the Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with SEC rules, the following table sets forth summary information with respect to the number of shares of common stock subject to stock option
awards made under the Plan to the Company&#146;s named executive officers, all current executive officers as a group, directors, associates of such executive officers, directors and nominees, each other person who received or is to receive 5% of
such stock options and all employees (other than executive officers) as a group as of February&nbsp;23, 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Individual or Group</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number&nbsp;of&nbsp;Shares<BR>Underlying</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Stock&nbsp;Option&nbsp;Awards</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc H. Hedrick, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">913,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President, Chief Executive Officer and Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Sims</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">311,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Norman LaFrance, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">194,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Howard Clowes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">An van <FONT STYLE="white-space:nowrap">Es-Johansson,</FONT> M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard J. Hawkins</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chairman of the Board</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Lenk, PhD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greg Petersen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers as a group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,419,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current directors who are not executive officers as a group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">372,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All nominees for election as a director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Each associate of any such director, executive officer or nominees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Each other person who received or is to receive 5% of such awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All employees, including current officers who are not executive officers as a group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">222,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Required Vote </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proposal to approve the third amendment and restatement of our 2020 Stock Incentive Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">requires the affirmative vote of a majority of the common stock having voting power present in person or represented by proxy at the Annual
Meeting.&nbsp;Abstentions are considered present and entitled to vote with respect to this proposal and will, therefore, be treated as votes against this proposal. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>YOUR BOARD UNANIMOUSLY RECOMMENDS A VOTE &#147;FOR&#148; THE APPROVAL OF THE THIRD AMENDMENT AND RESTATEMENT OF OUR 2020 STOCK INCENTIVE
PLAN. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx417044_14"></A>OTHER MATTERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the time of preparation of this Proxy Statement, neither the Board nor management intends to bring before the meeting any business other
than the matters referred to in the Notice of Annual Meeting and this Proxy Statement. If any other business should be properly brought before the meeting, or any adjournment or postponement thereof, the designated proxy holders will vote on such
matters according to their best judgment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholders Sharing the Same Address </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders who hold their shares through a bank, broker or other holder of record (a &#147;street-name stockholder&#148;) and share a single
address, may receive only one copy of the Proxy Materials to that address unless contrary instructions from any stockholder at that address were received. This practice, known as &#147;householding,&#148; is intended to reduce our printing and
postage costs. However, any such street-name stockholder residing at the same address who wishes to receive a separate copy of this Proxy Statement or accompanying Annual Report to Stockholders may request a copy by contacting us by telephone at:
(737) <FONT STYLE="white-space:nowrap">255-7194.</FONT> Please contact your bank, broker or other holder of record if you wish to start or stop householding of our proxy materials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholder Proposals for the 2024 Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deadlines </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders interested
in submitting a proposal for consideration at our 2024 Annual Meeting must do so by sending such proposal to our Corporate Secretary at Plus Therapeutics, Inc., 4200 Marathon Blvd. Suite 200, Austin, TX 78756, Attention: Corporate Secretary. Under
the SEC&#146;s proxy rules, the deadline for submission of proposals to be included in our proxy materials for the 2024 Annual Meeting is November&nbsp;11, 2023. Accordingly, for a stockholder proposal to be considered for inclusion in our proxy
materials for the 2024 Annual Meeting, any such stockholder proposal must be received by our Corporate Secretary on or before November&nbsp;11, 2023 and comply with the procedures and requirements set forth in Rule
<FONT STYLE="white-space:nowrap">14a-8</FONT> under the Securities Exchange Act of 1934. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our bylaws require advance notice
of business to be brought before a stockholders&#146; meeting (other than proposals presented under Rule <FONT STYLE="white-space:nowrap">14a-8),</FONT> including nominations of persons for election as directors. To be timely, notice to our
Corporate Secretary must be received at our principal executive offices not less than 120 days prior to the anniversary date of the preceding year&#146;s proxy statement. Any stockholder proposal or nomination received after November&nbsp;11, 2023
(including nominations of persons for election as directors) will be considered untimely and will not be entertained at the annual meeting. In the event we hold the 2024 Annual Meeting of stockholders more than 30 days before or after the <FONT
STYLE="white-space:nowrap">one-year</FONT> anniversary date of the Annual Meeting, a proposal will be considered timely only if received by us a reasonable time before the proxy solicitation is made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than the
company&#146;s nominees must provide notice that sets forth the information required by Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> under the Exchange Act not earlier than the close of business prior to November&nbsp;11, 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Procedures </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the
timing requirements referenced above, for any stockholder proposal to be considered for inclusion in our proxy materials for the 2024 Annual Meeting, the notice to our Corporate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Secretary must contain certain information concerning the matters to be brought before such meeting and the stockholder proposing such matters. These requirements are more fully described in our
Bylaws. We will not entertain any proposals or nominations at the annual meeting that do not meet the additional requirements set forth in our bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, even if a stockholder&#146;s proposal is included in our proxy materials for the 2024 Annual Meeting, if such stockholder does not
also comply with the requirements of Rule <FONT STYLE="white-space:nowrap">14a-4(c)(2)</FONT> under the Exchange Act, we may exercise discretionary voting authority under proxies that we solicit to vote in accordance with our best judgement on any
such stockholder proposal or nomination. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By Order of the Board,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g417044g0224071627751.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">MARC H. HEDRICK</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>President and Chief Executive Officer</I></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Appendix A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Third Amended and Restated 2020 Stock Incentive Plan </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PLUS THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2020 STOCK INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Adopted by the Board of Directors on April&nbsp;30, 2020 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Approved by the Stockholders on June&nbsp;16, 2020 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Amended and Restated by the Board of Directors on March&nbsp;22, 2021 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Approved by the Stockholders on May&nbsp;17, 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Further Amended and Restated by the Board of Directors on March&nbsp;28, 2022 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Approved by the Stockholders on May&nbsp;16, 2022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Further Amended and Restated by the Board of Directors on February&nbsp;24, 2023 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Approved by the Stockholders on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ], 2023 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table of Contents </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECTION&nbsp;1.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ESTABLISHMENT AND PURPOSE.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECTION 2.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DEFINITIONS.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(a)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Affiliate&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(b)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Award&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(c)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Award Agreement&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(d)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Board of Directors&#148; or &#147;Board&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(e)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Cause&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(f)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Change in Control&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(g)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Code&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(h)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Committee&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(i)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Company&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(j)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Consultant&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(k)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Disability&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(l)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Effective Date&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(m)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Employee&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(n)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Exchange Act&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(o)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Exercise Price&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(p)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Fair Market Value&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(q)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;ISO&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(r)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Nonstatutory Option&#148; or &#147;NSO&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(s)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Offeree&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(t)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Option&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(u)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Optionee&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(v)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Outside Director&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(w)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Parent&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(x)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Participant&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(y)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Plan&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(z)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Purchase Price&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(aa)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Restricted Share&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(bb)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Restricted Share Agreement&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- i
- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(cc)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;SAR&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(dd)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;SAR Agreement&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(ee)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Service&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(ff)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Share&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(gg)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Stock&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(hh)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Stock Option Agreement&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(ii)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Stock Unit&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(jj)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Stock Unit Agreement&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(kk)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Subsidiary&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECTION 3.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ADMINISTRATION.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(a)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Committee Composition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(b)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Committee for <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(c)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Committee Procedures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(d)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Committee Responsibilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(e)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancellation and <FONT STYLE="white-space:nowrap">Re-Grant</FONT> of Stock Awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECTION 4.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ELIGIBILITY.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(a)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General Rule</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(b)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Limit on Grants to Outside Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(c)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Ten-Percent</FONT> Stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(d)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attribution Rules</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(e)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECTION 5.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">STOCK SUBJECT TO PLAN.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(a)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic Limitation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(b)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(c)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Substitution and Assumption of Awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECTION 6.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RESTRICTED SHARES.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(a)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted Stock Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(b)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment for Awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(c)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(d)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Voting and Dividend Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(e)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restrictions on Transfer of Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECTION 7.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TERMS AND CONDITIONS OF OPTIONS.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-
ii - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(a)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock Option Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(b)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(c)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise Price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(d)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Withholding Taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(e)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisability and Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(f)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(g)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Rights as a Stockholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(h)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Modification or Extension of Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(i)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restrictions on Transfer of Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(j)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Buyout Provisions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECTION 8.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PAYMENT FOR SHARES.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(a)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General Rule</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(b)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surrender of Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(c)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Services Rendered</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(d)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cashless Exercise</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(e)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise/Pledge</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(f)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Exercise</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(g)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Promissory Note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(h)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Forms of Payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(i)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Limitations under Applicable Law</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECTION 9.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">STOCK APPRECIATION RIGHTS.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(a)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SAR Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(b)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(c)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise Price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(d)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisability and Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(e)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Rights as a Stockholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(f)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of SARs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(g)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Modification, Extension or Assumption of SARs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(h)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Buyout Provisions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECTION 10.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">STOCK UNITS.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(a)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock Unit Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(b)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment for Awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-
iii - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(c)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting Conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(d)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Voting and Dividend Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(e)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form and Time of Settlement of Stock Units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(f)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Death of Recipient</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(g)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Creditors&#146; Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECTION 11.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ADJUSTMENT OF SHARES.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(a)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(b)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dissolution or Liquidation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(c)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reorganizations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(d)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reservation of Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(e)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in Control</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECTION 12.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DEFERRAL OF AWARDS.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(a)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Committee Powers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(b)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General Rules</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECTION 13.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AWARDS UNDER OTHER PLANS.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECTION 14.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LEGAL AND REGULATORY REQUIREMENTS.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECTION 15.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WITHHOLDING TAXES.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(a)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Withholding Taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(b)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share Withholding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECTION 16.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OTHER PROVISIONS APPLICABLE TO AWARDS.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(a)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transferability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(b)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Performance Criteria</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECTION 17.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NO EMPLOYMENT RIGHTS.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECTION 18.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 409A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECTION 19.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DURATION AND AMENDMENTS.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(a)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term of the Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(b)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Right to Amend or Terminate the Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">(c)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of Termination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECTION 20.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AWARDS TO <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> PARTICIPANTS.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECTION 21.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FORFEITURE, CANCELLATION OR CLAWBACK OF AWARDS.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECTION 22.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GOVERNING LAW.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-
iv - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PLUS THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2020 STOCK INCENTIVE PLAN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 1.
ESTABLISHMENT AND PURPOSE. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Plan was adopted by the Board of Directors on April&nbsp;30, 2020 and approved by the
Company&#146;s stockholders on June&nbsp;16, 2020. The Plan was amended and restated by the Board of Directors on March&nbsp;22, 2021, subject to approval of the Company&#146;s stockholders, which approval occurred on May&nbsp;17, 2021. The Plan was
further amended and restated by the Board of Directors on March&nbsp;28, 2022, subject to approval of the Company&#146;s stockholders, which approval was obtained on May&nbsp;16, 2022. The Plan was further amended and restated by the Board of
Directors on February&nbsp;24, 2023, subject to approval of the Company&#146;s stockholders. The Plan was initially effective upon approval by the stockholders of the Company on the Effective Date. The Plan is a successor to the 2014 Equity
Incentive Plan of Plus Therapeutics, Inc. (the &#147;Predecessor Plan&#148;). From and after 12:01 a.m. Central time on the Effective Date, no additional stock awards will be granted under the Predecessor Plan. All Awards granted on or after the
Effective Date will be granted under the Plan as in effect on the date of grant of each Award. All stock awards granted under the Predecessor Plan will remain subject to the terms of the Predecessor Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Any Shares that would otherwise remain available for future grants under the Predecessor Plan as of 12:01 a.m. Central Time
on the Effective Date (the &#147;Predecessor Plan&#146;s Available Reserve&#148;) will cease to be available under the Predecessor Plan at such time. Instead, that number of Shares equal to the Predecessor Plan&#146;s Available Reserve will be added
to the Absolute Share Limit (as further described in Section&nbsp;5(a) below) and be then immediately available for grants and issuance pursuant to Awards hereunder, up to the maximum number set forth in Section&nbsp;5(a) below. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In addition, from and after 12:01 a.m. Central time on the Effective Date, with respect to the aggregate number of Shares
subject, at such time, to outstanding stock options and stock awards granted under the Predecessor Plan that (i)&nbsp;expire or terminate for any reason prior to exercise or settlement; or (ii)&nbsp;are forfeited because of the failure to meet a
contingency or condition required to vest such Shares or otherwise return to the Company (such Shares the &#147;Predecessor Plan Returning Shares&#148;) will immediately be added to the Absolute Share Limit (as further described in Section&nbsp;5(a)
below) as and when such a Share becomes a Predecessor Plan Returning Share, up to the maximum number set forth in Section&nbsp;3(a) below. For the avoidance of doubt, Predecessor Plan Returning Shares will not include any Shares subject to
outstanding stock options or stock awards granted under the Predecessor Plan that are reacquired, withheld (or not issued) to satisfy (i)&nbsp;a tax withholding obligation in connection with an award or (ii)&nbsp;the purchase price or exercise price
of an award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(b)</I> The purpose of the Plan is to promote the long-term success of the Company and the creation of stockholder value
by (a)&nbsp;encouraging Employees, Outside Directors and Consultants to focus on critical long-range objectives, (b)&nbsp;encouraging the attraction and retention of Employees, Outside Directors and Consultants with exceptional qualifications and
(c)&nbsp;linking Employees, Outside Directors and Consultants directly to stockholder interests through increased stock ownership. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 1
- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Plan seeks to achieve this purpose by providing for Awards in the form of restricted shares, stock units, options (which may constitute incentive stock options or nonstatutory stock options) or
stock appreciation rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 2. DEFINITIONS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(a)</I> <I>&#147;</I><I>Affiliate</I><I>&#148;</I> shall mean any entity other than a Subsidiary, if the Company and/or one or more
Subsidiaries own not less than 50% of such entity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(b)</I> <I>&#147;</I><I>Award</I><I>&#148;</I> shall mean any award of an Option, a
SAR, a Restricted Share or a Stock Unit under the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(c)</I> <I>&#147;</I><I>Award Agreement</I><I>&#148;</I><I> </I>shall mean a
Stock Option Agreement, SAR Agreement, Restricted Share Agreement or Stock Unit Agreement, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(d)</I> <I>&#147;</I><I>Board
of Directors</I><I>&#148;</I><I> </I>or <I>&#147;</I><I>Board</I>&#148;<I> </I>shall mean the Board of Directors of the Company, as constituted from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(e)</I> &#147;<I>Cause</I>&#148; shall mean, unless such term or an equivalent term is otherwise defined by the applicable Award Agreement
or other written agreement between a Participant and the Company, a Subsidiary or an Affiliate applicable to an Award, any of the following: (i)&nbsp;the Participant&#146;s theft, dishonesty, willful misconduct, breach of fiduciary duty for personal
profit, or falsification of any documents or records of the Company, a Subsidiary or any Affiliate; (ii)&nbsp;the Participant&#146;s material failure to abide by a code of conduct or other policies of the Company, a Subsidiary or an Affiliate
(including, without limitation, policies relating to confidentiality and reasonable workplace conduct); (iii) the Participant&#146;s unauthorized use, misappropriation, destruction or diversion of any tangible or intangible asset or corporate
opportunity of the Company, a Subsidiary or an Affiliate (including, without limitation, the Participant&#146;s improper use or disclosure of confidential or proprietary information of the Company, a Subsidiary or an Affiliate); (iv) any intentional
act by the Participant which has a material detrimental effect on the reputation or business of a Company, a Subsidiary or an Affiliate; (v)&nbsp;the Participant&#146;s repeated failure or inability to perform any reasonable assigned duties after
written notice from the Company, a Subsidiary or an Affiliate of, and a reasonable opportunity to cure, such failure or inability; (vi)&nbsp;any material breach by the Participant of any employment, service,
<FONT STYLE="white-space:nowrap">non-disclosure,</FONT> <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation</FONT> or other similar agreement between the Participant and the Company, a
Subsidiary or an Affiliate, which breach is not cured pursuant to the terms of such agreement; or (vii)&nbsp;the Participant&#146;s conviction (including any plea of guilty or nolo contendere) of any criminal act involving fraud, dishonesty,
misappropriation or moral turpitude, or which impairs the Participant&#146;s ability to perform his or her duties with the Company, a Subsidiary or an Affiliate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(f)</I> <I>&#147;</I><I>Change in Control</I><I>&#148;</I> shall mean the occurrence of any of the following events: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) A change in the composition of the Board of Directors occurs, as a result of which fewer than <FONT
STYLE="white-space:nowrap">one-half</FONT> of the incumbent directors are directors who either: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2
- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) Had been directors of the Company on the &#147;look-back date&#148; (as
defined below) (the &#147;original directors&#148;); or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) Were elected, or nominated for election, to the Board of
Directors with the affirmative votes of at least a majority of the aggregate of the original directors who were still in office at the time of the election or nomination and the directors whose election or nomination was previously so approved (the
&#147;continuing directors&#148;); or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Any &#147;person&#148; (as defined below) who by the acquisition or aggregation
of securities, is or becomes the &#147;beneficial owner&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act), directly or indirectly, of securities of the Company representing 50% or more of the combined
voting power of the Company&#146;s then outstanding securities ordinarily (and apart from rights accruing under special circumstances) having the right to vote at elections of directors (the &#147;Base Capital Stock&#148;); except that any change in
the relative beneficial ownership of the Company&#146;s securities by any person resulting solely from a reduction in the aggregate number of outstanding shares of Base Capital Stock, and any decrease thereafter in such person&#146;s ownership of
securities, shall be disregarded until such person increases in any manner, directly or indirectly, such person&#146;s beneficial ownership of any securities of the Company; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The consummation of a merger or consolidation of the Company with or into another entity or any other corporate
reorganization, if persons who were not stockholders of the Company immediately prior to such merger, consolidation or other reorganization own immediately after such merger, consolidation or other reorganization 50% or more of the voting power of
the outstanding securities of each of (A)&nbsp;the continuing or surviving entity and (B)&nbsp;any direct or indirect parent corporation of such continuing or surviving entity; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) The sale, transfer or other disposition of all or substantially all of the Company&#146;s assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of subsection 2.f)i) above, the term &#147;look-back&#148; date shall mean the date 24 months prior to the date of the event that
may constitute a Change in Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of subsection 2.f)iii)) above, the term &#147;person&#148; shall have the same meaning
as when used in Sections 13(d) and 14(d) of the Exchange Act but shall exclude (1)&nbsp;a trustee or other fiduciary holding securities under an employee benefit plan maintained by the Company or a Parent or Subsidiary and (2)&nbsp;a corporation
owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of the Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any other provision of this Section&nbsp;2.f) notwithstanding, a transaction shall not constitute a Change in Control if its sole purpose is
to change the state of the Company&#146;s incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&#146;s securities immediately before such transaction, and a Change
in Control shall not be deemed to occur if the Company files a registration statement with the United States Securities and Exchange Commission for the offering of securities or debt to the public. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3
- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(g)</I> <I>&#147;</I><I>Code</I><I>&#148;</I> shall mean the Internal Revenue Code of
1986, as amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(h)</I> <I>&#147;</I><I>Committee</I><I>&#148;</I> shall mean the Compensation Committee as designated by the Board
of Directors, which is authorized to administer the Plan, as described in Section&nbsp;3 hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(</I><I>i</I><I>)</I>
<I>&#147;</I><I>Company</I><I>&#148;</I> shall mean Plus Therapeutics, Inc., a Delaware corporation, or any successor corporation thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(j)</I> <I>&#147;</I><I>Consultant</I><I>&#148;</I> shall mean an individual who is a consultant or advisor and who provides bona fide
services to the Company, a Parent, a Subsidiary or an Affiliate as an independent contractor (not including service as a member of the Board of Directors) or a member of the board of directors of a Parent or a Subsidiary, in each case who is not an
Employee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(k)</I> <I>&#147;</I><I>Disability</I><I>&#148;</I> shall mean any permanent and total disability as defined by section
22(e)(3) of the Code </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(l)</I> <I>&#147;</I><I>Effective Date</I>&#148; shall mean the effective date of this Plan document, which is the
date of the annual meeting of stockholders of the Company held in 2020. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(m)</I> <I>&#147;</I><I>Employee</I><I>&#148;</I> shall mean
any individual who is a <FONT STYLE="white-space:nowrap">common-law</FONT> employee of the Company, a Parent, a Subsidiary or an Affiliate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(n)</I> <I>&#147;</I><I>Exchange Act</I><I>&#148;</I> shall mean the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(o)</I> <I>&#147;</I><I>Exercise Price</I><I>&#148;</I> shall mean, in the case of an Option, the
amount for which one Share may be purchased upon exercise of such Option, as specified in the applicable Stock Option Agreement. &#147;Exercise Price,&#148; in the case of a SAR, shall mean an amount, as specified in the applicable SAR Agreement,
which is subtracted from the Fair Market Value of one Share in determining the amount payable upon exercise of such SAR. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(p)</I>
<I>&#147;</I><I>Fair Market Value</I><I>&#148;</I> with respect to a Share, shall mean the market price of one Share, determined by the Committee as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) If the Stock was traded <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> on
the date in question, then the Fair Market Value shall be equal to the last transaction price quoted for such date by the OTC Bulletin Board or, if not so quoted, shall be equal to the mean between the last reported representative bid and asked
prices quoted for such date by the principal automated inter-dealer quotation system on which the Stock is quoted or, if the Stock is not quoted on any such system, by the Pink Sheets LLC; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) If the Stock was traded on any established stock exchange (such as The Nasdaq Global Market, The Nasdaq Global Select
Market or the New York Stock Exchange) or national market system on the date in question, then the Fair Market Value shall be equal to the closing price reported for such date by the applicable exchange or system; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4
- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) If none of the foregoing provisions is applicable, then the Fair
Market Value shall be determined by the Committee in good faith on such basis as it deems appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In all cases, the determination of Fair Market
Value by the Committee shall be conclusive and binding on all persons. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(q)</I> <I>&#147;</I><I>ISO</I><I>&#148;</I> shall mean an
employee incentive stock option described in Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(r)</I> <I>&#147;</I><I>Nonstatutory</I><I>
Option</I><I>&#148;</I> or <I>&#147;</I><I>NSO</I><I>&#148;</I> shall mean an employee stock option that is not an ISO. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(s)</I>
<I>&#147;</I><I>Offeree</I><I>&#148;</I> shall mean an individual to whom the Committee has offered the right to acquire Shares under the Plan (other than upon exercise of an Option or SAR). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(t)</I> <I>&#147;</I><I>Option</I><I>&#148;</I> shall mean an ISO or Nonstatutory Option granted under the Plan and entitling the holder to
purchase Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(u)</I> <I>&#147;</I><I>Optionee</I><I>&#148;</I> shall mean the holder of an Option or SAR. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(v)</I> <I>&#147;</I><I>Outside Director</I><I>&#148;</I> shall mean a member of the Board of Directors who is not a <FONT
STYLE="white-space:nowrap">common-law</FONT> employee of, or paid consultant to, the Company, a Parent or a Subsidiary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(w)</I>
<I>&#147;</I><I>Parent</I><I>&#148;</I> shall mean any corporation (other than the Company) in an unbroken chain of corporations ending with the Company, if each of the corporations other than the Company owns stock possessing 50% or more of the
total combined voting power of all classes of stock in one of the other corporations in such chain. A corporation that attains the status of a Parent on a date after the adoption of the Plan shall be a Parent commencing as of such date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(x)</I> <I>&#147;</I><I>Participant</I><I>&#148;</I> shall mean the holder of an Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(y)</I> <I>&#147;</I><I>Plan</I><I>&#148;</I> shall mean this 2020 Stock Incentive Plan of Plus Therapeutics, Inc., as amended from time to
time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(z)</I> <I>&#147;</I><I>Purchase Price</I><I>&#148;</I> shall mean the consideration for which one Share may be acquired under
the Plan (other than upon exercise of an Option or SAR), as specified by the Committee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(aa)</I> <I>&#147;</I><I>Restricted
Share</I><I>&#148;</I> shall mean a Share awarded under the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(bb)</I> <I>&#147;</I><I>Restricted Share Agreement</I><I>&#148;</I>
shall mean the agreement between the Company and the recipient of a Restricted Share which contains the terms, conditions and restrictions pertaining to such Restricted Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(cc)</I> <I>&#147;</I><I>SAR</I><I>&#148;</I> shall mean a stock appreciation right granted under the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(</I><I>dd</I><I>)</I> <I>&#147;</I><I>SAR Agreement</I><I>&#148;</I> shall mean the agreement between the Company and an Optionee which
contains the terms, conditions and restrictions pertaining to his or her SAR. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5
- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(</I><I>ee</I><I>)</I> <I>&#147;</I><I>Service</I><I>&#148;</I> shall mean service as an
Employee, Consultant or Outside Director, subject to such further limitations as may be set forth in the Plan or the applicable Stock Option Agreement, SAR Agreement, Restricted Share Agreement or Stock Unit Agreement, and as determined in the sole
discretion of the Committee. Service does not terminate when an Employee goes on a bona fide leave of absence, that was approved by the Company in writing, if the terms of the leave provide for continued Service crediting, or when continued service
crediting is required by applicable law. However, for purposes of determining whether an Option is entitled to ISO status, an Employee&#146;s Service will be treated as terminating three months after such Employee went on leave, unless such
Employee&#146;s right to return to active work is guaranteed by law or by a contract. Service terminates in any event when the approved leave ends, unless such Employee immediately returns to active work. The Company determines which leaves count
toward Service, and when Service terminates for all purposes under the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(</I><I>ff</I><I>)</I>
<I>&#147;</I><I>Share</I><I>&#148;</I> shall mean one share of Stock, as adjusted in accordance with Section&nbsp;11 (if applicable). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(gg)</I> <I>&#147;</I><I>Stock</I><I>&#148;</I> shall mean the Common Stock of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(</I><I>hh</I><I>)</I> <I>&#147;</I><I>Stock Option Agreement</I><I>&#148;</I> shall mean the agreement between the Company and an Optionee
that contains the terms, conditions and restrictions pertaining to such Option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(ii)</I> <I>&#147;</I><I>Stock Unit</I><I>&#148;</I>
shall mean a bookkeeping entry representing the Company&#146;s obligation to deliver one Share (or distribute cash) on a future date in accordance with the provisions of a Stock Unit Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(</I><I>jj</I><I>)</I> <I>&#147;</I><I>Stock Unit Agreement</I><I>&#148;</I> shall mean the agreement between the Company and the recipient
of a Stock Unit which contains the terms, conditions and restrictions pertaining to such Stock Unit. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(</I><I>kk</I><I>)</I>
<I>&#147;</I><I>Subsidiary</I><I>&#148;</I> shall mean any corporation, if the Company and/or one or more other Subsidiaries own not less than 50% of the total combined voting power of all classes of outstanding stock of such corporation. A
corporation that attains the status of a Subsidiary on a date after the adoption of the Plan shall be considered a Subsidiary commencing as of such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 3. ADMINISTRATION. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(a)</I>
<I>Committee Composition</I>. The Plan shall be administered by a Committee appointed by the Board of Directors, or by the Board of Directors acting as the Committee. The Committee shall consist of two or more directors of the Company. In addition,
the composition of the Committee shall satisfy such requirements as the Securities and Exchange Commission may establish for administrators acting under plans intended to qualify for exemption under Rule <FONT STYLE="white-space:nowrap">16b-3</FONT>
(or its successor) under the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(b)</I> <I>Committee for <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Grants</I>. The
Board of Directors may also appoint one or more separate committees of the Board, each composed of one or more directors of the Company who need not satisfy the requirements of Section&nbsp;3.a), who may administer the Plan with respect to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6
- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Employees who are not considered officers or directors of the Company under Section&nbsp;16 of the Exchange Act, may grant Awards under the Plan to such Employees and may determine all terms of
such grants. Within the limitations of the preceding sentence, any reference in the Plan to the Committee shall include such committee or committees appointed pursuant to the preceding sentence. To the extent permitted by applicable law, the Board
of Directors may also authorize one or more officers of the Company to designate Employees, other than officers under Section&nbsp;16 of the Exchange Act, to receive Awards and/or to determine the number of such Awards to be received by such
persons; provided, however, that the Board of Directors shall specify the total number of Awards that such officers may so award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(c)</I> <I>Committee Procedures</I>. The Board of Directors shall designate one of the members of the Committee as chairman. The Committee
may hold meetings at such times and places as it shall determine. The acts of a majority of the Committee members present at meetings at which a quorum exists, or acts reduced to or approved in writing (including via email) by all Committee members,
shall be valid acts of the Committee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(d)</I> <I>Committee Responsibilities</I>. Subject to the provisions of the Plan, the Committee
shall have full authority and discretion to take the following actions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) To interpret the Plan and to apply its
provisions; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) To adopt, amend or rescind rules, procedures and forms relating to the Plan; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) To adopt, amend or terminate <FONT STYLE="white-space:nowrap">sub-plans</FONT> established for the purpose of satisfying
applicable foreign laws including qualifying for preferred tax treatment under applicable foreign tax laws; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) To
authorize any person to execute, on behalf of the Company, any instrument required to carry out the purposes of the Plan; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) To determine when Awards are to be granted under the Plan; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) To select the Offerees, Optionees and Participants; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) To determine the type of Award and number of Shares or amount of cash to be made subject to each Award; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) To prescribe the terms and conditions of each Award, including (without limitation) the Exercise Price and Purchase
Price, and the vesting or duration of the Award (including accelerating the vesting of Awards, either at the time of the Award or thereafter, without the consent of the Participant), to determine whether an Option is to be classified as an ISO or as
a Nonstatutory Option, and to specify the provisions of the agreement relating to such Award; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7
- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) To amend any outstanding Award Agreement, subject to applicable legal
restrictions and to the consent of the Participant if the Participant&#146;s rights or obligations would be materially impaired; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) To prescribe the consideration for the grant of each Award or other right under the Plan and to determine the sufficiency
of such consideration; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) To determine the disposition of each Award or other right under the Plan in the event of a
Participant&#146;s divorce or dissolution of marriage; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) To determine whether Awards under the Plan will be granted in
replacement of other grants under an incentive or other compensation plan of an acquired business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) To correct any
defect, supply any omission, or reconcile any inconsistency in the Plan or any Award Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv) To establish or
verify the extent of satisfaction of any performance goals or other conditions applicable to the grant, issuance, exercisability, vesting and/or ability to retain any Award; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xv) To take any other actions deemed necessary or advisable for the administration of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the requirements of applicable law, the Committee may designate persons other than members of the Committee to carry out its responsibilities and
may prescribe such conditions and limitations as it may deem appropriate, except that the Committee may not delegate its authority with regard to the selection for participation of or the granting of Awards under the Plan to persons subject to
Section&nbsp;16 of the Exchange Act. All decisions, interpretations and other actions of the Committee shall be final and binding on all Offerees, all Optionees, all Participants and all persons deriving their rights from an Offeree, Optionee or
Participant. No member of the Committee shall be liable for any action that he has taken or has failed to take in good faith with respect to the Plan, any Award, or any right to acquire Shares under the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(e)</I> <I>Cancellation and <FONT STYLE="white-space:nowrap">Re-Grant</FONT> of Stock Awards</I>. Notwithstanding any contrary provision of
the Plan, neither the Committee nor its designees shall have the authority to: (i)&nbsp;amend the terms of outstanding Options or SARs to reduce the Exercise Price thereof, or (ii)&nbsp;cancel outstanding Options or SARs with an Exercise Price above
the current Fair Market Value per Share in exchange for another Option or SAR with a lower exercise price or for another Award or for cash, unless the stockholders of the Company have previously approved such an action or such action relates to an
adjustment pursuant to Section&nbsp;11. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 4. ELIGIBILITY. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(a)</I> <I>General Rule</I>. Only <FONT STYLE="white-space:nowrap">common-law</FONT> employees of the Company, a Parent or a Subsidiary
shall be eligible for the grant of ISOs. Only Employees, Consultants and Outside Directors shall be eligible for the grant of Restricted Shares, Stock Units, Nonstatutory Options or SARs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8
- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(b)</I> <I>Limit on Grants to Outside Directors</I>. Notwithstanding any other provision
of the Plan to the contrary, the Board of Directors may establish compensation for Outside Directors from time to time, subject to the limitations in the Plan. The Board of Directors will from time to time determine the terms, conditions and amounts
of all such Outside Director compensation in its discretion and pursuant to the exercise of its business judgment, taking into account such factors, circumstances and considerations as it shall deem relevant from time to time, provided that the sum
of any cash compensation, or other compensation, and the value (determined as of the grant date in accordance with Financial Accounting Standards Board Accounting Standards Codification of Topic 718, or any successor thereto) of Awards granted to
Outside Directors as compensation for services as an Outside Director during any calendar year of the Company may not exceed $500,000 (increased to $700,000 in the calendar year of his or her initial service as an Outside Director). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(c)</I> <I><FONT STYLE="white-space:nowrap">Ten-Percent</FONT> Stockholders</I>. An Employee who owns more than 10% of the total combined
voting power of all classes of outstanding stock of the Company, a Parent or Subsidiary shall not be eligible for the grant of an ISO unless such grant satisfies the requirements of Section&nbsp;422(c)(5) of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(d)</I> <I>Attribution Rules</I>. For purposes of Section&nbsp;4.c) above, in determining stock ownership, an Employee shall be deemed to
own the stock owned, directly or indirectly, by or for such Employee&#146;s brothers, sisters, spouse, ancestors and lineal descendants. Stock owned, directly or indirectly, by or for a corporation, partnership, estate or trust shall be deemed to be
owned proportionately by or for its stockholders, partners or beneficiaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(e)</I> <I>Outstanding Stock</I>. For purposes of
Section&nbsp;4.c) above, &#147;outstanding stock&#148; shall include all stock actually issued and outstanding immediately after the grant. &#147;Outstanding stock&#148; shall not include shares authorized for issuance under outstanding options held
by the Employee or by any other person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 5. STOCK SUBJECT TO PLAN. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(a)</I> <I>Basic Limitation</I>. Shares offered under the Plan shall be authorized but unissued Shares or treasury Shares. Subject to
Section&nbsp;5.b) below, the maximum aggregate number of Shares authorized for issuance as Awards under the Plan shall not exceed 4,659,286 Shares, which is the sum of (i) 550,000 Shares approved at the Company&#146;s 2020 annual meeting of
stockholders, <I>plus </I>(ii) 1,000,000 Shares approved at the Company&#146;s 2021 annual meeting of stockholders, <I>plus</I> (iii) 2,000,000 Shares approved at the Company&#146;s 2022 annual meeting of stockholders, <I>plus</I> (iv) 1,000,000
Shares approved at the Company&#146;s 2023 annual meeting of stockholders, (v)&nbsp;the number of shares subject to the Predecessor Plan&#146;s Available Reserve, <I>plus</I> (vi)&nbsp;the number of shares that are Predecessor Plan Returning Shares,
as such shares become available from time to time (the &#147;Absolute Share Limit&#148;). The number of Shares that may be delivered in the aggregate pursuant to the exercise of ISOs granted under the Plan shall not exceed 4,000,000 Shares plus, to
the extent allowable under Section&nbsp;422 of the Code and the Treasury Regulations promulgated thereunder, any Shares that become available for issuance under the Plan pursuant to Section&nbsp;5.b). The limitations of this Section&nbsp;5.a) shall
be subject to adjustment pursuant to Section&nbsp;11. The number of Shares that are subject to Options or other Awards outstanding at any time under the Plan shall not exceed the number of Shares </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 9
- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which then remain available for issuance under the Plan. The Company shall at all times reserve and keep available sufficient Shares to satisfy the requirements of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(b)</I> <I>Additional Shares</I>. If Restricted Shares are forfeited, then such Shares shall again become available for Awards under the
Plan. If Stock Units, Options or SARs are forfeited or terminate for any reason before being exercised or settled, then the corresponding Shares shall again become available for Awards under the Plan. If Stock Units are settled, then only the number
of Shares (if any) actually issued in settlement of such Stock Units shall reduce the number available in Section SECTION 5(a) and the balance shall again become available for Awards under the Plan. The full number of Options exercised shall be
counted against the number of Shares available for Awards under the Plan, regardless of the number of Shares actually issued upon exercise of such Options. The full number of SARs settled shall be counted against the number of Shares available for
Awards under the Plan, regardless of the number of Shares actually issued in settlement of such SARs. For the avoidance of doubt, any Shares withheld to satisfy the exercise price or tax withholding obligation pursuant to any Award shall not be
added to the Shares available for Awards under the Plan. Notwithstanding the foregoing provisions of this Section SECTION 5(b), Shares that have actually been issued shall not again become available for Awards under the Plan, except for Restricted
Shares that are forfeited and do not become vested. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(c)</I> <I>Substitution and Assumption of Awards</I><I>. </I>The Committee may make
Awards under the Plan by assumption, substitution or replacement of stock options, stock appreciation rights, stock units or similar awards granted by another entity (including a Parent or Subsidiary), if such assumption, substitution or replacement
is in connection with an asset acquisition, stock acquisition, merger, consolidation or similar transaction involving the Company (and/or its Parent or Subsidiary) and such other entity (and/or its affiliate). The terms of such assumed, substituted
or replaced Awards shall be as the Committee, in its discretion, determines is appropriate, notwithstanding limitations on Awards in the Plan. Any such substitute or assumed Awards shall not count against the Absolute Share Limit set forth in
Section&nbsp;5.a) (nor shall Shares subject to such Awards be added to the Shares available for Awards under the Plan as provided in Section&nbsp;5.b) above), except that Shares acquired by exercise of substitute ISOs will count against the maximum
number of Shares that may be issued pursuant to the exercise of ISOs under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 6. RESTRICTED SHARES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(a)</I> <I>Restricted Stock Agreement</I>. Each grant of Restricted Shares under the Plan shall be evidenced by a Restricted Stock Agreement
between the recipient and the Company. Such Restricted Shares shall be subject to all applicable terms of the Plan and may be subject to any other terms that are not inconsistent with the Plan. The provisions of the various Restricted Stock
Agreements entered into under the Plan need not be identical. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(b)</I> <I>Payment for Awards</I>. Restricted Shares may be sold or
awarded under the Plan for such consideration as the Committee may determine, including (without limitation) cash, cash equivalents, full-recourse promissory notes, past services and future services. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(c)</I> <I>Vesting</I>. Each Award of Restricted Shares may or may not be subject to vesting. Vesting shall occur, in full or in
installments, upon satisfaction of the conditions specified in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-
10 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Restricted Stock Agreement. A Restricted Stock Agreement may provide for accelerated vesting in the event of the Participant&#146;s death, Disability or retirement or other events. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(d)</I> <I>Voting and Dividend Rights</I>. The holders of Restricted Shares awarded under the Plan shall have the same voting, dividend and
other rights as the Company&#146;s other stockholders. Holders of Restricted Shares must invest any cash dividends received in additional Restricted Shares. Such additional Restricted Shares shall be subject to the same conditions and restrictions
(including without limitation, any forfeiture conditions) as the Award with respect to which the dividends were paid. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(e)</I>
<I>Restrictions on Transfer of Shares</I>. Restricted Shares shall be subject to such rights of repurchase, rights of first refusal or other restrictions as the Committee may determine. Such restrictions shall be set forth in the applicable
Restricted Stock Agreement and shall apply in addition to any general restrictions that may apply to all holders of Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 7. TERMS AND
CONDITIONS OF OPTIONS. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(a)</I> <I>Stock Option Agreement</I>. Each grant of an Option under the Plan shall be evidenced by a Stock
Option Agreement between the Optionee and the Company. Such Option shall be subject to all applicable terms and conditions of the Plan and may be subject to any other terms and conditions which are not inconsistent with the Plan and which the
Committee deems appropriate for inclusion in a Stock Option Agreement. The Stock Option Agreement shall specify whether the Option is an ISO or an NSO. The provisions of the various Stock Option Agreements entered into under the Plan need not be
identical. Options may be granted in consideration of a reduction in the Participant&#146;s other compensation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(b)</I> <I>Number of
Shares</I>. Each Stock Option Agreement shall specify the number of Shares that are subject to the Option and shall provide for the adjustment of such number in accordance with Section&nbsp;11. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(c)</I> <I>Exercise Price</I>. Each Stock Option Agreement shall specify the Exercise Price. The Exercise Price of an ISO shall not be less
than 100% of the Fair Market Value of a Share on the date of grant, except as otherwise provided in 4(c), and the Exercise Price of an NSO shall not be less 100% of the Fair Market Value of a Share on the date of grant. Notwithstanding the
foregoing, Options may be granted with an Exercise Price of less than 100% of the Fair Market Value of a Share on the date of grant pursuant to a transaction described in, and in a manner consistent with, Section&nbsp;424(a) of the Code. Subject to
the foregoing in this Section&nbsp;7.c), the Exercise Price under any Option shall be determined by the Committee at its sole discretion. The Exercise Price shall be payable in one of the forms described in Section&nbsp;8. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(d)</I> <I>Withholding Taxes</I>. As a condition to the exercise of an Option, the Optionee shall make such arrangements as the Committee
may require for the satisfaction of any federal, state, local or foreign withholding tax obligations that may arise in connection with such exercise. The Optionee shall also make such arrangements as the Committee may require for the satisfaction of
any federal, state, local or foreign withholding tax obligations that may arise in connection with the disposition of Shares acquired by exercising an Option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-
11 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(e)</I> <I>Exercisability and Term</I>. Each Stock Option Agreement shall specify the
date when all or any installment of the Option is to become exercisable. The Stock Option Agreement shall also specify the term of the Option; provided that the term of an ISO shall in no event exceed 10 years from the date of grant (five years for
Employees described in Section&nbsp;4.c)). A Stock Option Agreement may provide for accelerated exercisability in the event of the Optionee&#146;s death, Disability, or retirement or other events and may provide for expiration prior to the end of
its term in the event of the termination of the Optionee&#146;s Service. Options may be awarded in combination with SARs, and such an Award may provide that the Options will not be exercisable unless the related SARs are forfeited. Subject to the
foregoing in this Section&nbsp;7(e), the Committee at its sole discretion shall determine when all or any installment of an Option is to become exercisable and when an Option is to expire. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(f)</I> <I>Exercise of Options</I>. Each Stock Option Agreement shall set forth the extent to which the Optionee shall have the right to
exercise the Option following termination of the Optionee&#146;s Service with the Company and its Subsidiaries, and the right to exercise the Option of any executors or administrators of the Optionee&#146;s estate or any person who has acquired such
Option(s) directly from the Optionee by bequest or inheritance. Such provisions shall be determined in the sole discretion of the Committee, need not be uniform among all Options issued pursuant to the Plan, and may reflect distinctions based on the
reasons for termination of Service. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(g) No Rights as a Stockholder</I><I>.</I><I> </I>An Optionee, or a transferee of an Optionee,
shall have no rights (including voting, dividend and other rights) as a stockholder with respect to any Shares covered by his Option until such person has satisfied all of the terms and conditions to receive such Shares, has satisfied any applicable
withholding or tax obligations relating to the Award and the Shares have been issued (as evidenced by an appropriate entry on the books of the Company or a duly authorized transfer agent of the Company). The Company will issue (or cause to be
issued) such Shares promptly after the Option is exercised. No adjustments shall be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Section&nbsp;11. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(h)</I> <I>Modification or Extension of Options</I>. Within the limitations of the Plan, the Committee may modify or, extend outstanding
Options or may accept the cancellation of outstanding Options (to the extent not previously exercised), whether or not granted hereunder, in return for the grant of new Options for the same or a different number of Shares and at the same or a
different Exercise Price; provided, however, that other than in connection with an adjustment of Awards pursuant to Section&nbsp;11, the Committee may not modify outstanding Options to lower the Exercise Price nor may the Committee assume or accept
the cancellation of outstanding Options in return for cash or the grant of new Options or SARs with a lower Exercise Price, unless such action has been approved by the Company&#146;s stockholders. The foregoing notwithstanding, no modification of an
Option shall, without the consent of the Optionee, materially impair his or her rights or obligations under such Option. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(</I><I>i</I><I>)</I> <I>Restrictions on Transfer of Shares</I>. Any Shares issued upon exercise of an Option shall be subject to such
special forfeiture conditions, rights of repurchase, rights of first refusal and other transfer restrictions as the Committee may determine. Such restrictions shall be set forth in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-
12 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable Stock Option Agreement and shall apply in addition to any general restrictions that may apply to all holders of Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(j)</I> <I>Buyout Provisions</I>. Except with respect to an Option whose Exercise Price exceeds the Fair Market Value of the Shares subject
to the Option, the Committee may at any time (a)&nbsp;offer to buy out for a payment in cash or cash equivalents an Option previously granted or (b)&nbsp;authorize an Optionee to elect to cash out an Option previously granted, in either case at such
time and based upon such terms and conditions as the Committee shall establish. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 8. PAYMENT FOR SHARES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(a)</I> <I>General Rule</I>. The entire Exercise Price or Purchase Price of Shares issued under the Plan shall be payable in lawful money of
the United States of America at the time when such Shares are purchased, except as provided in Section&nbsp;8.b) through Section&nbsp;8.h) below. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(b)</I> <I>Surrender of Stock</I>. To the extent that a Stock Option Agreement so provides, payment may be made all or in part by
surrendering, or attesting to the ownership of, Shares which have already been owned by the Optionee or his representative. Such Shares shall be valued at their Fair Market Value on the date when the new Shares are purchased under the Plan. The
Optionee shall not surrender, or attest to the ownership of, Shares in payment of the Exercise Price if such action would cause the Company to recognize compensation expense (or additional compensation expense) with respect to the Option for
financial reporting purposes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(c)</I> <I>Services Rendered</I>. At the discretion of the Committee, Shares may be awarded under the
Plan in consideration of services rendered to the Company or a Subsidiary prior to the award. If Shares are awarded without the payment of a Purchase Price in cash, the Committee shall make a determination (at the time of the Award) of the value of
the services rendered by the Offeree and the sufficiency of the consideration to meet the requirements of Section&nbsp;6.b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(d)</I>
<I>Cashless Exercise</I>. To the extent that a Stock Option Agreement so provides, payment may be made all or in part by delivery (on a form prescribed by the Committee) of an irrevocable direction to a securities broker to sell Shares and to
deliver all or part of the sale proceeds to the Company in payment of the aggregate Exercise Price. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(e)</I> <I>Exercise/Pledge</I>. To
the extent that a Stock Option Agreement so provides, payment may be made all or in part by delivery (on a form prescribed by the Committee) of an irrevocable direction to a securities broker or lender to pledge Shares, as security for a loan, and
to deliver all or part of the loan proceeds to the Company in payment of the aggregate Exercise Price. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(f)</I> <I>Net Exercise</I>. To
the extent that a Stock Option Agreement so provides, payment may be made by a &#147;net exercise&#148; arrangement pursuant to which the number of Shares issuable upon exercise of the Option shall be reduced by the largest whole number of Shares
having an aggregate Fair Market Value that does not exceed the aggregate Exercise Price (plus tax withholdings, if applicable) and any remaining balance of the aggregate Exercise Price (and/or applicable tax withholdings) not satisfied by such
reduction in the number of whole Shares to be issued shall be paid by the Optionee in cash or other form of payment permitted under the Stock Option Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-
13 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(g)</I> <I>Promissory Note</I>. To the extent that a Stock Option Agreement or Restricted
Stock Agreement so provides, payment may be made all or in part by delivering (on a form prescribed by the Company) a full-recourse promissory note. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(h)</I> <I>Other Forms of Payment</I>. To the extent that a Stock Option Agreement or Restricted Stock Agreement so provides, payment may be
made in any other form that is consistent with applicable laws, regulations and rules. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(</I><I>i</I><I>)</I> <I>Limitations under
Applicable Law</I>. Notwithstanding anything herein or in a Stock Option Agreement or Restricted Stock Agreement to the contrary, payment may not be made in any form that is unlawful, as determined by the Committee in its sole discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 9. STOCK APPRECIATION RIGHTS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(a) SAR Agreement</I>. Each grant of a SAR under the Plan shall be evidenced by a SAR Agreement between the Optionee and the Company. Such
SAR shall be subject to all applicable terms of the Plan and may be subject to any other terms that are not inconsistent with the Plan. The provisions of the various SAR Agreements entered into under the Plan need not be identical. SARs may be
granted in consideration of a reduction in the Participant&#146;s other compensation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(b)</I> <I>Number of Shares</I>. Each SAR
Agreement shall specify the number of Shares to which the SAR pertains and shall provide for the adjustment of such number in accordance with Section&nbsp;11. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(c)</I> <I>Exercise Price</I>. Each SAR Agreement shall specify the Exercise Price. The Exercise Price of a SAR shall not be less than 100%
of the Fair Market Value of a Share on the date of grant. Notwithstanding the foregoing, SARs may be granted with an Exercise Price of less than 100% of the Fair Market Value of a Share on the date of grant pursuant to a transaction described in,
and in a manner consistent with, Section&nbsp;424(a) of the Code. Subject to the foregoing in this Section&nbsp;9.c), the Exercise Price under any SAR shall be determined by the Committee in its sole discretion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(d)</I> <I>Exercisability and Term</I>. Each SAR Agreement shall specify the date when all or any installment of the SAR is to become
exercisable. The SAR Agreement shall also specify the term of the SAR. A SAR Agreement may provide for accelerated exercisability in the event of the Participant&#146;s death, Disability or retirement or other events and may provide for expiration
prior to the end of its term in the event of the termination of the Participant&#146;s service. SARs may be awarded in combination with Options, and such an Award may provide that the SARs will not be exercisable unless the related Options are
forfeited. A SAR may be included in an ISO only at the time of grant but may be included in an NSO at the time of grant or thereafter. A SAR granted under the Plan may provide that it will be exercisable only in the event of a Change in Control.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(e)</I> <I>No Rights as</I> a <I>Stockholder</I><I>. </I>A Participant, or a transferee of a Participant, shall have no rights
(including voting, dividend and other rights) as a stockholder with respect to any Shares pertaining to his SAR until the date such person has satisfied all of the terms and conditions to receive such Shares, has satisfied any applicable withholding
or tax obligations relating to the Award and any Shares have been issued pursuant to the SAR (to the extent the SAR is settled in Shares and as evidenced by an appropriate entry on the books of the Company or a duly authorized transfer agent of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-
14 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company). No adjustments shall be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Section&nbsp;11. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(f)</I> <I>Exercise of SARs</I>. Upon exercise of a SAR, the Optionee (or any person having the right to exercise the SAR after his or her
death) shall receive from the Company (a)&nbsp;Shares, (b) cash or (c)&nbsp;a combination of Shares and cash, as the Committee shall determine. The amount of cash and/or the Fair Market Value of Shares received upon exercise of SARs shall, in the
aggregate, be equal to the amount by which the Fair Market Value (on the date of surrender) of the Shares subject to the SARs exceeds the Exercise Price. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(g)</I> <I>Modification, Extension or Assumption of SARs</I>. Within the limitations of the Plan, the Committee may modify, extend or assume
outstanding SARs or may accept the cancellation of outstanding SARs (whether granted by the Company or by another issuer) in return for the grant of new SARs for the same or a different number of Shares and at the same or a different Exercise Price;
provided, however, that other than in connection with an adjustment of Awards pursuant to Section&nbsp;11, the Committee may not modify outstanding SARs to lower the Exercise Price nor may the Committee assume or accept the cancellation of
outstanding SARs in return for cash or the grant of new Options or SARs with a lower Exercise Price, unless such action has been approved by the Company&#146;s stockholders. The foregoing notwithstanding, no modification of a SAR shall, without the
consent of the holder, materially impair his or her rights or obligations under such SAR. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(h)</I> <I>Buyout Provisions</I>. Except with
respect to a SAR whose Exercise Price exceeds the Fair Market Value of the Shares subject to the SAR, the Committee may at any time (a)&nbsp;offer to buy out for a payment in cash or cash equivalents a SAR previously granted, or (b)&nbsp;authorize
an Optionee to elect to cash out a SAR previously granted, in either case at such time and based upon such terms and conditions as the Committee shall establish. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 10. STOCK UNITS. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(a)</I>
<I>Stock Unit Agreement</I>. Each grant of Stock Units under the Plan shall be evidenced by a Stock Unit Agreement between the recipient and the Company. Stock Units shall be subject to all applicable terms of the Plan and may be subject to any
other terms that are not inconsistent with the Plan. The provisions of the various Stock Unit Agreements entered into under the Plan need not be identical. Stock Units may be granted in consideration of a reduction in the Participant&#146;s other
compensation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(b)</I> <I>Payment for Awards</I>. To the extent that an Award is granted in the form of Stock Units, no cash
consideration shall be required of the Award recipients. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(c)</I> <I>Vesting Conditions</I>. Each Award of Stock Units may or may not be
subject to vesting. Vesting shall occur, in full or in installments, upon satisfaction of the conditions specified in the Stock Unit Agreement. A Stock Unit Agreement may provide for accelerated vesting in the event of the Participant&#146;s death,
Disability or retirement or other events. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(d)</I> <I>Voting and Dividend Rights</I>. The holders of Stock Units shall have no voting
rights. Prior to settlement or forfeiture, any Stock Unit awarded under the Plan may, at the Committee&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-
15 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
discretion, carry with it a right to dividend equivalents. Such right entitles the holder to be credited with an amount equal to all cash dividends paid on one Share while the Stock Unit is
outstanding. Dividend equivalents may be converted into additional Stock Units. Settlement of dividend equivalents may be made in the form of cash, in the form of Shares, or in a combination of both. Dividend equivalents shall not be distributed
prior to settlement of the Stock Unit to which the dividend equivalents pertain. Prior to distribution, any dividend equivalents which are not paid shall be subject to the same conditions and restrictions (including without limitation, any
forfeiture conditions) as the Stock Units to which they attach. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(e)</I> <I>Form and Time of Settlement of Stock Units</I>. Settlement
of vested Stock Units may be made in the form of (a)&nbsp;cash, (b) Shares or (c)&nbsp;any combination of both, as determined by the Committee. The actual number of Stock Units eligible for settlement may be larger or smaller than the number
included in the original Award, based on predetermined performance factors. Methods of converting Stock Units into cash may include (without limitation) a method based on the average Fair Market Value of Shares over a series of trading days. Vested
Stock Units may be settled in a lump sum or in installments. The distribution may occur or commence when all vesting conditions applicable to the Stock Units have been satisfied or have lapsed, or it may be deferred to any later date, subject to
compliance with Section&nbsp;409A of the Code. The amount of a deferred distribution may be increased by an interest factor or by dividend equivalents. Until an Award of Stock Units is settled, the number of such Stock Units shall be subject to
adjustment pursuant to Section&nbsp;11. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(f)</I> <I>Death of Recipient</I>. Any Stock Units Award that becomes payable after the
recipient&#146;s death shall be distributed to the recipient&#146;s beneficiary or beneficiaries. Each recipient of a Stock Units Award under the Plan shall designate one or more beneficiaries for this purpose by filing the prescribed form with the
Company. A beneficiary designation may be changed by filing the prescribed form with the Company at any time before the Award recipient&#146;s death. If no beneficiary was designated or if no designated beneficiary survives the Award recipient, then
any Stock Units Award that becomes payable after the recipient&#146;s death shall be distributed to the recipient&#146;s estate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(g)</I> <I>Creditors</I><I>&#146;</I><I> Rights</I>. A holder of Stock Units shall have no rights other than those of a general creditor of
the Company. Stock Units represent an unfunded and unsecured obligation of the Company, subject to the terms and conditions of the applicable Stock Unit Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 11. ADJUSTMENT OF SHARES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(a)</I> <I>Adjustments</I>. In the event of a subdivision of the outstanding Stock, a declaration of a dividend payable in Shares, a
declaration of a dividend payable in a form other than Shares in an amount that has a material effect on the price of Shares, a combination or consolidation of the outstanding Stock (by reclassification or otherwise) into a lesser number of Shares,
a recapitalization, a <FONT STYLE="white-space:nowrap">spin-off</FONT> or a similar occurrence, the Committee shall make appropriate and equitable adjustments in: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The class(es) and maximum number of securities available for future Awards under Section&nbsp;5; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-
16 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The class(es) and number of securities that may be issued pursuant to
the exercise of ISOs pursuant to Section&nbsp;5; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The class(es) and number of securities covered by each outstanding
Option and SAR; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) The Exercise Price under each outstanding Option and SAR; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) The classes and number of securities subject to any outstanding Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Committee will make such adjustments, and its determination will be final, binding and conclusive. Except as provided in this Section&nbsp;11, a
Participant shall have no rights by reason of any issue by the Company of stock of any class or securities convertible into stock of any class, any subdivision or consolidation of shares of stock of any class, the payment of any stock dividend or
any other increase or decrease in the number of shares of stock of any class. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(b)</I> <I>Dissolution or Liquidation</I>. To the extent
not previously exercised or settled, Options, SARs and Stock Units shall terminate immediately prior to the dissolution or liquidation of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(c)</I> <I>Reorganizations</I>. In the event that the Company is a party to a merger or other reorganization, outstanding Awards shall be
subject to the agreement of merger or reorganization. Subject to compliance with Section&nbsp;409A of the Code, such agreement shall provide for: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The continuation of the outstanding Awards by the Company, if the Company is a surviving corporation; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The assumption of the outstanding Awards by the surviving corporation or its parent or subsidiary; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The substitution by the surviving corporation or its parent or subsidiary of its own awards for the outstanding Awards;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Full exercisability or vesting and accelerated expiration of the outstanding Awards, provided, however, that the
Committee may require Participants to complete and deliver to the Company a notice of exercise before the effective date of the merger or reorganization, which exercise is contingent upon the effectiveness of such merger or reorganization; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Cancellation of the Award, to the extent not vested or not exercised prior to the effective time of the merger or
reorganization, in exchange for such cash consideration, if any, as the Committee, in its sole discretion, may consider appropriate; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) Settlement of the intrinsic value of the outstanding Awards (whether or not then vested or exercisable) in cash or cash
equivalents or equity (including cash or equity subject to deferred vesting and delivery consistent with the vesting restrictions applicable to such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-
17 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Awards or the underlying Shares) followed by cancellation of such Awards (and, for the avoidance of doubt, if as of the date of the occurrence of the transaction the Committee determines in good
faith that no amount would have been attained upon the exercise of such Award or realization of the Participant&#146;s rights, then such Award may be terminated by the Company without payment, and such amount may be delayed to the same extent that
payment of consideration to the holders of Common Stock in connection with the merger or reorganization is delayed as a result of escrows, earnouts, holdbacks or other contingencies); in each case without the Participant&#146;s consent. Any
acceleration of payment or an amount that is subject to Section&nbsp;409A of the Code will be delayed, if necessary, until the earliest time that such payment would be permissible under Section&nbsp;409A of the Code without triggering any additional
taxes applicable under Section&nbsp;409A of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company need not take the same action or actions with respect to all Awards or portions thereof
or with respect to all Participants. The Company may take different actions with respect to the vested and unvested portions of an Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(d)</I> <I>Reservation of Rights</I>. Except as provided in this Section&nbsp;11, an Optionee, Offeree or Participant shall have no rights
by reason of any subdivision or consolidation of shares of stock of any class, the payment of any dividend or any other increase or decrease in the number of shares of stock of any class. Any issue by the Company of shares of stock of any class, or
securities convertible into shares of stock of any class, shall not affect, and no adjustment by reason thereof shall be made with respect to, the number or Exercise Price of Shares subject to an Award. The grant of an Award pursuant to the Plan
shall not affect in any way the right or power of the Company to make adjustments, reclassifications, reorganizations or changes of its capital or business structure, to merge or consolidate or to dissolve, liquidate, sell or transfer all or any
part of its business or assets. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(e)</I> <I>Change in Control</I>. In its discretion, the Committee pay provide in the Award Agreement
governing an Award or at any other time may take such action as it deems appropriate to provide for acceleration of the exercisability, vesting and/or settlement in connection with a Change in Control of each or any outstanding Award or portion
thereof and shares acquired pursuant thereto upon such conditions, including termination of the Participant&#146;s Service prior to, upon or following such Change in Control, and to such extent as the Committee shall determine. In the absence of
such provision in an Award Agreement or any such action taken by the Committee, no acceleration will occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 12. DEFERRAL OF AWARDS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(a)</I> <I>Committee Powers</I>. Subject to compliance with Section&nbsp;409A of the Code, the Committee (in its sole discretion) may permit
or require a Participant to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Have cash that otherwise would be paid to such Participant as a result of the exercise of
a SAR or the settlement of Stock Units credited to a deferred compensation account established for such Participant by the Committee as an entry on the Company&#146;s books; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Have Shares that otherwise would be delivered to such Participant as a result of the exercise of an Option or SAR
converted into an equal number of Stock Units; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-
18 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Have Shares that otherwise would be delivered to such Participant as a
result of the exercise of an Option or SAR or the settlement of Stock Units converted into amounts credited to a deferred compensation account established for such Participant by the Committee as an entry on the Company&#146;s books. Such amounts
shall be determined by reference to the Fair Market Value of such Shares as of the date when they otherwise would have been delivered to such Participant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(b)</I> <I>General Rules</I>. A deferred compensation account established under this Section&nbsp;12&nbsp;may be credited with interest or
other forms of investment return, as determined by the Committee. A Participant for whom such an account is established shall have no rights other than those of a general creditor of the Company. Such an account shall represent an unfunded and
unsecured obligation of the Company and shall be subject to the terms and conditions of the applicable agreement between such Participant and the Company. If the deferral or conversion of Awards is permitted or required, the Committee (in its sole
discretion) may establish rules, procedures and forms pertaining to such Awards, including (without limitation) the settlement of deferred compensation accounts established under this Section&nbsp;12. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 13. AWARDS UNDER OTHER PLANS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may grant awards under other plans or programs. Such awards may be settled in the form of Shares issued under this Plan. Such
Shares shall be treated for all purposes under the Plan like Shares issued in settlement of Stock Units and shall, when issued, reduce the number of Shares available under Section&nbsp;5. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 14. LEGAL AND REGULATORY REQUIREMENTS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares shall not be issued under the Plan unless the issuance and delivery of such Shares complies with (or is exempt from) all applicable
requirements of law, including (without limitation) the Securities Act of 1933, as amended, the rules and regulations promulgated thereunder, state securities laws and regulations and the regulations of any stock exchange on which the Company&#146;s
securities may then be listed, and the Company has obtained the approval or favorable ruling from any governmental agency which the Company determines is necessary or advisable. The Company shall not be liable to a Participant or other persons as
to: (a)&nbsp;the <FONT STYLE="white-space:nowrap">non-issuance</FONT> or sale of Shares as to which the Company has not obtained from any regulatory body having jurisdiction the authority deemed by the Company&#146;s counsel to be necessary to the
lawful issuance and sale of any Shares under the Plan; and (b)&nbsp;any tax consequences expected, but not realized, by any Participant or other person due to the receipt, exercise or settlement of any Award granted under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 15. WITHHOLDING TAXES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(a)</I> <I>Withholding Taxes</I>. To the extent required by applicable federal, state, local or foreign law, a Participant or his or her
successor shall make arrangements satisfactory to the Company for the satisfaction of any withholding tax obligations that arise in connection with the Plan. The Company shall not be required to issue any Shares or make any cash payment under the
Plan until such obligations are satisfied. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-
19 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(b)</I> <I>Share Withholding</I>. The Committee may permit a Participant to satisfy all
or part of his or her withholding or income tax obligations by having the Company withhold all or a portion of any Shares that otherwise would be issued to him or her or by surrendering all or a portion of any Shares that he or she previously
acquired. Such Shares shall be valued at their Fair Market Value on the date when taxes otherwise would be withheld in cash. In no event may a Participant have Shares withheld that would otherwise be issued to him or her in excess of the number
necessary to satisfy the maximum legally required tax withholding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 16. OTHER PROVISIONS APPLICABLE TO AWARDS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(a)</I> <I>Transferability</I>. Unless the agreement evidencing an Award (or an amendment thereto authorized by the Committee) expressly
provides otherwise, no Award granted under this Plan, nor any interest in such Award, may be sold, assigned, conveyed, gifted, pledged, hypothecated or otherwise transferred in any manner (prior to the vesting and lapse of any and all restrictions
applicable to Shares issued under such Award), other than by will or the laws of descent and distribution; provided, however, that an ISO may be transferred or assigned only to the extent consistent with Section&nbsp;422 of the Code. Any purported
assignment, transfer or encumbrance in violation of this Section&nbsp;16.a) shall be void and unenforceable against the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(b)</I> <I>Performance Criteria</I>. The number of Shares or other benefits granted, issued, retainable and/or vested under an Award may be
made subject to the attainment of performance goals. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Committee may utilize performance criteria including, but not
limited to any of the following performance criteria: (a)&nbsp;cash flow (including operating cash flow), (b) earnings per share, (c)&nbsp;earnings before any combination of interest, taxes, depreciation or amortization, (d)&nbsp;return on equity,
(e)&nbsp;total stockholder return, (f)&nbsp;share price performance, (g)&nbsp;return on capital, (h)&nbsp;return on assets or net assets, (i)&nbsp;revenue, (j) income or net income, (k)&nbsp;operating income or net operating income,
(l)&nbsp;operating profit or net operating profit, (m)&nbsp;operating margin or profit margin (including as a percentage of revenue), (n) return on operating revenue, (o)&nbsp;return on invested capital, (p)&nbsp;market segment shares,
(q)&nbsp;costs, (r) expenses, (s)&nbsp;achievement of target levels of discovery and/or development of products or services, including but not limited to research or regulatory achievements, (t)&nbsp;third party coverage and/or reimbursement
objectives, (u)&nbsp;test volume metrics, (v)&nbsp;objective customer indicators (including, without limitation, customer satisfaction), (w) improvements in productivity, (x)&nbsp;attainment of objective operating goals, (y)&nbsp;objective employee
metrics or (z)&nbsp;any other measures of performance selected by the Committee (&#147;Qualifying Performance Criteria&#148;), any of which may be measured either individually, alternatively or in any combination, applied to either the individual,
the Company as a whole or to a business unit or subsidiary of the Company, either individually, alternatively or in any combination, and measured either annually or cumulatively over a period of years, or on the basis of any other specified period,
on an absolute basis or relative to a <FONT STYLE="white-space:nowrap">pre-established</FONT> target, to previous years&#146; results or to a designated comparison group or index, and subject to specified adjustments, in each case as specified by
the Committee in the Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Unless specified otherwise by the Committee at the time the performance goals are
established, the Committee shall appropriately adjust the method of evaluating </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-
20 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
performance under a Qualifying Performance Criteria for a performance period as follows: (a)&nbsp;to exclude asset write-downs, (b)&nbsp;to exclude litigation or claim judgments or settlements,
(c)&nbsp;to exclude the effect of changes in tax law, accounting principles or other such laws or provisions affecting reported results, (d)&nbsp;to exclude accruals for reorganization and restructuring programs, (e)&nbsp;to exclude any
extraordinary nonrecurring items as determined under generally accepted accounting principles and/or described in managements&#146; discussion and analysis of financial condition and results of operations appearing in the Company&#146;s annual
report to stockholders for the applicable year, (f)&nbsp;to exclude the dilutive and/or accretive effects of acquisitions or joint ventures, (g)&nbsp;to assume that any business divested by the Company achieved performance objectives at targeted
levels during the balance of a performance period following such divestiture, (h)&nbsp;to exclude the effect of any change in the outstanding shares of common stock of the Company by reason of any stock dividend or split, stock repurchase,
reorganization, recapitalization, merger, consolidation, <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash
dividends, (i)&nbsp;to exclude the effects of stock based compensation; (j)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles and
(k)&nbsp;to make other appropriate adjustments selected by the Committee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Committee shall establish in writing the applicable performance goals (and
any variation to the adjustments specified in the preceding subparagraph (ii)), and an objective method for determining the Award earned by a Participant if the goals are attained, while the outcome is substantially uncertain, and shall determine
and certify in writing, for each Participant, the extent to which the performance goals have been met prior to payment or vesting of the Award. The Committee may reserve the right, in its sole discretion, to reduce the amount of compensation
otherwise payable under the Plan upon the attainment of the <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 17. NO
EMPLOYMENT RIGHTS. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No provision of the Plan, nor any right or Award granted under the Plan, shall be construed to give any person any
right to become, to be treated as, or to remain an Employee, Consultant or Outside Director. The Company and its Subsidiaries and Affiliates reserve the right to terminate any person&#146;s Service at any time and for any reason, with or without
notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 18. SECTION 409A. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan is intended to comply with Section&nbsp;409A of the Code to the extent subject thereto, and, accordingly, to the maximum extent
permitted, the Plan shall be interpreted and administered to be in compliance therewith. Notwithstanding the foregoing, neither the Company nor the Committee shall have any obligation to take any action to prevent the assessment of any additional
tax or penalty on any Participant under Section&nbsp;409A of the Code and neither the Company nor the Committee will have any liability to any Participant for such additional tax or penalty. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Award that provides for &#147;nonqualified deferred compensation&#148; within the meaning of Section&nbsp;409A of the Code shall be
subject to such additional rules and requirements as specified by the Committee from time to time in order to comply with Section&nbsp;409A of the Code. If any amount </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-
21 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under such an Award is payable upon a &#147;separation from service&#148; (within the meaning of Section&nbsp;409A of the Code) to a Participant who is then considered a &#147;specified
employee&#148; (within the meaning of Section&nbsp;409A of the Code), then no such payment shall be made prior to the date that is the earlier of (i)&nbsp;six months and one day after the Participant&#146;s separation from service, or (ii)&nbsp;the
Participant&#146;s death, but only to the extent such delay is necessary to prevent such payment from being subject to interest, penalties and/or additional tax imposed pursuant to Section&nbsp;409A of the Code. In addition, the settlement of any
such Award may not be accelerated except to the extent permitted by Section&nbsp;409A of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 19. DURATION AND AMENDMENTS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(a)</I> <I>Term of the Plan</I>. The Plan, as set forth herein, shall become effective on the Effective Date. No Award may be granted
hereunder prior to the Effective Date. The Board of Directors may suspend or terminate the Plan at any time. No ISOs may be granted after the tenth anniversary of the earlier of (i)&nbsp;the date the Plan, as amended and restated herein, is adopted
in 2022 by the Board of Directors, or (ii)&nbsp;the date the Plan, as amended and restated herein is approved the stockholders of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(b)</I> <I>Right to Amend or Terminate the Plan</I>. The Board of Directors may amend or terminate the Plan at any time and from time to
time. Rights and obligations under any Award granted before amendment of the Plan shall not be materially impaired by such amendment, except with consent of the Participant. An amendment of the Plan shall be subject to the approval of the
Company&#146;s stockholders only to the extent required by applicable laws, regulations or rules. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(c)</I> <I>Effect of Termination</I>.
No Awards shall be granted under the Plan after the termination thereof. The termination of the Plan shall not affect Awards previously granted under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 20. AWARDS TO <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> PARTICIPANTS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Awards may be granted to Participants who are <FONT STYLE="white-space:nowrap">non-United</FONT> States nationals or employed or providing
services outside the United States, or both, on such terms and conditions different from those applicable to Awards to Participants who are employed or providing services in the United States as may, in the judgment of the Committee, be necessary or
desirable to recognize differences in local law, currency or tax policy or custom. The Committee also may impose conditions on the exercise, vesting or settlement of Awards in order to minimize the Company&#146;s obligation with respect to tax
equalization for Participants on assignments outside their home country. The Committee may, in its sole discretion, adjust the value of any Awards or any amounts due to Participants hereunder to reflect any foreign currency conversions or
fluctuations in foreign currency exchange rates; provided, however, that none of the Company or any Parent, Subsidiary or Affiliate shall be liable for any foreign exchange rate fluctuations between a Participant&#146;s local currency and the United
States Dollar that may affect the value of any Awards or of any amounts due to a Participant hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 21. FORFEITURE, CANCELLATION OR
CLAWBACK OF AWARDS. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Committee may specify in an Award Agreement that the Participant&#146;s rights, payments, and benefits
with respect to an Award shall be subject to reduction, cancellation, forfeiture, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-
22 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or recoupment upon the occurrence of specified events, in addition to any otherwise applicable vesting or performance conditions of an Award. Such events may include, but shall not be limited to,
termination of Service for Cause or any act by a Participant, whether before or after termination of Service, that would constitute Cause for termination of Service. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If the Company is required to prepare an accounting restatement due to the material noncompliance of the Company, as a result of
misconduct, with any financial reporting requirement under the securities laws, at the discretion of the Committee, any Participant who knowingly or through gross negligence engaged in the misconduct, or who knowingly or through gross negligence
failed to prevent the misconduct, and any Participant who is one of the individuals subject to automatic forfeiture under Section&nbsp;304 of the Sarbanes-Oxley Act of 2002, shall reimburse the Company for (i)&nbsp;the amount of any payment in
settlement of an Award received by such Participant during the twelve (12)&nbsp;month period following the first public issuance or filing with the United States Securities and Exchange Commission (whichever first occurred) of the financial document
embodying such financial reporting requirement, and (ii)&nbsp;any profits realized by such Participant from the sale of securities of the Company during such twelve- (12)&nbsp;month period. In addition, to the extent claw-back or similar provisions
applicable to Awards are required by applicable law, listing standards and/or policies adopted by the Company, Awards granted under the Plan shall be subject to such provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 22. GOVERNING LAW. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan,
each Award Agreement and each Award and all disputes or controversies arising out of or relating thereto and all other matters shall be governed by, and construed in accordance with, the internal laws of the State of Delaware as to matters within
the scope thereof, without regard to the laws of any other jurisdiction that might be applied because of the conflicts of laws principles of any state. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-
23 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g417044g27u30.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">PLUS THERAPEUTICS PLUS THERAPEUTICS, INC. C/O Broadridge P.O. Box 1342 Brentwood, NY 11717 SCAN TO VIEW MATERIALS&nbsp;&amp; VOTE VOTE
BY INTERNET - www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 P.M. ET on 4/19/2023. Have your proxy card in hand when you access the web
site and follow the instructions to obtain your records and to create an electronic voting instruction form. During The Meeting - Go to www.virtualshareholdermeeting.com/PSTV2023 You may attend the meeting via the Internet and vote during the
meeting. Have the information that is printed in the box marked by the arrow available and follow the instructions. VOTE BY PHONE -
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-690-6903</FONT></FONT></FONT> Use any touch-tone telephone to transmit your voting instructions up until 11:59 P.M. ET on 4/19/2023. Have your
proxy card in hand when you call and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way,
Edgewood, NY 11717. TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. 0000592434_1 R1.0.0.6 For All Withhold All
For All Except The Board of Directors recommends you vote FOR the election of each of the nominees listed under proposal 1 as Directors. [&nbsp;&nbsp;&nbsp;&nbsp;] [&nbsp;&nbsp;&nbsp;&nbsp;] [&nbsp;&nbsp;&nbsp;&nbsp;] To withhold authority to vote
for any individual nominee(s), mark &#147;For All Except&#148; and write the number(s) of the nominee(s) on the line below. 1. Election of Directors Nominees 01) Howard Clowes 02) An Van <FONT STYLE="white-space:nowrap">Es-Johansson</FONT> 03)
Richard J. Hawkins 04) Marc H. Hedrick, M.D. 05) Robert Lenk 06) Greg Petersen The Board of Directors recommends you vote FOR proposals 2 and 3. For Against Abstain The Board of Directors recommends you vote FOR proposals 5 and 6. For Against
Abstain 2. Ratification of the appointment of BDO USA, LLP as our independent registered public accounting firm for the 2023 fiscal year. [&nbsp;&nbsp;&nbsp;&nbsp;] [&nbsp;&nbsp;&nbsp;&nbsp;] [&nbsp;&nbsp;&nbsp;&nbsp;] 5. Approval of an amendment to
our Amended and Restated Certificate of Incorporation as amended, to effect a reverse stock split of our issued and outstanding shares of common stock, at a specific ratio, ranging from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-three</FONT></FONT> (1:3) to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-fifteen</FONT></FONT> (1:15). [&nbsp;&nbsp;&nbsp;&nbsp;]
[&nbsp;&nbsp;&nbsp;&nbsp;] [&nbsp;&nbsp;&nbsp;&nbsp;] 3. <FONT STYLE="white-space:nowrap">Non-binding</FONT> advisory vote on compensation of our named executive officers. [&nbsp;&nbsp;&nbsp;&nbsp;] [&nbsp;&nbsp;&nbsp;&nbsp;]
[&nbsp;&nbsp;&nbsp;&nbsp;] The Board of Directors recommends you vote 1 YEAR on the following proposal: 1 year 2 years 3 years Abstain 4. <FONT STYLE="white-space:nowrap">Non-binding</FONT> advisory vote on the frequency of holding future <FONT
STYLE="white-space:nowrap">non-binding</FONT> advisory votes on executive officer compensation. [&nbsp;&nbsp;&nbsp;&nbsp;] [&nbsp;&nbsp;&nbsp;&nbsp;] [&nbsp;&nbsp;&nbsp;&nbsp;] 6. Approval of the third amendment and restatement of the Plus
Therapeutics, Inc. 2020 Stock Incentive Plan which increases the authorized number of shares by 1,000,000. [&nbsp;&nbsp;&nbsp;&nbsp;] [&nbsp;&nbsp;&nbsp;&nbsp;] [&nbsp;&nbsp;&nbsp;&nbsp;] NOTE: In addition to the above, we may transact such other
business as may be properly brought before the meeting or any adjournment or postponement thereof. Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as
such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer. Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date
</FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g417044g34e99.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The Combined Document is available at
www.proxyvote.com 0000592434_2 R1.0.0.6 PLUS THERAPEUTICS, INC. PROXY SOLICITED BY THE BOARD OF DIRECTORS FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON APRIL&nbsp;20, 2023 The undersigned hereby appoints each of Marc H. Hedrick, M.D. and
Andrew Sims, or either of them, as proxy holders each with full power of substitution, to appear on behalf and to vote all shares of common stock of Plus Therapeutics, Inc. (the &#147;Company&#148;) that the undersigned is entitled to vote at the
Annual Meeting of Stockholders of the Company which will be held virtually via live webcast at www.virtualshareholdermeeting.com/PSTV2023 on April&nbsp;20, 2023, and at any postponement thereof. When properly executed, this proxy will be voted as
directed. If properly executed and no instructions are specified, this proxy will be voted FOR the election of the listed Nominees as Directors under Proposal 1, FOR Proposals 2, 3, 5, 6, 1 YEAR on Proposal 4, and at the discretion of the proxies
with respect to such other business as may properly come before the meeting. The proxies, in their discretion, are further authorized to vote (a)&nbsp;for the election of a person to the Board of Directors if any nominee named herein becomes unable
to serve or for good cause will not serve, (b)&nbsp;on any matter which the Board of Directors did not know would be presented at the Annual Meeting of Stockholders by a reasonable time before the proxy solicitation was made, and (c)&nbsp;on other
matters which may properly come before the Annual Meeting of Stockholders and any adjournments or postponements thereof. This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this proxy will
be voted in accordance with the Board of Director&#146;s recommendations. PLEASE COMPLETE, DATE AND SIGN THIS PROXY AND RETURN IT IN THE ACCOMPANYING ENVELOPE. Continued and to be signed on reverse side </FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g417044dsp1a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g417044dsp1a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MSO"OY7/[6/W$_9R_Y(;\,_\ L6;7_P!&SU_1?"?_ "3F3_\ 8/'\V?R=QO\
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MI4HOK.\O:-*_+"+O;FC?\F]#TB[U_6]'T*QC::]UC5-/TJUB0$LT]_=Q6L8
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M*6"GEM+&5:6 J3=2="$W&G.;C&+E.,6N?W8Q5I72MHKG2UUG"% 'XM?M8?\
M)?/'/_<O?^HUI-?S]QM_R4V8_P#<#_U'I']2>'/_ "1V4^N)_P#4JL?4G[ _
M_(O_ !(_[#F@_P#INO*^R\,O]US;_K]1_P#3<C\_\8?]]R/_ *\8C_TY _0&
MOT\_&PH * &LH961AE6!5@>X(P1^5#6EN@T^5JVCCM\C^?;QEH4_A?Q=XH\.
M72&.;0_$&KZ8RD8^6TOIXH7 _NO"(W4]PX/>OY>Q^&E@L=C,)-<LL-7JT[?X
M9M)_-6:\F?V7E>,AC\MR_'4W>&+P]&JO6=.+:]8RNGYH_4K]B[QU9^(/A:OA
M%YT&L>![ZZM)+4L!*^CZG=3ZCIMXJ$Y:$23W=J2!A6M!G&]<_LWA_F5/%9*L
M"Y)5\MG*+CU]E4DZE.5NUY2AY./FC^?O%'**N"XA>8J#^JYK3A.,[:*M2A&E
M5@WTE:,*GFIZ;,^P:^[/S0* /S5_;L\;V=YJ/A#X?64Z2W&C_:?$>MHC!OLT
MU["+/2+:4#[DYM3?3E3R$N(6Z.,_D?B1F-.=7 973DI3H<U>JD_A<UR4HOL^
M7GE;M*+ZG[IX1935I4<SSFK!QIXCDPU!M6YE3ESUI+O%2]G!-?:C-;IGB'[(
M_AZ77?CCX9G6-FMO#EIJ_B"[<#*Q+!82Z=:ECVS?ZC:@?CZ5\[P-A98GB/"2
M2]S"1JUI/M:#IQ_\GG$^L\2,;'!<)8ZG?EGCIT</!=VZBJ3^ZG2F?LS7[\?R
M^<?XM\?^#O 8T<^+M?L-"77=232=+:^D,:W%XZECDJI\FV0;?,N)-D,7F1^8
MZ[USP8[,\!EOL/KV*AAEB*BIT^=VO+_VV*^U-VC&ZYFKH]/+<FS/-_K*RW!5
M,6\'2=:JJ:OR03MMIS2>O+"-YRM+EB^5VZY'21%DC97C=5='1@R.C ,K*RDA
ME*D$$<$&NY--)IW3V:VMT/-:<6TURN.C3T::Z6Z6'4Q'-^*_"/AWQOHEYX=\
M4:5:ZMI5[$T<D%S$K-"Y4JES:2D;[2\C)W1SQ%71@"#7)C<#A<PP]3"XRC&O
M0FFG&26G12B]XR6\9*S3V9W9=F6-RG%TL;E^(GAL11::E%M72>L9K:<);2A*
M\9+1H_ K7M.CT?7M<TB&;[3#I.LZKID-QP?M$6GW]Q:13DKQETA5N./FXK^9
M<326'Q.)P\9<T:%6I34NZA.44_FE<_L3!UY8G!X3$RA[.6(H4:LH_P KJ4XS
M<?\ MUNWR/V _9"N+FX^ _A07!9A;7GB*UMBV3BUBU_4#&JD_P *LSJ/]W':
MOW;@64Y<-8'FVA*O&/\ A5:=ODM4C^:?$JG3I\7YC[-)<\,-.5OYWAZ=_F[)
ML^F:^O/@PH * "@ H ^-OV_/^34_B9_UT\(_^IIX?K?#_P :'S_)F&)_@R^7
MYH_ CX+?\EC^$W_93/ G_J4Z57HS^"?^&7Y,\RG_ !(?XH_FC^L"O'/:"@ H
M * "@#\6OVL/^2^>.?\ N7O_ %&M)K^?N-O^2FS'_N!_ZCTC^I/#G_DCLI]<
M3_ZE5B3X%?M#W?P/L/$5C:^%;;Q$/$%[8WKR3ZO+IAM38V\MN(U2/3[D2AA*
M6R2F,8P:?#?%,^'*6*I0P4<5]:G";;JNGR\D7&UE"=[W\K"XMX*I<55L%5J9
MC+ _4H5()1HJKS<\E*]W4I\MN6UM;GO/_#?.J_\ 1,=/_P#"JN/_ )0U]+_Q
M$VM_T)X?^%,O_E)\A_Q!W#?]#^I_X21_^: _X;YU7_HF.G_^%5<?_*&C_B)M
M;_H3P_\ "F7_ ,I#_B#N&_Z']3_PDC_\T"']OK554G_A6.G_ "@G'_"57 Z#
M_L T/Q-K)?\ (GAI_P!1,O\ Y2->#N&NE_;]3_PDC_\ -!^CFFW9OM.L+XH(
MC>65K=F,-N$9N((YB@8@;@I?&<#..E?J]&?M*5*I;EYX1E;M=)VOY7/P^M3]
MC6JTD^94IR@GM?EDXWMTO8_-S]L_X,WUIJY^+GA^S>?2[^&VM?&,5O&6;3KZ
MV1+6RUN1$'%E<6R0V\TF,1RV\;.?]()7\F\0.'ZE.O\ VYA:;E1J*,<4HK^'
M.*4856EM"4>6$G]F44W\6G[EX6\44JF&7#6,JJ%>@Y3P3D[>TA)N<Z";^W"3
ME.$?M0E))>XK_%O@CQSXG^'?B"T\3^$M3DTO5+0-&6"B6UO+5RIFL=0M7^2[
MLY-J[HVZ%5="KHK+^?9=F6,RK%0QF!K.C6AIWC*+WA.+TE%VU3V=FFFDU^I9
MKE& SK!5,!F5!5\//5:VG3FOAJ4YK6$XW=FMTW&2<6T_N[P_^WK"MG''XJ^'
ML[7Z*!+=>'M7A%I,P&"Z66I0K); GG:;F?']ZOTG"^)D532QN5R]HMY4*JY7
MZ0J)./ISR]3\BQG@_+VC>7YU%46](XFC+GBNSG2DXRMW]G#T,/QE^W;K%[8S
M6?@7P;%H=U*C(NL:_?1ZI-:[A@2VVEVL$<)F7JIFGE0'[T;#BN?'^)->I3E3
MRW+UAYR5E5K351Q\XTXI1NNG-*2[Q9UY7X18:C5C4S?-'BZ<6FZ&'INDI6Z2
MJSDY*+Z\D(RMM)/4^$=4U34]>U2\U?5[VZU35]4NGNKV]NG:>[O+N=OF=VQE
MW9BJJB@  *B*  !^:UJU;$UJE>O4E6KUI.4YR=Y2DWU\^B2VT25K(_7</A\/
M@L/2PN%I0PV&PT%"G3@E&%.$5LNR6[;WU;;;;/UE_9)^#-Y\-O"5WXE\26AM
M/%GC%;:5[*9=MSHVA6X:2PT^=2,Q7DTDKW-Q'U0F")@'@:OV_@?A^IE&!GBL
M7#V>-Q_*W!JTJ5&.L(/M*3;G-=/=B]8L_G/Q'XHI9YF5/ X&ISY=E;E%3B_=
MK5Y652I'O"*2ITWU2G-7C-'UST]L?AC%?<'YOM\C\6/VG)OB==?$S4;CXE:=
M+IH#36WA6"!Y+C0%\/Q2L;<:+>E%2[9P1+<L52;SG82QQA41/Y]XPEG$\WJS
MS:DZ*5XX:,6W1]BG[OLIV2DWO4=E+F?O1C9)?U+P#'(*60T*>15E7=HRQ<I)
M1Q'UAI*7MZ=VX*/PTDG*'(ER2DW*3B^%G[2_Q+^%<,&EV=[#XB\-086/P]X@
M,T\-G&/X-*OXW%SIJC)Q$&E@!.1#FEDO%^;Y+&-&G46+P<=J%:[45VIS3YZ:
M[1O*"_D*X@X#R'B"4L14I2P&/EOB,-RQ<WWK4VO9U'WE:-1_SGUKI?[>GA.2
M%?[:\ ^([*Y"C>NEZAI>IVY8#G9)=-8N%ST!C_&OMZ/B7@7%?6,LKTY=53G3
MJ+Y.3IO\#\XQ'@_F,9/ZKG&%JPZ>UIU:4K=+J"K*_P S@OB+^W%J.L:1>:1\
M/?#-QX>GO(9+=O$.LW<%QJ%G%(I1Y--T^S#0PW@4G9/+<2A#\PB+ $>;FOB-
M5KT*E#*\'+"RFG'V]647.">C<(0O%2[2E*26_+?;V,D\)J&%Q-+$YUCXXR%&
M2DL-0A*-.;6J56K.TG#O",(N2TYTKH^%]'TC5?$6KV&B:-:7&IZSK%Y%9V-I
M"&DGNKNX?"@GDXR2[R,<*JN[D*I(_-\/0KXNO2PV'IRK8BO-0A%:N4F]/\Y-
MZ)7;T3/UO$XG#8'#5L7BJD</A<)!SJ3EI&$(+^E&*U;M%*[2/W>^%W@J+X=?
M#_PKX,CD2:30]*A@O)T&$N-2G9[O4[A,@'RY+^>Y9<\[2H/2OZ3R;+XY5E>"
MR^+4GAJ:C)K9U'>522\G.4FO*Q_(F?YK+.LYS#,W%P6+K.4(O>-**4*47YQI
MQBG;JF=]7IGCA0 4 % !0!X9^TC\*-4^-WP<\5_#31M6L-#U'Q"VB-!J6IPW
M$]E;C2M>TW5Y/-BM?WK;XK%XUV]&=2> :TI35*<96NHWT^5C.K!U*;@GRWMK
MZ.Y^;O@/_@F;\1?"/CGP9XKNOB9X*N[7PQXK\.^(;BTM]*UU)[J#1=7L]2FM
MX'D^1)I([9D5F^4,P)XKJEBX.,H\C5TUNNUCDC@Y1E%\Z]UIVL^C/V5KA.\*
M "@ H * /@WXR_LD>*?B9\1_$/C73O%WA_2[/6/[,\FQO;+49;F'[!I5EI[^
M9)!\AW/:LXV] P!YK\US_@?&YOFV*S"CCJ%&G7]G:$X5')<E.$'=QTU<;JW0
M_7N%_$?+\@R/!957RW$5ZN%]K>I3G34'[2M4J*REJK*:3OU1YA_PP9XV_P"A
M]\*_^"[5Z\;_ (AIF/\ T,L-_P" 53Z#_B+^4_\ 0GQ?_@VB'_#!GC;_ *'W
MPK_X+M7H_P"(:9C_ -#+#?\ @%4/^(OY3_T)\7_X-HA_PP9XV_Z'WPK_ ."[
M5Z/^(:9C_P!#+#?^ 50_XB_E/_0GQ?\ X-HB-^P7XW*D?\)[X5&01_R#M7XR
M,4GX:9C:W]IX;_P"J"\8,I37_"/B]/\ I[1/TTTNT:PTW3K%V5WLK&TM'= 0
MCM;6\<+,H/(4E"1GG!K]@HP=*C2I-W=.$8MK^[%+]#\&KU%5KUJJ7*JDYS2>
MZ4I-I?*Y9GMX+J":UNH8KBVN(I(+BWGC26">&52DL,T4BE98G1F5D8$$$@C!
MJI1C.,H3BI0DFI1:3335FFGHTUHT]+$0G.E.,Z<G3G!J491;C*,D[IQ:LTTU
M=-:I['Q'\1_V)/"'B&ZN-4\ ZQ)X+NYV:5]'GMVU/PZ96.2+6,2QW.EH23\D
M<D\2](XD48K\\S;P\P&*G*MEE=Y?4EJZ3C[2A?\ NJZG37DG**Z12/U7(_%;
M,\%3IX;.,,LTI0LE6C+V6)27\[M*G5:[RC";WE-O4^<;_P#8C^,EI*R6=SX.
MU2)3A9H-:O+7<!T)BO-*0J?;)^M?)U?#O/Z<K4YX6M%;-591_"5-6/N:/BMP
MQ4BG5IXW#RZQE0A+\85G?[D:&C?L-_%6]E4:QK?@_0[?(WNEYJ.JW(7//EV\
M%A#&[ =FN$'O6N'\.<ZFU[?$87#0ZM2G4E\HQA%/YS1AB?%GAZC%_5<)C<7-
M;)PI48W\Y2J3DEZ0?H?7WPE_92^'WPQN[;7+UI_&/BFT99+75-7@BBL--G7I
M-I6CH7C@G4_=GGDN94(!C:,U]WD?!65Y/.&(J7Q^-AK&I5BE"FUUITE=1DND
MI.<E]EQ/S7B/Q#SK/J<\)24<KR^:M*C1DW4JQ_EK5G:4HOK"$:<'M*,CZAK[
M$^ "@#GO$_A+PUXTTF;0O%6BZ?KNE3\O9ZA LJHX!"S6\G$EK<*"=LT+QR+G
MY6%<N,P.$Q]"6&QN'AB:,MX3C=)]'%[QDNDHM271G;@,QQV58B&+R[%5,'B*
M>TZ<G%VZQDOAE%]8R3B^J9\3>-?V$_#U[++=> ?%M[H&XEDTC7K<ZS8(3D^7
M!?PR0W<,0X \X7;8ZL:_/,P\-\+4E*>68Z>%OM2K1]K!>2FG&<5_BYWYGZKE
M7BYC:,8TLXRV&,Y='6P\O85/65-J=*3_ ,/LEY'AM[^Q#\8K:4I:7W@O4(@<
M++%K&H6N0.A,=SHZE?IDU\Y4\.L^@[4ZF$JI;-59Q_"5+0^LI>*_#,XKVE''
M4)=4Z-.7XQKO\D;6@_L*_$:\FC_X2'Q/X4T*TW#S?L)U'6KT)_%Y<)M;*$MC
M^]<#Z5T87PWS6<E]:QF&PT.O)SU9V\ERTX_^3G+C/%S)*4']2R_%XNHOA]I[
M*A"_2\E.K)?*!]N?"']GKP%\'E-YI$$^L>)9H3!<^)]7$3WXB< 2V^GPQH(=
M+M7Q\R0@R..)99 !C]$R+A;+,@7M,/%U\7)<LL15LYVZQ@E[M.+ZJ.KVE*1^
M4\2\:9QQ,U2Q,XX; 0ES0PM&ZIW6TJDFW*K-=')\L7K"$=3W:OI#Y$* "@ H
M * "@ H * "@#SOQQ\6_AC\,Y].MOB!X[\,>#I]6BN)],A\0:M:Z9)?PVCQ1
MW,EJMS(IF2)YX58KG!E7/6JC"<O@BY6[(F4X4[<TE&^UW8Q/#'[0'P2\9ZY8
M^&?"?Q3\$>(?$&I&<:?HVD:_87NH79M;:6\N!;VT,I>3R[6":5L#A8F)X%-T
MJD5=P<4NMA1J4VU&,TWT29VESXZ\'67B[3? %WXET:V\:ZOITVKZ7X6FOH$U
MN_TNV%T9[^UL&;S9K6,65WND52!]GD_NFIY9<O-9\L=+]!\T5)0NE+HNOW"3
M>._!MMXPM/A_/XFT:'QO?Z8^M67A5[Z!=<N=)B,ZR:C#IY;S7M%-K< R!=H\
ME^?EHY9<O-9\JTOTN'-%2Y+KFW2ZV,;QO\7?AA\-+C3[3Q_X\\+^#KG5(9[C
M38/$&KVFF2WL%J\<5Q+;)<2*98XY)HE8KG!D4'K3C"<OABY6[()3A"RE)1[7
M=BIX+^-?PD^(FJ3:'X$^(OA'Q;J]O92:E/IN@ZU9ZC>0V$,T%O+=R06\C,MN
MDUS;H7(P&F0?Q"G*G."]Z+BO-"C4A)VA)2:Z)D?C'XX_!_X>ZP/#_CCXD^#O
M"FM_9(+\:5KFMV6GWWV*Y:5+>Z^SW$BMY$CP3!6Q@F)L=*(TYR5XQ;2[()5*
M<':4U%]FSI/!OQ!\#?$*PFU/P)XN\.^+M/MI1!<W7A[5[+58[6=@66&Z^QS.
M;:5E4L$E"$@9 (YI2C*&DHN/:ZL.,HR7NR32[,T?%'BGP[X)T'4O%'BS6+#P
M_P"'M'A6XU/5]3G6VL;*%YH[>-YYFX7=/-%&HY+-(J@$D"DDVU&*NWLAMJ*N
MWRJ/4D\-^)-!\7Z%IGB;PQJUEKOA_6;5+W2M6TZ9;BROK5RRK-;S+PR[E93T
M(92" 00!IQ;37*X] BTTG%W3V9R?C?XP?"WX:W=C8>/_ !]X6\'WNIVTMWIU
MKX@U>TTV:\M8)1#+/;QW$BF6))65"RY ) IQA.7PQ;2[(F4X0LI24>UW8U?!
MGQ$\!_$2RGU'P'XP\-^+[*TE6"[G\/:Q8ZJMI,X8I%=BTF=K9V56*K*%+!25
MR!1*,H:2BX]KJPXRC+X9)I=F<WXO^.?P<\ :RWAWQM\2_!OA77$MK>\;2=;U
MRRT^^6TNM_V:X-O/*K"*3RI-K8P=AQTIQISDKQ@VEV0I5*<':4U%KHV:_@;X
MJ?#?XE_VE_PK[QOX:\8_V/\ 91JO_"/:K:ZG_9YO?/-F+O[,[>3YPM;C9NQN
M\E\?=-*4)0MS1<>UU8<9PE?DDI<N]F:F@^.O!WB?5O$F@^'/$NC:UK7@Z]CT
M[Q3I>FWT%U>^'[^5KA(K358(F+6<[-:7("2 $F!_[IH<912;3BGL"E%MI--Q
MT:[!H7CKP;XFUGQ)X=\/>)M&UC7/!]U%8^*=)TZ^@N;[P_>3F=8;;5;>)B]G
M,[6MP%60 GR7_NFDXRBDVFE+8%*+;2:;CNNQYUJ?[2W[/^BZEJ&CZK\8?A]I
MVJ:5>W6G:E87?B73H+JQO[&9[:[M+F%Y@T,\,\<D;HP!5D(/(JU2J65J<K=-
M&3[6DM/:1372YWO@GXB^!/B187>J> ?%N@^+M.L+S^S[V]T#4;?4;:UOA!%<
M_9)I;=V6.?[//#)L)SME4]#4RC*%E*+CV3T*C*,E[DE)+L3^%/'?@WQS'JTO
M@[Q-HWB6/0=5GT/67T:^@OETS6+4*;C3;TP,?(O(@REHFPPW#(I.,H6NG&ZN
MK]@C*,K\K3Y='8S/'7Q4^&_PPM[:Z^(/C?PUX/BO"PLEUW5K2QGO-A <V=I)
M)Y]TJ$@,T4;!<C<1D4XPE+2$7*W9!*<(?%)1[79H^#?'W@GXAZ7_ &WX%\5Z
M!XLTI9/)DO= U2TU*&"<#/D7/V:5FM9]N#Y4P1\$'&"*)1E!VDG%^81E&2O%
MJ278Y7QI\=?@W\.M8A\/^./B7X.\+ZY/'%*FDZOK=G;7Z0S8,,US;&0O9PR#
ME'G$:L.02!FG&G.2O&#:75(4JE.#Y9347VN>D:5JVEZYI]IJVB:E8:OI5_"M
MQ8ZEIEW;W]A>0-]V:UN[61XIXC@X9'8<=:EIK2UFNA:::T=T:%( H * "@ H
M * "@ H \2^-_P +/AQX^\*:YJ_C7P5X=\3ZGX;\)^)WT&^UK38+VYTEWTV6
MY=K&652;<FXM;:0E<?-"AZJ*TISE!I1DXIM72,ZD(2B^:*;BG:Z\CY._X)X_
M"WX=7'P,\ ?$V;P7X>D^(,&I^,8XO&#Z= =?1%UK5]*55U KY@ TUVML _ZL
ME>AK;$SDJDH<S45;3ILNACA80]G&7*N97UZ[M''?M(Z]X_\ #/[='PCUCX8^
M"[?X@>,K;X-ZI'IWA:ZU:WT2&]@N+SQM#J$S:E=.D<)MK)I9PK,-YC"CDBJI
M*+P\U*7+'FWM>VW0FJY1Q,.2/-)0T5[=S&^'_BCXI>+/V_? FI?%SX=VGPS\
M31?!_7[.VT"SURU\017&CQ#79;;5#?6DLB(\MS->0F'(*BT#$?/DDHPCAI*$
MN9<RUM;L*#F\3'GCR-0=E?IW-']NFTO[W]HG]F:TTOP%IGQ1U";3/&BVO@#6
M;BUM-+\3NK6;-8WEQ? V\,4<:O<@R@KNM%'4BC#V5*K[W(E;5= Q"?M:*45+
M1^Z]$_O/HC]F'PGK6FZ_XFU7Q-^RGX$_9]O8-)L[+2=;\+ZEX?U2]UZ"]NI)
M=4TV9]'0/:VT+6.G38D.V1G7',=956K12K.IY.ZMVW-J,6F[T8T;;-6^>Q\D
M_M*:MX6T3]N*WO\ QA\*-6^,VB1?!;3UE\%:-H%OXDO#.;_5FBU@Z9<@Q^19
M*DN^8_ZO[0#WK:DF\/:,_9M2W;MVT,*K4<0KPYTH;)7[ZV\CK?V&=*M/&/QM
M^+7QP^&W@N/X9?!75-"MO!NG>$H]0M)3<^*+230[VYN&TRSF9-/\F.&[N2@5
M8XSK@CMVD5IBJQ#Y:<*<I<U1.]_+5?UZ%8=7J3J0CR4[62\].G3_ ()L?\%!
M_BEX4.L_"7X#^)O$1\/>%/$GB/3/&/Q6U2WCN[B>P\%:5?-'8V2V^GPS7$MQ
M?7<&H2QHD3%9=,M9"-A)"PT&E.HE=Q5HKS_X 8F<4Z=)OEBVG+T7I_6A:_X)
MV?%30+JW^)GP,TGQ /$&C>!/$NJ^(?AMJSQW5M)JO@#6-4E5@MK?113V[VFH
M203R1R1(ROKN,8448F#7)4MRN22DNS2_I?(>%FO?I)W47>+_ +O_  /U.6_;
M=U+POH_[3_[.>I>,_!FH?$+PQ:>%_%K:KX-TO18O$-_KD3R7,4$%MHL[I'?M
M#=O;W)1F 5;5GZI3PZ;I55&7*[JS;M;Y].PJ[C&M2YH\R2>B5_P-/]E#P;J&
MJ_M,>-_BYX ^$?B;X(_!6Y\#KX>70/$>F2>'CXAU]KG3I4N;/0F<I#'&]K<S
MM]G,D$!  D$EXZ!5I)48TY34YIWNM;+U"C%^VE.,'2IVM9Z:^AP?[0.FZSJ?
M[=&IVNA?!GP_\=;X?!W1I3X(\2WVFZ?IL<"7)637!<:J#!]IM&>.)%(W$7[[
M>AJJ5EAU>;II2W7Y:$5$_K+2IJI:"]UZ+UU['W5^S#X:U#1?#_B6^UW]GSPC
M^S[K=]K%O:OHWA2\T;4$U_2K"RCEL=3O+O1T";XKN^U*!(9,LH5F'$E<]5JZ
M2J.HDMW=6^_Y'31CRIWI*D[[*VW38\-_9'GAB_:5_;>L7D2.\?XCZ/>);,P6
M=[5;WQ:IN%C/S-"#/"-X&/WR<_,,Z5M*6'\HO]#.AI5Q"_O+]0_9%ECNOVD?
MVW;JV=9[9OB+H<*W$1#PM+!=^+HI8UE7*LZR1NI /!4T5M*6'Z6B_P! H?Q<
M1VYE^IYS^W?\(?A?X=D^#.N:'X#\,Z7K'C3X]:%:>+=2LM+@@O/$-KJ[W5UJ
MEOJLR*&O(KJX9I)5?.YB2:O#SG[Z<G:,'9=K;?<3B(0C[.T4G*:OI^9^D/@?
MX<> _AII]WI7@#PEH?A#3;^\_M&]LM!L(=/MKF^,$5L;J:*%0'G^SP0Q[CSM
MB4=JY92E+XFY6VN=481@K1BHKLCXD_X)Z_\ ('_:'_[."\7_ /HBSK?$_P#+
MK_ CGPNU7_&SS?X*^!_!?QU_:R_:>U3XV:=8^+O$7@/Q!%X?\%>#_$JB[TS3
M?"EOJ.JZ?'J%KH]P?)NH8;6RTD M&\:/K$DY7S;M9!<Y2I4:*I^ZI*[:[Z:7
M^_[B*<8U*U7VGO.#LD]K:K8^^OAA\&?A)\)K[Q?+\,?#&D>&[KQ'J-G<>)8-
M+GDE$-Q:V2&RL4MI+B0:3:)#<O<QV42PQAM0>14"RKCFG.<U'F;?+M_74ZH4
MX4[\D5&^]OP]#\W_ (E?!?XE?#OXP?&KXCR_ ?P'^T_\/O'NLR:M?I>W=O<>
M,O!ML(6O)='L;>5I;O2[F"SNH4S9V=XSV]I8.C08\NNJ$X2ITX>TE1E'3R?G
M_3.2=.<)U)^SC6C)_->7R\C[T_93\8_#;QM\#_"&I?"CPW-X.\(6"7NBP>%K
MAC+/H>H:==R#4[6:\,DAU)WNI6N/MK.SW NA+)MD=T7GK1E"HU-W>]_ZV.FC
M*$J<?9KEBM+=K'T561J% !0 4 % !0 4 % &;K.EPZWH^K:+<R2Q6^KZ;?:7
M/+ 5$T<-_:RVDLD)=642JDK%2RL,@9!'%-/E:_N_H)K1K;2QYQ\$?@_H/P)^
M'>D?#;PUJ.KZKI&CW.J7-O>ZX]G)J4CZKJ%QJ,ZS/86EM"56:X=4VPJ=JC))
MY-5)NI)R:LWT7EH33IJE!03;4>YG:O\  [PWK'QR\)_'FXU76XO$WA#PI?\
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MIHPNH2QA/+2%8251RC&+2O#9];=A0I*G.4HMI2WCT]?(DT?]G?P58_%_QO\
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F % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g417044g0224071627751.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g417044g0224071627751.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% /\# 2(  A$! Q$!_\0
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IBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g417044g0224071628329.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g417044g0224071628329.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %3 FD# 2(  A$! Q$!_\0
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MS0?\\8_^^!4M% $7V:#_ )XQ_P#? H^S0?\ /&/_ +X%2T4 1?9H/^>,?_?
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MOLT'_/&/_O@5S^X^IKI:YF@#H;;_ (]8?]P?RJ6HK;_CUA_W!_*I: "BBB@
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M_P#?;?XU+10!%Y"?[?\ WVW^-'D)_M_]]M_C4M% $7D)_M_]]M_C1Y"?[?\
MWVW^-2T4 1>0G^W_ -]M_C1Y"?[?_?;?XU+10!%Y"?[?_?;?XT>0G^W_ -]M
M_C4M% $7D)_M_P#?;?XT>0G^W_WVW^-2T4 1>0G^W_WVW^-'D)_M_P#?;?XU
M+10!%Y"?[?\ WVW^-'D)_M_]]M_C4M% $7D)_M_]]M_C1Y"?[?\ WVW^-2T4
M 1>0G^W_ -]M_C1Y"?[?_?;?XU+10!%Y"?[?_?;?XT>0G^W_ -]M_C4M% $7
MD)_M_P#?;?XT>0G^W_WVW^-2T4 1>0G^W_WVW^-'D)_M_P#?;?XU+10!%Y"?
M[?\ WVW^-'D)_M_]]M_C4M% $7D)_M_]]M_C1Y"?[?\ WVW^-2T4 1>0G^W_
M -]M_C1Y"?[?_?;?XU+10!%Y"?[?_?;?XT>0G^W_ -]M_C4M% $7D)_M_P#?
M;?XT>0G^W_WVW^-2T4 1>0G^W_WVW^-'D)_M_P#?;?XU+10!%Y"?[?\ WVW^
M-'D)_M_]]M_C4M% $7D)_M_]]M_C1Y"?[?\ WVW^-2T4 1>0G^W_ -]M_C3U
M4(,#/XDFG44 %<S735S- '0VW_'K#_N#^52U%;?\>L/^X/Y5+0 4444 9NN&
M%=+=YQ<>6C*Y>W7<\9!R& P<X(]#61<SW+Z99R7EG/-<BZ4I)':-O\I9%.6
M!*D@9QWQ74T4 <YKLS7BPBT:ZC:WGQ)/! 9'B.S. N.<AL$]LUGQVMREHUHV
MGS++<Q0")EC)5-I/WC_"1][!]?6NR5%0$*H4$Y.!CFEH Y:S<VDL#SVT\*V
MG:>5HB%8,QQM/\6>O'IZTVXMKB>::TCM9A,UV;@3F,A-I3KN]?X<=?PKJF17
M7:ZAAG.",TM '("WGN["8Q6$\8BL4A:.2(H793DJ >O /MS6UI.Z6ZOKL02P
MQ3.NQ98RC'"X)VGGV_"M6B@ J,F;)PL>.V6/^%244 19G_NQ_P#?1_PHS/\
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M  J6B@"+,_\ =C_[Z/\ A1F?^['_ -]'_"I:* (LS_W8_P#OH_X49G_NQ_\
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MV>G?'K0!$FNW,=O-)=6D:MY"SPK')G<"<8.1P>GMS5_3KRXN'N(+N*..X@8
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M ,C0G_7LG\VKCZZ[XC!AXF3<VX_9TYQCNU<C7L4/X:/)K?Q&%%%%:F04444
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M\[_IG)_WS1YW_3.3_OF@"6BHO._Z9R?]\T>=_P!,Y/\ OF@"6BHO._Z9R?\
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M5'_<7\J?10 SRH_[B_E1Y4?]Q?RI]% 'DGQ' 7Q.@  'V9.@]VKD*[#XD_\
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MH7=O;3N-0>TBN-\6T!;C88R 2._)_*G"UU(P26]Q:S2SW<</[[ (3:3G>>Q
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M (MDO_/;_P =%&R7_GM_XZ*EHH BV2_\]O\ QT4;)?\ GM_XZ*EHH BV2_\
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M?E4M% $7G?\ 3*3\J/._Z92?E4M% 'D?Q&;=XF0[2O\ HZ<$>[5R-=A\2?\
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MH\[_ *92?E4M% $7G?\ 3*3\J/._Z92?E4M% $7G?],I/RIZMN&=I7V(IU%
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M_P#/1/\ OH4NQ/[J_E1L3^ZOY4 >3?$=E;Q.A4@C[,G0^[5R%=?\2 !XG3
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M%G#4PTY2;1Y%17KO_"N]"_N3?]_#1_PKO0O[DW_?PU?URGYD?5*AY%17KO\
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MW'^R*!DM%1>7)_SW;_OD4>7)_P ]V_[Y%("6BHO+D_Y[M_WR*/+D_P">[?\
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MYFNFKF: .AMO^/6'_<'\JEJ*V_X]8?\ <'\JEH **** "BBB@ HHHH ****
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M-P!W,00HZYXJF]_=7\%LTTRO(DCQB2-@P;&,'( !Z]@*[KRX\$;%YZ\=: B
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M_'K#_N#^52U%;?\ 'K#_ +@_E4M !1110 4444 %%%% !1110 4444 %%%%
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M **** "N9KIJYF@"RM]<HH59,*HP!M%']H77_/7_ ,='^%%% !_:%U_SU_\
M'1_A1_:%U_SU_P#'1_A110 ?VA=?\]?_ !T?X4?VA=?\]?\ QT?X444 ']H7
M7_/7_P ='^%']H77_/7_ ,='^%%% !_:%U_SU_\ '1_A1_:%U_SU_P#'1_A1
M10 ?VA=?\]?_ !T?X4?VA=?\]?\ QT?X444 ']H77_/7_P ='^%']H77_/7_
M ,='^%%% !_:%U_SU_\ '1_A1_:%U_SU_P#'1_A110 ?VA=?\]?_ !T?X4?V
MA=?\]?\ QT?X444 ']H77_/7_P ='^%']H77_/7_ ,='^%%% !_:%U_SU_\
M'1_A1_:%U_SU_P#'1_A110 ?VA=?\]?_ !T?X4?VA=?\]?\ QT?X444 ']H7
M7_/7_P ='^%']H77_/7_ ,='^%%% !_:%U_SU_\ '1_A1_:%U_SU_P#'1_A1
M10 ?VA=?\]?_ !T?X4?VA=?\]?\ QT?X444 ']H77_/7_P ='^%']H77_/7_
M ,='^%%% !_:%U_SU_\ '1_A1_:%U_SU_P#'1_A110 ?VA=?\]?_ !T?X4?V
MA=?\]?\ QT?X444 ']H77_/7_P ='^%']H77_/7_ ,='^%%% !_:%U_SU_\
M'1_A1_:%U_SU_P#'1_A110 ?VA=?\]?_ !T?X4?VA=?\]?\ QT?X444 ']H7
M7_/7_P ='^%']H77_/7_ ,='^%%% !_:%U_SU_\ '1_A1_:%U_SU_P#'1_A1
M10 ?VA=?\]?_ !T?X4?VA=?\]?\ QT?X444 ']H77_/7_P ='^%']H77_/7_
M ,='^%%% !_:%U_SU_\ '1_A1_:%U_SU_P#'1_A110 ?VA=?\]?_ !T?X4?V
MA=?\]?\ QT?X444 ']H77_/7_P ='^%']H77_/7_ ,='^%%% !_:%U_SU_\
M'1_A1_:%U_SU_P#'1_A110 ?VA=?\]?_ !T?X4?VA=?\]?\ QT?X444 ']H7
M7_/7_P ='^%']H77_/7_ ,='^%%% !_:%U_SU_\ '1_A1_:%U_SU_P#'1_A1
M10 ?VA=?\]?_ !T?X4?VA=?\]?\ QT?X444 ']H77_/7_P ='^%']H77_/7_
M ,='^%%% !_:%U_SU_\ '1_A1_:%U_SU_P#'1_A110 ?VA=?\]?_ !T?X4?V
MA=?\]?\ QT?X444 ']H77_/7_P ='^%']H77_/7_ ,='^%%% !_:%U_SU_\
D'1_A1_:%U_SU_P#'1_A110 ?VA=?\]?_ !T?X57P*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g417044g0224071628626.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g417044g0224071628626.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %, FD# 2(  A$! Q$!_\0
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M!_SQC_[X%2T9% $7V:#_ )XQ_P#? H^S0?\ /&/_ +X%2T4 1?9H/^>,?_?
MH^S0?\\8_P#O@5+10!%]F@_YXQ_]\"C[-!_SQC_[X%2T4 1?9H/^>,?_ 'P*
M/LT'_/&/_O@5+10!%]F@_P">,?\ WP*/LT'_ #QC_P"^!4M% $7V:#_GC'_W
MP*/LT'_/&/\ [X%2T4 1?9H/^>,?_? H^S0?\\8_^^!4M% $7V:#_GC'_P!\
M"C[-!_SQC_[X%2T4 1?9H/\ GC'_ -\"C[-!_P \8_\ O@5+10!%]F@_YXQ_
M]\"C[-!_SQC_ .^!4M% $7V:#_GC'_WP*/LT'_/&/_O@5+10!%]F@_YXQ_\
M? KG]Q]372US- '0VW_'K#_N#^52U%;?\>L/^X/Y5+0 4444 %%%% !1110
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MRJYZ&K]%--K5":3T9@?\(7H'_0/3\S1_PA>@?] ]/S-;]%5[2?<GV<.Q@?\
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MD_\ 363_ +ZH\G_IK)_WU4M% $7D_P#363_OJFR6J2QM'(\C(X*L"W4&IZ*
M,#_A"] _Z!Z?F:/^$+T#_H'I^9K?HJ_:3[D>SAV,#_A"] _Z!Z?F:/\ A"]
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MFLG_ 'U3U7:,;B?<FG44 %<S735S- '0VW_'K#_N#^52U%;?\>L/^X/Y5+0
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M]FI:* (O(']^3_OLUQ<_%Q*/]L_SKN:X:X_X^9?]\_SKHP^[,:W0CHHHKJ,
MHHHH *MZ8-VI0#)&6[&JE7-+_P"0G;_[]3+X6..Z.L\@?WY/^^S1Y _OR?\
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M-V/O;2,#&/3%=.>AKE+*Q@74]+O4TO2K%)&8Q2VS,SRYC8[<>6N..<D]L=Z
M-K7(I)--W1HSF*:*8HHR6".K$ =S@52?3[Z7Q&MTMM!;QQL&:ZBF(:X3!'EN
MF.<'N2<<8]M^BH<$W<Z*>(E3CRI=_P ;?Y'-+IVL.+J1[>S24WB742BY9E;
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M_P E_P */+?_ )[O^2_X5+10!%Y;_P#/=_R7_"CRW_Y[O^2_X5+10!%Y;_\
M/=_R7_"CRW_Y[O\ DO\ A4M% $7EO_SW?\E_PH\M_P#GN_Y+_A4M% $7EO\
M\]W_ "7_  H\M_\ GN_Y+_A4M% $7EO_ ,]W_)?\*/+?_GN_Y+_A4M% $7EO
M_P ]W_)?\*XN?_CXE[_.?YUW-<-<?\?,O^^?YUT8?=F-;H1T445U& 4444 %
M6],!.I0 $@[NHJI5S2_^0G;_ ._4R^%CCNCK/+?_ )[O^2_X4>6__/=_R7_"
MI:*\\["+RW_Y[O\ DO\ A1Y;_P#/=_R7_"I:* (O+?\ Y[O^2_X4>6__ #W?
M\E_PJ6B@"+RW_P">[_DO^%'EO_SW?\E_PJ6B@"+RW_Y[O^2_X4>6_P#SW?\
M)?\ "I:* (O+?_GN_P"2_P"%'EO_ ,]W_)?\*EHH B\M_P#GN_Y+_A1Y;_\
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M:I6=[A1117.;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3[NQ-L5N[KS+K;N!6/YAM5CZG';WKIJ*7LUW-7C9-_"OQZ;==CF#::I_:/\
M:_\ 9Y\PR;?LOFIN"[",YSMZGIGI4$6CZE;P/9_9U=+I8S),)!B(AB6&.IX/
M&*ZZBE[)=Q_7YI6Y5T[]-NO3_A[G.7?VZ\D-Y9V+2)/!);X=U4K\W#\GE3R>
M.>E5AHNH>7_9GDC[.LWFBZWC!&P#&WKG(^F*ZRBFZ:>XHXV45:*7X_+KT_X<
MY&:TOWT^4W5K]GD^RQV<2[PV]R1\W'09Q[UUPZ44548\IC6KNJDFK6_X'^0U
MPYQL<+]5S3-DW_/5?^^/_KU+15&!%LF_YZK_ -\?_7HV3?\ /5?^^/\ Z]2T
M4 1;)O\ GJO_ 'Q_]>C9-_SU7_OC_P"O4M% $6R;_GJO_?'_ ->C9-_SU7_O
MC_Z]2T4 1;)O^>J_]\?_ %Z-DW_/5?\ OC_Z]2T4 1;)O^>J_P#?'_UZ-DW_
M #U7_OC_ .O4M% $6R;_ )ZK_P!\?_7HV3?\]5_[X_\ KU+10!%LF_YZK_WQ
M_P#7HV3?\]5_[X_^O4M% $6R;_GJO_?'_P!>C9-_SU7_ +X_^O4M% $6R;_G
MJO\ WQ_]>C9-_P ]5_[X_P#KU+10!%LF_P">J_\ ?'_UZ-DW_/5?^^/_ *]2
MT4 1;)O^>J_]\?\ UZ-DW_/5?^^/_KU+10!%LF_YZK_WQ_\ 7HV3?\]5_P"^
M/_KU+10!%LF_YZK_ -\?_7HV3?\ /5?^^/\ Z]2T4 1;)O\ GJO_ 'Q_]>C9
M-_SU7_OC_P"O4M% $6R;_GJO_?'_ ->C9-_SU7_OC_Z]2T4 1;)O^>J_]\?_
M %Z-DW_/5?\ OC_Z]2T4 1;)O^>J_P#?'_UZ-DW_ #U7_OC_ .O4M% $6R;_
M )ZK_P!\?_7HV3?\]5_[X_\ KU+10!%LF_YZK_WQ_P#7HV3?\]5_[X_^O4M%
M $6R;_GJO_?'_P!>C9-_SU7_ +X_^O4M% $6R;_GJO\ WQ_]>C9-_P ]5_[X
M_P#KU+10!%LF_P">J_\ ?'_UZ-DW_/5?^^/_ *]2T4 1;)O^>J_]\?\ UZ-D
MW_/5?^^/_KU+10!%LF_YZK_WQ_\ 7K,U+29[Z=9!-'\J[>01WK8HJHR<7=":
M35F<W_PCEQ_SVB_6C_A'+C_GM%^M=)15^VF1[*)S?_".7'_/:+]:/^$<N/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_':-DO\ SV_\=J6B@"+9+_SV_P#':-DO_/;_ ,=J6B@"+9+_ ,]O_':-DO\
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M-%-3=Y:[OO8&?K3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS_W(_P C_C0!L45C_P!JS_W(_P C_C1_:L_]R/\ (_XT ;%%8_\ :L_]R/\
M(_XT?VK/_<C_ "/^- &Q16/_ &K/_<C_ "/^-']JS_W(_P C_C0!L45C_P!J
MS_W(_P C_C1_:L_]R/\ (_XT ;%%8_\ :L_]R/\ (_XT?VK/_<C_ "/^- &Q
M16/_ &K/_<C_ "/^-']JS_W(_P C_C0!L45C_P!JS_W(_P C_C1_:L_]R/\
M(_XT ;%%8_\ :L_]R/\ (_XT?VK/_<C_ "/^- &Q16/_ &K/_<C_ "/^-']J
MS_W(_P C_C0!L45C_P!JS_W(_P C_C1_:L_]R/\ (_XT ;%%8_\ :L_]R/\
M(_XT?VK/_<C_ "/^- &Q16/_ &K/_<C_ "/^-']JS_W(_P C_C0!L45C_P!J
MS_W(_P C_C1_:L_]R/\ (_XT ;%%8_\ :L_]R/\ (_XT?VK/_<C_ "/^- &Q
M16/_ &K/_<C_ "/^-']JS_W(_P C_C0!L45C_P!JS_W(_P C_C1_:L_]R/\
M(_XT ;%%8_\ :L_]R/\ (_XT?VK/_<C_ "/^- &Q16/_ &K/_<C_ "/^-']J
MS_W(_P C_C0!L45C_P!JS_W(_P C_C1_:L_]R/\ (_XT ;%%8_\ :L_]R/\
M(_XT?VK/_<C_ "/^- &Q16/_ &K/_<C_ "/^-']JS_W(_P C_C0!L45C_P!J
MS_W(_P C_C1_:L_]R/\ (_XT ;%%8_\ :L_]R/\ (_XT?VK/_<C_ "/^- &Q
M16/_ &K/_<C_ "/^-']JS_W(_P C_C0!L45C_P!JS_W(_P C_C1_:L_]R/\
M(_XT ;%%8_\ :L_]R/\ (_XT?VK/_<C_ "/^- &Q16/_ &K/_<C_ "/^-']J
MS_W(_P C_C0!L45C_P!JS_W(_P C_C1_:L_]R/\ (_XT ;%%8_\ :L_]R/\
M(_XT?VK/_<C_ "/^- &Q16/_ &K/_<C_ "/^-']JS_W(_P C_C0!L45C_P!J
MS_W(_P C_C1_:L_]R/\ (_XT ;%%8_\ :L_]R/\ (_XT?VK/_<C_ "/^- &Q
M16/_ &K/_<C_ "/^-']JS_W(_P C_C0!L45C_P!JS_W(_P C_C1_:L_]R/\
M(_XT ;%%8_\ :L_]R/\ (_XT?VK/_<C_ "/^- &Q16/_ &K/_<C_ "/^-']J
;S_W(_P C_C0!L5S-7O[5G_N1_D?\:I8H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g417044g27u30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g417044g27u30.jpg
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M P,# P,# P,# P,# P,# P,# __  !$( UT"F0,!$0 "$0$#$0'_Q "Z  $
M @(" P$!            !P@%!@0) @,* 0L! 0$! 0                 !
M @,0  $$ P$   0# @<)"P8"&P4" P0&  $'"!$2$PD4%18A%S$BD]-6-U?1
M([34=975EI=!421TM=<8F-A9"F%Q,K9W6!E",R4G.+@Y<R9VUH?'>1J1L5*S
M-#4VMRAX8E-4$0$!  (" @$# P4          1$"(1(Q00-1(A/P<3)A@9&A
M,__:  P# 0 "$0,1 #\ ^_C 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MM_\ EU@=(GVU_N*2_MP=\O/>87+1O57KOSLYSW=<)7-VELCDG+=6[9LHT6:
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MD:7IU,<S%$1OS.&AU.U)<;@S5K92K6]ZVEO6]?LP+ 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8'S[_;/_P#ISW_B%?\ VA?;Q_\ H7CF!]!& P.B'_P[?_SAW1O_
M .^SW-_]$-;\"X/O'[@PG[?I7FUNZ_1E2O.U\K'7AL_J0LM*_.*UW*E4Q^_\
MMY5(K6@TB-,3W437S(L-+3+0XFPQHL-3*]3$+0;UU[>/*CO3_O"]TY4P0JMN
M\M4\!U\+=_!'.K+5970.E6875[;[-Y!U+I]C&S(G-^+7?HE@=Y%.YVD5MD,
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M<:Y9W6KPZ5V"BU[H=4'VZDWR$"LL+4X?&M_.;2*NM*/--;4C:9H"SA(TIO\
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MZ8#SIY2X=Y0K<JG\(KEEJ=5D0:X+8KQGJ75^BAPHFI0'Q==$56!TV[W&/3A
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MT&I=J\W='W1?MDG^E>8C_JKC'GGA'Z.[MY3%;HIHT*ZJ5Y1SBN4OIBZ!>K*
MH'47.;301H2Y!D3EK@;+[G1$NJ:5M(>OV+YF7T7R1Y'%43Q_UOG;7);,8LU=
M\^4:G>8^]5[D?YI4[4!@ ^M\'Z=?QG,^J5L@P>6G388NJ=7YDG4AE]M3*L#M
M*\A"NB@O+W! ?6^>4ODW2 W+*>)MW-.=(9:I%'*#1$>'NMUN/'(%XT,<,CLH
M;TPU+ELQU:VVV^\A*7%!8S 8# 8# 8# 8# 8# 8# 8# 8# UVQ6^IU!(5=LL
M]?K"+)8A-0KR["9'!D';8>=6P#K =1&3&22L!I]M2(D-GYY$E>OE;0K?[,"*
MI'J7S+$L];I,KT5PN-<[E^J_TA4I'6J"Q9[5^A#!NO7;]-@73Z2IS]'GZR2A
M%/PK3OX"6/DLO_(XPZE ?/G[#^W_ /\ AM?=O8[?[ [WZ%\WD[Y?YU=K5SOE
M0]VUBHUBQ66N58>'"L3(P?I:*ZU9VZ@&BMJ;CI9=>CQDNK0I6UN*#+5#['/V
M0/(_5H-#Y_WGI/F7N'7J<X,'4VG_ '#^A<?ZGT^@'G9K*QT*N">C@;5<ZH8D
MAY&M-MLR(SST1?RZVMK>TA';'_AJ?_#SSQ)&R1?K300RC57J18_']B6&2('\
MWOOYDJD]#(E6[>N%%I5S_*)>Q95UQ,$C^%>VPZY]-?P#N'\R0OMG_;-\Q4WB
MW'>V<%XOY]K9*\S 9"\>A*K)B$CV^@D:_P!!GSKM=K@ZX5)C^D;?$3T[D?*/
M(M?@-H96UIE(3W%]X^'ITYP9"]C^699%FFRNC/0(WH#E#\UKGT*O.6Z9>78K
M5L4^W3XE4:43=);3J&@>G<A3FF=?/@;=6_6?EBY5YFW5#TKP*TU617+I<&++
M7.P\]-@'JES>2(A]$L[1<;89(]=>H4NPP&C4W3FXXMR='3)6UMYO2@U$_P"\
MO#U4*W0':/8_EFN&N;DU!>AB#OH#E @G1#*":@BQ-R@S[9'E5DD@RG<3;$U+
M#NI.MM;3\_\ %P+#TJ\4OI54 WSG=NK-]H]I'LEJS<::=%V>K6(5(^;3!,'8
M LJ:*+#WOEW\CS#KC:OA^S>!M& P& P&!C#!L-7H"RI\L,!C&GX,5PB8GQ1D
M!N43G1A8V,N9-=8CH?($IC,=A&U?,Z^ZAM.MK4G6PR> P& P& P-1_>!0_U0
MQ1_UM4OUI)>*QX]1_48?]3OR 0FO'S;#('\9^:N/!P5M%392=-;5'B$XCSFD
MMR&5+#-&S@6LABUCLA<77Z\!&S3!P\;(1!08*(&QG)A$J6*3W8\$<-@1&5NO
MOO+0TTVC:E*TG6]X%<)GN'Q:/K5#N<_UWYBA4_J1(N'YG:Y7>N61ZWT,O7Y@
M\>?%4@X[:D"[41!SRL5B8Q!=?=BO26D.I2IQ&MAO]J]%>?J+TJI<9NW<^/T_
MK]_8ARJ+RNT]*IH#HUSC$9DT</D52DE3,2R6%F>0&R&&%1(SR77F'$)WM2%:
MT$R8# P("TUBUM%'JO8@5D9!GC%6-.@2T NV(L]>EJ@'ZZ36/D2$P#H2<A3,
MN([M$B,[K:'$)5KX8'F6LM< 2Z] .GPH6=;C6ZW5(98I!'2K-8DAC%B4!K\>
M6^R\9,IK]>GSMQ8^G']0X,A[Y?ILN*2&;P& P& P& P& P& P& P& P& P&
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MR)\7J,WJ-,>4N0QIM/R+3\NO@&WX# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8$
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M!! VL0Q9B^VXJ>%)7KI%[Y'8#(39GY%&)L\NS"W-W'DK6'D,\\<)0CL5CO\
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MKIH^OH$\,33SHL'E#ZI^ $#9(314E%?U->?VXD.SC 8# 8# 8# 8# 8# 8#
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M]C"RHTRN?AD1=%H,AR3I\,?!H/VJ7 T.>)[W64M!*##)L6(64J&C%=JW(A/
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M*&N?(Q,;^C(0$]TF_>$?W.=[J'/PE_G<R34Z(8MABQ$^OJAW#G<RXFN04W5
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M8:;4B4EXW9B"I#PA^NPMZTOXI>U'U]73GS+^8+?8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8%?O3Q
MFD ^0%'[YS4=V :4M'.JD$YL28"/,VJ[7KH-9I5&A(<L*5"QZV;78(CZYB];
MW"9:6_K6]M_# J&.Z]X/.ULL7Z#Q>F56UC;-:N VZBJY Q>#3-P;OMU#&* &
M=H]7-QK@P<N(*;)@[@Z6XXHK&4MJ-)(:94&$@=T^VL2JIX.[RNI:$64; F$Z
MF(\UVTS$N,#GP4-9(,<.-$<UVS;R7.J*1'F)\2 U)>K\%3BWM-ZCR%(#->A^
MB<#Y>Q4YB/(M(ZESNT<!ZWV1^Q0A%&!S!',JKJ!:;T.8IA\ R>F3K,0ZC"_"
M0&$H>GFCFVEH;>4M>PD*B=W\(]HLH;SX$$4B=9@G-KA4VN8V/DLT)JATJ(^+
MBWSEQ."?JL$=3=M;I\%Z>!=5'V[''19&VEM(CN8%,*-[Y^VTA/+3QGA5<Y2B
MW<KMUF1-+<SJ<PG2A51MCO+:I1I8RH1#AF59+Q2!9(Y&APF7?PE3&[>FJ:0[
M%0X&T4OMGVT>=W'JTGDL%74B7:[E"J?3=Q:V=L/.0,&F.7\_6TS)!$%NOBN:
M0>D:(AX4B(S-0T>G,L?'49$?;03P&ZE]NCIQVFB87,:N>+EYM9HP-LEYFMS.
M@3%]HH.N<\CV-PISIAFF5N^\XCQ(=?DE-Q(4X5#6U&7MN*\EH-G[)!\EU6!2
M9('SWQ7L!XB,O?-:LS @<N@ :W3*-7K=8.ECS=X-MN"*O7*X*G%69,5/U7_Q
M9-UK;*6WI;S81Z'Z!]NNQ<_N5E <,H%@B4CD,WMY&L N)UXZDV%Y#3ZM//!:
M#8Q8J9SCHUHYX./!@\]@ 8(1X[\Z/$6\IMS>!(+'IGPN)Y]T.[/"P%;I5 C<
MV,]#<*<@+@80P%%ZP2!U>V/(G5>)".5/F?7_ ,WW-*0E2H5>(P)\EQQK2%.J
M"F]7^YS]FD!6*E-K6J56*E=W!S]*=C>>#P,99"VJN5Z/)$B&=4N/MP]2W--#
MR412$.AK 4@"G--3)D=A068X']P?P9?K;U&E<"<GN=!YS1K#>>JT>J\>M86U
M@ W-:[5Y)H><!M5^&Z]90#MFB@-#TZ<F:-QWQ:4_B(CK3882?]X7Q^DC'BU.
M9TCI\,V!EFZ1+YCS:V6MWH"0XGKQZR*JS:!D,>^$KPGA]BW)*O2V1[<D<_'6
MXAQO7SAF(WW;O(*>:-=*L)'I-08:I)&\&JK8N:V./;*]"! .!66QBR4..Q('
MN& 0OTK55N-1Y+R7_P 2_IA3NX[FM!H5D^\[Y8KM4Z,=2*Z(8.489T^S!JB,
MKV_S+H=,YG;BU5<LE.FS'(@Z>Y94A)$N(.^?9&,U]%N:S&?E16W@D0Q]V_Q@
M"9!?F-EZ.T4L=:/'A-7;Y!T-ZXOE:MTU_C]AH+M1:!*L$7H8GH,-^ X+=CH6
MIQE?R+7\-?$-%*_>B\:0K8"KXR1U&Q"I%TO=(NEJ$<ON+H[F[]"0VR4M%D@*
M%)+RZ$@S'(CY!F"S)AP)(J1^)4VWMA;H;&4^[SY+AW"M50:OIIW5F<,I%3H/
M,KDS,L<=9N#3^9%N<5J:'CV/JU?[G?WY &I3P$:=$(DH#Z=K;;2EQ0:SS#[T
M_C'I8@3N/)ZD*O11VEC?W7HY;<;#<(]KO]]IO/Z[0E)KHH@*<O+9'I5;DD!V
MI&G1L,TVX_M/X>;^&#FQ_O4^#'8Q*5+MW4PK,..A8QRP\)ZR"8MI&=,I\.MU
M^FS2=5C#[)8+FJ\P'1$9A[>YD93C^MI9;4O ])G[TGBG3FHG/R?3^ND?SB@"
M78M#Y;;7&(35^K<:U:+D)IZ %99'TD63@?J)EO3I(4]/::5%6XE]+(; )^\#
MXS*0B:D%NJN&QK([<6N"N(=7.$[E,<03=LT3F21M2<UT5% C!)L@X\-TX@?$
MB..N?#2=ZT$R6S[B7F&F0A!<N>O<BO$.!5?TP4M 'D_1[)6Z7R2_"[.4YL8O
MQD#6B$2H%>F;I)>( '3%-SB1$>N(VW^(<8;>"%)WWD/$(PWNO$#O8HQ6"Y(@
M6MC?GSL;S?/K&)(V^#;*?T*1&I[[%1ME%8YY8)IJ%+4A<$<&DR=[4UMG;P1?
M8?O-T$1UGH7+P7FKO71G*(!O)YB7S5FIVVP6:!5*QTFV!3@NCQ#39R/2[S"Y
MLJ&-+/[0VX7,BX7TE.S$_*&65]V6<1!4BT4OR9T+H(&V\2]']JEN5+J_&R!@
M/%\GV '7.T4E-;39=&Y=['SK:'T.$O-0R4A<Y3$N/ E1GV$!R+3]XOD0$8WT
M +QKK-^X*3F=P8J7<*5/YP5 7T=P>A%K?;;73*FY<XUZ*4.,<KD\!,/N#V X
MHFJ!^*DH018WH,TU]U%J8[$@#/)W<"AM_F7:KA)$P;-QN6\,N7GCIQSDG7Z0
M21#Z#)G1@U;NE=DP8EDW'_*ST]3,$3J=.=_#)#L9XKU4!W3CO*NU52-/A5GK
MG.J7TH# +*'J+#Q-WKHZR0!Y;\IG%!B2L",22S)3'DOM(?0I*7%ZUI6PDW 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8%9O6TGDPKC1&S=SHQ.[\IIE@K-PN;XA!%V;SX57RK4
MYSK"F <V#8UC^;+1HI-6,VZ0C0F'GV6G=M;0H*L4ZR?;[8OE.V6Y0%Y;V-F/
M7J^ K=CYW86"X L*8I-U'52,6$C"-*WT6M"'JN3.Q84V02%*<A((+TXSK2 Q
M'HSGGV]2G(^-A;C#+TWGW3H,,_SE?&Z!=)9FT4DQ&@PI0B5JJ4.U6"LU&SIZ
MO!B2][;%RUNDV(Z7VU;^3 D\EZI\!] .,;L5CK<\L)YK&*1I-GH-V&(A<XE2
M:UT=<1IXO6(;#,)DY4 CDJ%^QU)=B%"<;_&;:C[#)=3LGB?RC(:N%NI\"HGN
MM4\^!AQ@-&M$HG=1JHL200KK\6! V+AV>TR)$(>C<]<2>1D*C1EN*2RG3056
M"=X^TV1AH_4'.@/,#;<FP61FK6[C=MKE[TBGO6&&Z4CB*^&GF=-61FK%XD&*
MG?U3L4?*A:8>0E4?82_2I_V_>J]3 <OHG'HEF,6LCU^V%R#_ #:Y5ZM5&ZUN
M73)_1J;9'K0,"P@UZ9+$QLJ96&TZE#9*$2GHC"E)=4$-KZY]OV%Z8(]8MPWH
M_&SOG*58QD"98:.9K?)[#= YCT-RN03^836Y[YJWH&\[LR*Y&FSFDD8'TW!T
M-R2RK307&ZQU_P 8V'@-'ZST9^";XO:K!),44Z"I-^(%X]F@@+D;.&1$&B 7
M;Y6"PBL5D^LK*0U%<CPH\QJ2O2%.(6$!#_0?VJN=$;C B/\ -:(4L?.B]5NU
M;E<WM]7EMTR&N92"-")U,C6("P!2SIH:HWY.F+&('FA<9S;4E+<1>PC*3V/[
M8%OH'<>40ZJ6!\M[, G\[Z$3K'-.F/.]9J#/.Q?2[8+ Q0E8/V*?1(E.O1=V
MQ.?0BLQYGYPY*1]=]R2^'II?BK[979HAR#4F;];!G#7K+U!C2F^@QQ([?5^J
M/=&M5_YQ)(U2' N\2_\ 9_//YF_. +(LS358:VE6]H;TX&LC.;_;"YQTBP7$
M!TKHU1MEWN]*C&.GU"X='B2;G>.E=:M'1!CYVRUX AF4.*=JES",F7)?4,D&
MY;Z9&_BVZA(8[H? ?MV^5NO\VY>2J'H2KSJA0T?INX4Y%T+4;FG.K96O5U@*
MQ&':V-).(%-"@_0'3++$)[4.)8I$J1M+#K[C(8JH^#/M%=5J?:;IS$?9.DQN
M-5-JNWW82^79N=^G^=UV%#KPH*2,+'-SQRP_*(@Z(1A/[8GL!D,N2766MZV$
M<S^>_:#5"I35E1W.*+7&MS[NS:^N*J'/D?DG19EO,3)\X6BM$%2;#5SU7T7"
M;)NO''G!S+_R2MZ<#<6^+_9^,VH7?V+'UDC83)G\P1T"&QWET7'/E3X?IIHO
M8K1#J'Z:$D0=EZ9 *&YQ!UK8=\LPF8ZPGY&T!N'&//?VP?1W1+10>-$>O7Z3
M9A/3.MW"R#K-?XM$D3[J7J J^*D$R;,"%#.=+9L XI^'AL-QB<-:YB-[6IU2
M@U*7PO[.S9R_5299+^R5FW>VP^F-;1V%E@0=L1FFB;+9[489J*85'J<RRV8,
MF.9<?'AHA&4E^&\R]MYW D;A?CK[<DFLWGJ'-0G:>;4[CUQYC3EV(D8Z12FW
M-4@)R/LG+KM"JQ8?#+L!*R[<0<R":G#VGOPXYJ0MU8YAAS017=>,?:(%CX=?
M)S>M6"ODBD.F.2QTGJ>JN*'0!-8'FK U;)PD6):"<QK#8&25)#)CLH!"=@2?
MBWM3;F@EX3X_^V)T'C]C[F&-=/L_-[?8^=U>Q3!MHZO*-V>\\^, J!R\'JDP
MAFK<0O0XHH:,@_AH&R)!O;"'5R&-IW@5PLOG/[4O;O/5:;?LGH6FC^JAS?Y'
M6ZY/O,OH$)RO3P_0;M74M[HEV@ %CY<YF49E?12F+'5(7M]MM#^TANR./_:(
M(!PDXM9NT'$TJ@':,/08;]!W&1#Y--1<J/<WF$S*6279N/!)PNPB91SZ<H"&
ME+F-M2(JIF_KAL':/,7VW?-MUK/%KC0_1*89VGK+3C%5?Z';JN(I\RI]TB%9
M9^?7F"Q\T3_3@BU:*_*Q,(JA%I$V2M:%2'D!-?,N.?;MZQSOT*-YIU^_6[EP
M&H#:OZ 'P;W;YE6+4"F58W4P4<G'G"%,VFLB*Q3R Z%(@:D(6D<YIIQ;B$JV
M$44R;]K7CHVHF*MV[N7*VJ0W=JW27S,CO%2.16NMG?U=UIL5^LJ5%/V=ZQF.
M9M&+5,7^.D(4.8D374[6UMP(<;Y9]F\07HP:CD>EF!/+Z)?.%ARU+LO3&>7\
MQY!)L@\)=*&4U AM5R=SZZF>AS/PK.X1$><FLR-(<VZRTM(2%1?)7VBNBVFN
MTRGRNS/66\5L!Q)@-(F^BZRF,"#1[EU2A46[H+ 1(ZG%WF01RUUQTYN$6D2-
M/E8+ZI,A,AT.Q2Z=_P"!>"ZS0^%3(IP< JG$CIWFPMI4.3N=7>:EZA485#%N
MN+BH060BV0VH274LQ$1F?E4ZCY=?$-P:]Y^3UINRI'6X(O7.BI0/<=FJ[< O
MY/,#*KRB>U?F=?BZEQH<&T0YKCK'U4('*=EJWJ/'D.-!EI/L;BCW!_\ I%U(
MA8^A<Z5<*U0T;IM5-S+%JS6;HH+E[$&16R,086A(%V:PL*FK>;1IF&E3Z?G3
M\GSAI/-_N'>6>CR^4UZ/>IM9O_7HM?77^<VVJ6T%;!\ZSURMV<)!.1YH-J(-
M8-C;9 V+GK=T.,?B$[@OR-;WO07>P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P*Q>O>Q<[XEQ"QVGK
M-?EVKG1=6Z?;ZY!@,DY1NOV$:39,"F(4@D)C2'2(QEYE*79#3:E.:TI24[VK
M0=8ES]'^0;IW'JD?K/D<O%C;KPV1>+64)4G=YAW"F=,.<ZZ:\^-#=.:@PW*3
M+Y2!:>DU>82L=MB_0:8C3(P_:$A,B?9'E Q$YD+,^9^H#*A2JK18M+-%Q')4
M5KG5%L>O-]GKKCB(/8)1,>)%C>B<])/MLQ9#L=&DITE3L.0V@*:M>@?MQ6VQ
ME7:IYG/52JS+%SU%QM -SFZ"-[LPRR#^M57F7Y,[;S0:/5[0=Y14"\\XS.@C
M'D[0B;.C);?=4%_P'5O'_MWLM1"V_@5@.W"F)O@:IW*_BZ?)K\&T\]<YC;.A
M4.')J_0#SYF56IUG"2VYFX<FOS'F%NCYS^DH6Z%6I?8O%O/NH]9KM_\ 'FZM
M4.7$2]!>Z%%MM0/#C)-!3N H5'M(PO?@JH+%N@\C(O US=2GX) I)W)W!W.7
M)EA9CR5TOR_V6Q]H]#<G\_\ [OR7-Q90@W>B4H0DU:9O0M'+'U-]VI@SQ&.&
M-[M]/=@SY[VE.ET0X_TI#D9EI#(<KSX4\2^MAG9G!?$(;1* 5$7WIPVWB83$
MVPE;J'Z8]#OX :S9RY6**)R[;;ORZ=\D+2IDN6]'WJ3IU;80J3]X>-37'Q !
M_@'0)W,>9U !=YH(Z.H)V-5J?T[GA&)7M,2Q?637YY<>A<XZ%/8^DB7+=BJF
MR6RSL1_?\8-3M'I7P@WTNX".B>/[F,-FIBJ(;<AA:Y9[$5LQ"]]FB]0W9JW1
M;L7C-R>;6"D3)D(['D3Y[VRV]!UI6V^E(3#Q\MY$Z34/2?7@7F\*!K_#*<W*
M'%CL\=8#]PI1[S&**N&)@X+:3R ;]BY:8;%R(TR8T<=CZTDBU'DZ^5(;MX'D
M>?$$O0]VXA4^OAR]IBUFWE!G1Y5(;&S:/JZ=VC4B'RX?42LL?7:7J\C;BB+&
M*:C%=?.EZ5KY'6E8%(!'I_P4:I%0N'8/#A&I/!Y %KC8"DCZG??S..*$T?LA
M(**DU2UC(L>;0['U;1"0U.:8&2IJ4/0WI$M&FF0OAZNZCYPIEUXGT/JG$]7X
M7UKE71H16YN+@0[/4.:00$ 9-8E4H^: S;1&D@.YF(L@>-;FV-ILA)9A0I"G
MWD)#4N%^H?%TJR!>'\WX]9:=+]2V&R0M5QR'3G:V<C3.9!.K3I11T1T,\+J]
M?*\TOS,Y@6Q]!;,J6_"_!LD%+86&([%:?"M#Z&0X[<_*YTM Y\['KY.ZBPM'
M;HM8CW%^N&CVUR2'3 EN2/$O>J&"$U;0QSY7RS[T;3KT76VP@M[VUX+32GR-
M.\UV ]4*G:JS7>D$2PZN$(5<!W^?QNFQ3#DT;=+60NI&V !57D)?:_$P-116
MY!8A"98=D;#:1'M3QAQ8C<Y'!//-MB=!H$ZZTJ*\^P(IE3FUUGH8.B] ="7"
MPW+8HO3:W=*5$B0Q(IN=/U&B,N!QRAZG'$A*W4!GCOR[VAKG/_1-#EH'5*"N
MV'2U-;KI0S/+2^Q4,=7*@JBV6SB2EA@GNAQP>XK(=J<U"?CM;D,1H+2WTA(C
M?0?-W+O&MEZ;POBT6V\/ZK>@U8EUG946&"]'$=$NE4\ZR+LX1MAB>S+HSU89
MB:@LN+0N4!A1F([#3:FDI"M'+^W^#>L77E- LWDP]7>M=<K_ "QH[7':>.LE
M1HC<^A\XM%#W/+@;+/!QZ[9JTP"C./PH^I,J /C1SS##3"&4!.76N]>.N$6(
M'X/G<FM-H5;'ZBY7J14Y( HS,NMNNH:14!SI^P]'$6>MVMHY)C%HI.<]";A-
MQD/1Y>EM-)T$&TCKGVYJS.!GQWE>QT&%*J4:*P<G!Z3(B5NIE^93927Y%:"]
M4/FQ(,IQ$6LF2*1QFX>XB=,3I/YJG<5(;KT;G'A7LGEX5W]-#O%%Y'SV= @P
MX-336>>V&ZP4W4NB;R^>JRS%J:!O=;Z8:%D("9XN0\=_%M(=7K3"G X73?>/
M@6WT\7Z,OO+KA:GA_*VI[>R0&MQ+4/YEU*@64O#87 GWP:-+IMU$>N*8,>.[
M+E*;"G4-:;TVXIT(V'^\/&O$J?U^M5[B4(0'Z(>O%8&UROR($<#<HD:O,,1?
MU972)O\ -Z-4[';;>\+TD1 FP&%RGYCB&7'G$8'Y/]3^$3=DK]7O7ELZT0D3
M*BT+B5H0+MUEK=M,F+JW?%2C- M9 #NIAH*H#CT@,9(N&HQR5#=B;W%FQTA-
M?JNR?;P\HGJ_3^K<*;*/7;5WZ4T-J(\038'R-PBAN8RY7)]V"S!PRV%:J[J#
M$C1- TEFM/+_  [B5O)",ZX2\G=1]F\875N.]1IG08EXN?/;P FVKGE-J]/Z
M%4N/^D0\4B<$5"T'[CT*Y1ZG12XV%/$SGJ[ 'RFU*EMST;BJ"4N\^R^65CJ_
MIFD=6X*HY-Y;4X_.0=@69JTF+<*;T"H\RM[\"RQW+#&L<*MV?I%R"!U1! PU
M.A-1EDY[4:%O2M!"_*N__;_$5Z5^:^5(M;VZ?Z,;L20->KM]K3%N&4E_GMB@
ML02=@9N.FR?)NL#P:'E XX%]!_0J.^YME2&PMG9+[YY$>&(]PY_Q:;>>"E[M
MS@6 I!4ZS6G#F[5WJGU>!?-V"RV"00;C ;@2;,QWI$M,U_4!&F=(^9I6@KMQ
M3TIXHM74O.X]WS!;^?>@[$*YJY%:%UF$5%<_;LG(.0[YV^>L]7M,H>:I[E*)
M5Z.(T^Q(?$)BI>EPQKR5+V'=7@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@56]C=67QCC,J])Y@]V!
M, ^+9<H;(]@BLNTN.1D*:^#X<ZB%IW\-]+<G45W;'U?FTG?_ *.PZ^.E>ZRH
M*S%:L2\7TB-=J59!UJG'#<PO:JPHS3?2<GEUYLH(F*XVP:&*B5:<3. +.48&
M,OS2.FTI<5]?3@;D2]Z"0,<8#/>3J^$N6QH6?91\TR2U0N<5@I3_ #A8ZC8;
MO<XO$Y1$75Y:>BH!LNL!9"TFZ?\ A&F5-IV]""*JK[-BA-E!ED\0T=UU@_>Z
MW&#4NJRQ,68"=Z21YW^@Z=#+\E;(6?JAZCNPS)@'.0'A.AX!"1]?33:6-!/O
M%/:T.;UCF?*[=Y7%\0;/559!NV!RKIFO5-+W):G?18B%^%Y75)D81%ICHT.2
M(RFA8J"3AMC4O.K3#0^'9'-YSSTCLWLA0Z9/W9GDR;)N;5PDK=@D(A2!J'S>
MWX*_S9Y Z8ZQI;_U%:9=6CX_*I6MAS E)IE:9DQZY4:Q7X\R%&&RV @ 4*9E
M#H;A!Z(/DM0(C"'X45XM*6VTK6VT*DN[3K6W%_$/$11Z97T&6Z_4ZY7TV-25
MG]@0HX*X9<;B:@-/$W1D>*[-?9A)TTAQS:EH;UI*=ZUK6!K%3XGR"C4\10*G
MS.D!::"%0P@RO1JV+6/9&P$_".P\B1&><G+^?XN..OJ=>>>4IQQ2G%*5L,W.
MYKSDI-;(DZ!22)!HC"+M3YU5!2YK98:2(F1Q-N5(@./H(P"Y>7*8>TKZC4F4
M\ZE6EN+4H.:*I%+!1#D )4*N'@V>80(V6$* "1\2PD"R5(*3CD:)$99+3"2%
M;U(=D)<6]K>]+WO R(NO@0GS_DH00(^I'8B.?E8V&/\ GBQI$Z7&C+_",M?-
M'CRB<EU"-_Q4.2'5:UK;B][#5W>4<M?"JK;W-: ]75)6E0!VG5UP*I+DP<06
ME0M8[<':5SP\1_>OI_M>BLK_ /2:1M(9TS4*G8I *78*O73LNK$62]9E&0@T
MG(KI:/MM4<H">FQGW!!%A3*-H?C[;=3M.O@K7PU@8X;SGGH;:5!Z'3!2DD'"
MR5#:N$@[25>([,/$T[BP6MZ(.EM_BE/?_)%2?[[O?S_QL#*RZK5Y\B1+G5L#
M-E2UI<E298<?(D27$I&I2Y(>>CK<>6E(:'K6U;WO6HC/_P#J1\H843S'FP"*
MY!!<]HX6$ZIM;L,34P(Z*XMI?U&EN1X<!EI:FU_M3O>OCK?[=8'$<Y%R=[2]
M/<PYX[IPR-L;FG*56UZ<L(:%L:'/+TH9OYS(H<K<>-*W_?V&-_(A24_LP,O8
M*)3[1-A%3M<%33HJ&3@@[-^$;C6NN,&8;T DNKVJ+IBPUF7)BOJ3M^!)COI^
M/Q2O6]:WH.()YM00E""<N'U  GG=<!A*V&ITL=')@882N-Q&@<#<$FF6W);&
MZ@,J;4]]1SZC:5[5M>OFP.5J@T1)0.;32JDDU7EON "^JX'T4!KE"X(.4L//
MU#_%C%R0HR-#<VRM&UQ8[36_BVVE.@_9M"HQ*PL6TC3*G/M<5N$S&L\VNAY5
MACM#9"Y8YI@T_#<)--P);BG64I=UIIQ6U)^&][W@&Z#162#9=FEU-HJU75U!
MHFW7 Z"#53<?W*<J[<U,/4E%=7*W]3<+2M1MN?QMH^/[<#($*S6RP696BM>!
MDZX02\B> ("8$T+.1(DJF2$3!4F.Y!DI?EJVZO2VU:4YO:M_%7[<#!S.8\V(
MBF01#GM'G!(Z!C<</,J8&4*8;"KG.!FV1[\!<1I EPG)5%TE&M,;D.[1\OU%
M?$/1)Y1RV8]#D2^:T"5('JDK'OR:=77WH*YNHZ9BX;KHY2XRI:8C6G=HVG;F
MFD?-\?EU\ ,\HY;&@!Q<?FM CC*[.@$Z^.9IU=:@ R0J62GBR >(@<F.,G#9
MQJ8]'=82AQEZ6\M&]*=7M09,_0J-:YT$G:*94[(2&1Y40:0/UT.8G#XDWY-S
M8L&61AR'XD>7]-/U4-J2ESY=?-K?PP/U%$H[9^';&Z;5$6D>V29@65%>$)/P
M6C$B3++M0S*8>B,9LK*F/.R4H<3I]QU:E_-M2M[ 3H=&-$HYDQ3*H6+PWR$F
M(5)UT1/)19)8/'KQ61'G2H;LIA\D B-09"TJTIZ&TAE>]MITG0>$6@42"0>+
MPJ3489:2,9"2"<6MAHY!\-&(++1Q#TUF$B2Z,CE'5241U*VTB0K;FDZ7O>\#
M)SJU7"@5RM$P 0C776F670$X5!EA7&8[S<AAIP5(8<@K:8D,H6A.V_@E:=*U
M\-ZUO QNJ!1-$@YG5)J6B]>=<? %=5L-^9 WGA$$ \\'G?@OQ0QUT",C0E*9
M4C:HD=IG?][;0G0;;@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@50]H^B"OE'A[W?D!PA:B4"_\M>[
MA+,ODF%4[@U@O]?JO6>F#/RQIY3TOE=5./6-]IY/T7!XN2G>]*VC>@ZB!WWD
M>[$C]7D2.3>>:F!D3/)VR'-[CU.U#?0_1Z_[TZ?*KGGRR\,H+%?D1;3$Y[SX
M\!*6]IYWYIY**?@PU0MBTNOAI-V^[)[UYNSSX3;N<^2I5DZ#Z/\ 7?"(DVC"
MN\W 8(:\?W)'/;6<( 5%PAA:;;8'-2HSC<C;(Z#K27]..[_8%G_8'W0NK>;/
M=_(?, >D\L*<SMX3R?(N=XL.[NDD.(>H^\W_ (9&F0#H9YRM@QU8F5:)-A1Y
MT9]X^_(5";=B*WJ2@,G$^X_Z58\=^\?3%MX#S^GV#Q<(N/,X]/<M9BPP>E>D
M.*,$XW:"0B4(^$QCA<\_+%1ZG]1+=CG-ZEJELQU?ATK"NI3[Q_J[E8H8#[YX
ML-5/HYNEP;4*0(K-[; C@A?U.,X77>B]9"E9*[)PRB6FJSW)D-@RN00T2C_(
MO>F7F]:#63OWP._#1K)RK\ X5UF?U*?-G<6XKS3L)@CW6C#Z?[0XIY5L/./3
M  B#AB*+UKH4/KBWJTVPZB''M R0%DHD::5,4&X\?^\[T[T1Z.\^\^Y/2>6)
MXSV.=:32[N4!]+-V"301OM#T%YMKSZ40"88=0; 2I?&(T^3^;LR6XYV<_%VU
MI$;>E!VP>@O63= XKZ[N/$ZIOK76?*-)*'S_ #NR?J3F%;D&8]3<N45EWH-D
MK"0A4'$KK3DZ9(";*J0VPN,G7XM2&MA0+T=]X%'))WE*N46G5FUV[I[_ "DM
MW\98XW0ZV.YQ4^C#N+$-3:<?E5R. M$%#'9HRGBT"69;$2&XT.5"6]-4N($#
MU#[WO4;"0I$27QSD;31ZU\^LA=0Z]V.6[)Y5U(OY&#!N6U)*A>M%?4E&7ZUC
M/GQJO^ ?2KDC3;3>YJ-Q VOJ_P![8M&[EU+G7">7A;51:K4*I%HMNOX7IM3.
M72_'TUNP6L^S3)P4-<M4[EU!)%2+PA0F.1M+P%^((GKGR8,*0&4\M_>S7V.S
M5 KU?F(/F/)C7'I]FL3H#70[UU:M7*M<^X%T K;U<\ U*?82'$KAKO484 D,
MP%D_Q@];DC7R/*1&"!I7W\>I_D)*YP/.M9> #^V.B)-=>F75R\0N0/7RY<\I
MT"0/%02C>NE],+<[/*B37T0QH"4)<A&(,?4L5-(!+8S[S'52-0*7A7/O/@\=
M7>V<2CG $[IAUJU:X%VNWAZK,CPA*H22$WM7"HY'9"[1X,8BW#:D0&F!RU3?
MG8#Z'<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@," /2=Z T3GHY
M=PKU4LM#NU_Y]RKH$&])B+IS-)ZC:1]'L$NR,DV) >2*3$-_3<8FI_!R/JZ:
M=W\J_P!H=8YO[BGE@190MKZ!YL%G>L<U@3AW%;A6*AS^Q3956+="GT@3KDES
MGN:,5>K2*I(&SI\C3@^$I,]"&4O,2(3LH-S]?>G_  A1!O(07<?*M7Z^/Z;6
M"W<JQ3[!RCCEF(@370@MGN*2!.K7F2F,'MW02E8G1R!%2FT.$=?%^0[\'EM!
M,],ZEYJ[OVD$HMY7!+](<MK%X*@3=WH7*#-OYV!Y'>['S2?NJ=*C/G)8L0CK
MP8N&';&24Z5(COR=-MLJVO80=2ON4>9;)0(T/H'$AU/#=.JQ"\]##N3..GZ#
M*M;W-!_2^BQ[JK5@BZVDC.)0QHLJ?@0]6Z8[]2)IUMM2]!R2WW">)] NM>D.
M^<VKE3#]>L0^_G[!KDACH5?IM3['RZC 9IJA+LI2U,UJ+TZX292 TYAHI)_"
ML$!L20I3NF@]%B]I^4>5=.[@X7\N!A\]=WJ-LLEUK]+YN&OG360=7XO>:3?K
M;3[<S2>F%;_7>B]0B-PX,B)-*B(P_9E2H[6D?$/=S?O_ (K[5Z,Y?RPKXA#A
M^T!"),T'LMGXUQ<^GD5I(S;KV"!.#WP*^<;CD+$2#D3LJ<#D.+B'"#:Y&]2I
M#SK8>17[IU))?J?GEJX;9-FQQHO7+V,?T)O-#35&.ZE.3F8+[XY2Y=B*&>>"
MY1!,%$%R/HNZ@.^KZNW%:"/;K]SGSG:.;B+#"\NOGRW-*E^\WD8/I CD33-3
MMPT+='>8RJ4!DV.7;HK:F:8XQ+-5T>XS5VW=?BWF&D+6D-\9]F^7(=JA4H=X
M\;1T %W^<&%U6& \]1C@KU<8O4:@'+ .8_5C,N _.GE/C(Z,AM R4[M<'<Y9
M#_@FPV>E>O?+_JXCVPD/\NN6^W4_S68+&2?5.=4!2+M3X@&J7LKQ0A99_P"?
MR'P#Q>YCM)9<U*!SI"),EKZB&$./!Y\P]H<:L%%Z[V#G7G"NA>K\?\G$KJRR
M-E\JBNFJ?S."6VYR/]=5602.4NGB;F%>8"-&8<"&2&?*5&QG8WS?($6G?>7C
M8$5ID@]Y)&N7#H5PL79*Q%&5G@AP^3ZL G=-K-=Z:X18/ZCP;7<7^/'61EFE
MR6)GT&H^UNI0Z[J.'-(^Y/(4 [+KRO'B7KT#O4[JT&M_H[@K1.7W =.*"^G7
MP 6?L: ;EVID@ M$ZQ_C&B4S7TE-;6T]&<>"QW(/?T;L??JWQ</RH[7&B@FT
M2+%.MMBIT(K52P$=,,B!L6$#L-CBW)5I"M(D[3"=;6,;TOZWU?E=^@&LV/[I
M_':VS/F2><]/=A XI=-@VO=#'EHA^OJG!+)50=:*72%8[H9I/0PA2NV/8B++
MC5^6->E3'6X'R25!-O-O:U-Z\2[PSSBD6^V@^""SLLM9@A"EDQMV*A;7?ZND
M!S]H?9Y4HU+)JYQ/D1WW4QHJD.,-_4^LMQ#05WN?W5N<#MBD4;G-DM,:Q'Z.
M/KIXQ9Z'519:LW,M3)D7H; @C9=W!FC$>:7F"<#%)8^&-+RWVQ.I+$]6T:#@
M/_=IYH*J/ZH,\AZ8PRNJEKN,?>*<J!PK-4*G-ZB%N!T5(-])8AC2$8]R LP-
M!39+9DO\[&XK+NOQ&V F_JOO.J\B[39^1F.?7>S:JT2JE3I^M?HZ) KP:U&>
M5U$=+F;LMU#RS#TVX]A#QDMQHZ-,,?B'75:0UI3@0#7?NW4:PO/D8O&[BY56
M:) NDV9'N'.]6*M(%.=J?Z='MU=(V(9L:Q017)&W-NQGYGXQ\EI&DH0UMU0;
M#=ONG\]'N'6.>T9RWMU[H?Z GFR72>45X=*U#Z%*I!NUU41(NCMHNM4BPXZ9
MT,C"B)%3I#J1^YL>9I:$!^C/NN\J)_AVX/+.H%=I&S[.5EP7^;QVQ%#KKUE@
M6VVF1TOH/YD (B2-.(;:KDI*3\J+N,^W'VAY6V@F&J?<'X_8^2R^P3A-@JM?
M%=H1Q.Q0K%/J<.943LR!'+BBEJG[L.Z\+%$11"&ZA:9KR5[F,_24ZEQ"U!KW
M.?N2<HZ-2>NWZ%2;N-!<CYX4Z<02\1Y\6($JN"-G*\8_$PJ[<R[E+*L$J_(<
M8B']C'9H_P"$QC2V$N*;#0[A]TFE0I-AC\_Y59+J/"].;Y5"NTFY\V"T X?@
M].B4JQR!QE%I)DORB#5$33T2<Y#;@RT,-15/,NO;VV$AA/:-MLOEN#Z*KG/Z
M\15*[+1J ^(*6&;7V(=*MG5JE0)5L5I@?8GGK% %V?4EL2ES3+LO6F=S$MZ4
M]@9*[^K.I :MZ+?@<^YS MG)>^"N05%D_P!3K@\ 8KQ>O\$LL"W6"?<R?,8#
M)R6&[$^_H.Q/0VB1$8A_CE.OI<V$5<E^X:<Z4[VW3-)%OQ^<<!L_; +K$&R"
M/D9K%6J!H1#NSLY1 >/D]/U:U3QP^'(?EAX,!]F6M]_X.8'Z;]S]FY[P:O=?
MZ/R8$.41[3S&OR4D(UGH3Y'A)L&"M'6^HBJ,??-6T9.YF*4;:C,S7-,&'!*'
MD[99E-ZT$E5KV79CWC?T%Z8D4VN"[/R:+Z,.5VDJ,RI48C5^8FKHGF9*QO+1
M!FP95OJX&')(-(^1J/+<D,M.[2U]3 ]E&]!]VM70_/M=V]QY^L]3B=5G6M_5
M:L(ZRC$\NF5U4F&$CB>I7@"R^8&V=G:%2)C^V5-[<4WO3NFT!V X# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M"YT@; LD!N%#B;CM;GMA,_K^^=GYT41.XGQ8%TT@KSYZ5OLHC-&0M2P'0*+
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MLJ02TP]'VQL+/];ZET /Y4UV2E\J!B;E:Y/+'"-#N5;/F7AW.[]U*LAK W<
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M*#1W@A"&:F<W!W%3WX&=U2W,QAU;O))ZJHBLKD$9KD?\6AMUA3SL(.S+ 8#
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MGN>2"'**V9-A:+*(B24<7U&RLR%%G8T=;[;VG7/C!W],._# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# JQ["MW<:1R2!8//@R4
M9OL/IG+WIPB)6-VUXQ0H=S%$NC $#DMN+B/6:EP9HUF<CY7($B8V^A6E(U@=
M>P[V][HK)9VND?*]SOQ*W6GI1VNRBG-[Y4QM$I=D:N%GXP"L!:O5HE!G)I8X
M4, V%?TW)[Q&?IS:VEZ;:?"[WE_N/6K>Y?J5Z!I[])Z'7>B=4#T9MT 9%P^I
M<^JES-,!NBUJ1^ <$L5N>&DP8T2&I]TNVW'U)F:VJ6U\0H=9_N9>BZ'5(ULZ
M%YU1SMV1 )1=ZO,#I(BEE;@%W>RK%$HZVZ"]>; ?ML$1!@1BDJ-#'0Y2'5SH
M<'XH0Z%N@/I[T<GB77[_ 'CSU)#7BHQ.?F*)5Z\%Z$>0;&]%0,;_ "\F*D !
M9Z:;YQ(E/+/_ (+6HS;+?S;7'0AQQ(5R1[H]NE>6KN,KR#-Y\0L]9L/Y&@I5
M>U6@MSBR5:IT$B_*OM- \ZEV,U"N]NNCP8!&%QG767Q[DB:I49J6J,$E]W]2
M^J>8PN#-5;C=BL[Y'G%)OG47H',>BVDU8B\VEWZ;=*<,A4ZIE0-(D4VPUL0L
MH@E)B3)+9]AD>C;C#R5!%U*]T>XR=FJJ#WD$GH'=K74 J8;U3Z;67*@&:L!>
MIV,G/,RP)9J3(O.Q[IT-MQE$0..@K9GO.:EQ)BPL#V_V!VBA=)Z3SCGW$6+H
MGF^ZD0,7".S>K6,AANBU0L<Y]&DUCFU8M-O?L)RS4,Z!FL,QE)#J( B4C>X<
MY6M!RN4>KO0_4.K4>@S?,QWFH=YTTOJI^ZB.@,PZ2Z-/]AC1*P$.KJ@ZI6PT
M0K=1K$Y,^).=%?\ UP*2AQS:6DN!$P[W1Z@L\N^.T;S/$M=:I]C[5#398,'K
M7X!^/R>V=)I;%1BJW0__ *Z+L4=IPXPM\+^.'*A$UP8GXH@RA#X><WWYW^KQ
M31VX>7RD>EUBI#SF[6S Z& _>.=*]/3S$13^?!+=4!4V'9#@R<(N42$16F2\
M%/M#6T.E!Y%+03+W?U!WSD=EW7Q?"9UJ:C<GK%F64K=2ZM>H!N]GYU@%V*"$
M(4ZJ2@(VM<ND"(+Y-)F>-G$(AMA<?Z6F5[<"O<7V=[:MU0YH8_Z+Y'E,N^7W
MF ";!)TGK5JLH&$N?Y[?Z2/(C6:/J  =)C^FV=8\D4_#"X$*F3OQ$G\4XC\,
M$G]6]>>HPGH"Y<8Y7YB(66OBU#HH+J=GKG38%+9EM#:D7+/D2H6N$89V"2C6
M22S W!<:0B2*>0XXYO;FHX<:@^K?55N5Z-MA'SX:KL?GO H%QYER(M4NAPBQ
M+J.C/1T(J)R[S*7#A6LE8 0,)/TU6D$-0(11MMYK4O6].!H5C]H>V!%[(CG_
M "WN!3.>]EDT^WE(%4ZK:IMWHL )U*+(LE48!UN9L=%*.4\;:1TIK\R2H:5C
M"GFTSG4.O!N@_P!>^OSBV+$)\KIBTO\ 4I)I0\\)ZT*O)&G I?(].E((R728
MZ!YFU0.HRG!D>8TVEG=:(?7WO>EHCA,,WL?H>/Z&[Y3D429ODU+Y#;+#S,AJ
MHV)TI=NA@ZKR@U'B K:T'75_RUR7<)\) ]UN=/DSXSJV5N-1WHT<(YK7I#U_
M9>(=ULQ#A<.C="J?*W;SR..3K?0K%LR2BWGK5+>KMLK+0.MDS%I_*N:03_X,
M-K2W(=CB-MM;U])V2$:U3V#[?"2>5U6W^7)%W?N=N%?F_11PF]540/IEAMCP
M>"&*A'*A(>!WT> ;?+.R'$Z$-PXFFI"F77M/:#<>B^V^[ NQ]HYS1.'Q;35>
M8W<51Y?08]<[/9(%(U+HG(+NBU7F#2*";<M40^[TN6-B":LL@5'N"]3)Z6HC
MCRXH1F0]U>S-EGILCR?8J6' 3BK9FNO\YZM>Y<ULU0)A.F"T6H*(#Q$FJ_9H
M3CYY3<% U$'Z;3,Q6GF9;H1^S]TGTV2D1JV+\CI_>;NA1+%:.5OJZ,_=N9.1
MW.&-D[C=1<6G_!VFSGNM2VXXR*O\_A:&MO2F_H/.+8"QO0/<_=JI=:_5(?EN
MR:+KXR+ZA9:"N/:+E>W'"R;E%DO5N7S4%9ZQ!KM:(U9.U-6)X'83"5KCQ!B)
MFD,J")A/MSVI<(]481YBN'.Y%BZ)0J[--E^>=&-#7@K/=A5(M*:T&B463(KC
MEKY8[+M*"-@GK$#AL5Q.I7U%-O8$V=(]8>NQ7:>F<NYYY0_'UNLG 8>H=(M#
MEZ< F!\BM#+#,M<O56JQ.),"F)4F<,A-1927XDX4O4GX_7^6.&)M7LWUL+D4
M9H-XOL<F.?N "LV";.D6O4:#LR&#W+2!2H%4F3/P[E1N@R-^:RXK0^'9!1L;
M*TA41"U!#B_N!^MJE!YU7K-YM?FVNS-1J_(E%J3VL:2D7 #RNR79(ET37^;D
M!!:P=SDU1^0%; OS(%2B[=2=6R\TEEP+7<:]0>C.@47O=ON_EBP4 MRFP)75
M*'(DFI5LNU>'%2V[+7QS;@-D4<O,6KA4RAKHJ3+%E)9:)'0MM"=ONAJ] ]:>
MK+-V7D5"MOCPU0:=>(Q!-OM!,H?FJK4\'JT [*N+-AUE05 \1;:?M^$L@Y#_
M #ROG1<N,IMQ:F5A%5I]E^SN613$0OYB/=0E/]7M+=/(5>C]&^K-Y>UV[O53
M'!CS(>MOCQ%LA\_YT$)0IR%/QIL Q'>4RZI>G7@ET?ZP]12>U<KY[.\E&15)
MMMJL=6MMYFR;/I@:JGDVJC938AR-6Y<"*!38(,\P&DDUQF;!6/PC\=;3KZM-
M!V/8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MEEIAIE#>@GO 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MT.S9/1\Y$BH:KO8J=3JM81;\^I/$B%AK-DARXOX1K2-)8=3@0IYC'>A..^A
M%F(\E]8;\SVNGWZH4RCVFP2N@V#G=S+C_';):R=%&6'I)TJ,$F[Y5+Y/@S5R
M"&VTN$)+'THY)I+X1F8J7K+H7G;AO,SG-/78_HO/>!==YPX>C6^159@WV/8%
M<]C>?^VG+B$ZE&E7#G=$:$VAR84F+G#XB9;6Y,)]<EE+81F2YI]R6TT8$QWJ
M@=;VCF'.>;5+GXKDUQ+68?TB1$KW5JW,=[Z#J/?N4="DW1-BJ(8PJR@#K3H>
M=8@\EQB4S")?1#OMY!+O4F"13?1]I"%F1E T]7S;U>,@Z^5>YY6I%G#U"[BD
MM&;Z/@V5V4W+)E&VWW2"7M,IU&TU@3%@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,"![QZA\[<U;)N7SL_.ZM^3&"%>*,EK,.8E0C@IRG,$1+\
M+3RY:9\.3T0 RXWI&U:?-P&OA]26PEP-4(^V?)HAZ0P5[YSD<]"IL+H)!N:;
M3&6+IA*')(#+ 7T\TC\IA$X41QR-J3])R0E/][2KXZ^(;:0]/>?!?(G>^3NP
M45GC$=V6Q,Z4DY&?J8]\=/DBBC!,I'VZT,?#DX3\>:B1]-<)YEQ#^FU(5K0<
M!/K+S4JGR+]^^WGB*?$T1_%'7K#$8BQMB:*OIY-$A#RD2678/.&U'74*1I2!
M.OQ6]?1_CX'- ^H?/%HLE!I]?[)S\M:.I5B!<^=@HEAA+(W"LEAQ(R'*A&-K
M2J6T9#!9TR&C7P=EQ(,E]E*VH[RT!C[%ZV\R5&V76AVCNO,J_<N=#W"=UK)>
MU#()@!&:%@C:VY,*0\AUXAH3:!DC\(SIR5MHC&WIO^_M?,&MK]S>/F]*W_TC
MN3N:37X5HUN/;!\KZH0@)CGXTF-^&6[^*D; 24SUQF_GE,PM+?<;2TVM:0RP
M'V1Y8LRJ1H)WGFLU'2:E<+]1)'ZCB1HEIHW/F'Y5XN0B;+W'B2*M5(D=3TZ?
M\^HL=G:%K7I#C>U!E*9ZO\T]#U%U2>Z<PLC\QH$^Q!&VX0X4^G9[ZYRVO[>$
MKDH)QME^CM_DC"76D*634F/K7U%H3L/=<_4WG7G5WG\WO79:#5+P)K[5K,UX
MV>C09@*M2()@E'.GG'MZB@A<@?7YSS;TMQE#C<5U2=[TC>!B@?L+RW93-*KP
M+O7,21OHK4=REC&+2.U*/.2[ ?J4.#';<=;^@7F6RJDQ3,)[Z4MTF/D1$-[D
M,K;2&X6ST'PRAZL>[KUSGE3_ $C8(M5M&K#:PXA0"QSJ4]T>&&*HG2V5PY\J
M@QG3+:%ZUM8UER1KXM-K4D-23Z_\M[J$R_;[]RI%.'18DLG8'KD&8@"VYS=O
M<C-%5/24.#)JOW?G$JC/I;D-N"):%H2N.XE(;!'])\$E\O*]JC=:H[_*P)+\
ME.7=LY%4%#'/SB#7M 2KFE?7''UG"<:(F"\A$M4B2TC3>U.(TH-6B>RO*D\H
M.#0O0'+99 G3Y5_9;CVP:ZQ%I<!-LW/LAB<AW<$ *'JH9M$AR<Y'^@Z)EMK^
M5<=U*0X+?MSR*N,#E[]%\E88L0VT%A6YEP%P7'(%+9*R+.[,CS'F) ET2P"G
M*4U+2P\O4*1]-*_HN?*'*%^T/)IDC4! _P!$<C=*WV?/$U(:]=0T.>8+C9@H
M=*$(B39,>1%+;GG8#+45]+3\AR=&2TA>WVM+"2N5]MY'W 87,\AZ+4NBBP!;
M\C,S:H8BEF1I-4**3CQY6XZU*;1/%3F)<5WX?2EQ'VWV5.-+2O82C@,!@,!@
M5G]#>Q/.'E)=3;[_ -*C\^7>$FEU9+]:N=A_-4U[8S1C:=U*N']1/P6S,;X_
M7^E\_P!7^)\WRJ^ 0U0?NC>$.GW:J\ZHO>X1ZYW8Z.K-7"HH/58"RIPM(1$'
MP4S2M%@C8NY$AS2?J/O--)^/Q4K6OVX&S]H^XGXV\\] )\M[%VB)3+X'ABYY
M$ [2ND&EQHAJ"T2&/;(5RG&!3NI4)]*_@A]2D_'X*TE7QU@97@_OCR3Z;NDK
MGG#>O1;W<80";:)09FG]! K:!#I@^!,G[FVBI@QRDLRRL='TTO;=5]3XZ3O6
ME;T$66#[L?V^ZJ?.5<_Z&@CSM;,$P!J KG?79"H)<-.?'$H>WXE ?BO[C38R
MT?.TM;:OE^*5;3O6]A-?,?;/F#LG-NE=>YMU*/9N=<@ASB'1;&W5;R,;K<0:
M%?L4YYP::K TR2TP&C+>^$./(4K2?E3K:]Z3L*^__# _;E_]Y*!_LU[+_P W
M>!8,[[8\P5K@U9].&^I1X/#;B2:$5N][JUY?9)$7IY<8W&2!BUE^TQMJG 9;
M?S/06T:^C\=[^52-J"OG_P ,#]N7_P!Y*!_LU[+_ ,W>!8'O7MKR_P"8I%1B
M]SZG&HC]\%S#53;>JMY/?FXR N&W+E)55JP<1$TRL@SKY)&VE[^?]B=_#?P"
M->;?<Z\,]>O=7YGSKN\.R7BYE&PU:!-T/J0U9,DZVZ\W%3/,T<<+B[4VRK?S
M/OM(_9_#\?A@93K_ -R'Q9P7H9_E/6NVQ*C?ZO\ EFSM?=I'2RZX'YP)@G!O
MS$*_3"PF1^)%$F'?[U(<^72_E5\%:4G0;7P#W1Y5]1V@Q2^#]8C7ZS 0#EG+
M"V:G?0"H8)HA %+G[E6NK H+R4SR;#?TVW5N[^?X_+\NE;T$+$ONX_;Q$$2
MDCZ+@QB N=+&SX^^<]@<W'FP9#D64QMQGGSC+FVGVE)^9"E)W\/CK>]?MP)T
MH/MOR]T_D/0N\T7J<8]R;E2R+5_MR*K>8#5?6*%0S9!*Q!6L0; 0_#BR#+O_
M  2)(TK2_E3\5:VG05^_^&!^W+_[R,#_ &:]E_YN\"P=O]L^8*%Q*D^C+9U*
M.(XQT6?"&4RZJJMYF,FIQ&,7EPF$A!]8EV6%M^.!EJ^:3#92GZ/PWO6U(TH(
M"C_=Y^W5*D,18_H^ X_)>:CL-_NW[&GZCS[B6FD?,OGB4)VMQ>M?'>]:U\?V
MX$[^@/<'EORT> 5GO/58U!.6<.Z?!0'JI>S^YXAF8X/<F)?JE7.Q8^DS&E(^
M1U;;F_A\=)^'[<#0^5?<M\1]MZ#6N6<O[E#M-]M\F5#K@!NB]/%+)280Z86E
M-I(':4,$QMM#X#SGQ>?;UOY/AK>U;UK8?G4_N7^(>*= LO+>G=RAU>^4^7'@
MV, Y1>GE%C94H?$*1VE$ =))BI/U($]ISXLON)U\_P -[TK6]:#?_/\ [=\N
M^I3=AKO!NJ1K\9JHA@Z?A,U6]5_8\5)EZ@LRU/VNL HTC2Y6](^1I;CFOX=I
MUK]N! COW?/MTL.NL.^D("'67'&74_NV['OY7&E[0M/Q3SS:=_*I.]?'6]ZP
M)_JGMGS!=^'W+TA5^I1BO%>?3Y@NX79-6O$1D-.@-AW9;"P<^LQ;-,VRV?B;
M^:/">1OZW[-[^5?RA7S_ .&!^W+_ .\E _V:]E_YN\"P/0/;7E_EG).=]UOO
M4XP#E/5]CM<_MBZK>2#=AV5$2CH_Z8D56)Y\?^($PW7O^%Q8_P ND_*KX+WI
M.P@T5]V[[>9HH-##/14&43+D(0L=%USGL#6Y,\A):B0X^G7^?-,-[>D/)3\R
MU)0GX_'>]:^.\"9>_>Z_*?EVUBJ1W?K,:A6DW7V;2+%/5*_'U2@,@B1%,D-2
MZK53L%I*R J0W]-QU+NOI_':?EVG>PUCCWW'?%W?>A ^5<C[9$M]^LB";@6O
MM4CI8=<Y 87,-$E:(6&F"1+'X88/>=W]60CYM(^5/Q5O2=AA^C_<\\+\DO5H
MYIT/O$.NW>EEG@=F!N4/J9%8LI'2A;T14X/1R R5M"7$[^=A]UO?Q_8K>!)O
M!O;7E_TVY<6N&]3C7M= %PC-O2S5KR!_)QA#<],.4O=IK /4S3VQC_\ %C_6
M6GZ?[=:^*?B%??\ X8'[<O\ [R4#_9KV7_F[P+!AO;'F&P<$L7IX1U*-,X74
MR2Q%@OFJM>&61Q%!02&7&4!DUEFTR-Z)'(K7S,P7$?%WYOC\J5;2%?/_ (8'
M[<O_ +R4#_9KV7_F[P+!]2]L>8>*\\YMU?IW4HU7H'7H4,CSJPN5:\%$62'/
M"QK#$>;' ZR3+C=/!YC;WRS(\=6M*^7>M+UM.@A6N?=A^W[;;"!JE>]"P2)^
MSFA5>!CT\\ZY&5/,&YS P7"U(F4"/$8W*G2D(^=UQ#:/F^*E)3K>]!)_=_?G
MD?S-=F.==PZ_%HMSD@8-F8"O4_H1U:P9.5/A09WXVKU(V-2E^2+?3]/;VG4_
M3^*DZUM.]AC^*_<0\<>B;] Y?QOL\6Z7LG!)DH(%JE]'"K?A!HJII)_4^R4\
M.*;U&BHVKY5OI4KX?!.M[_9@:E>_ND^#N9W6U\[O'?(0*Y4@^4J]H"KH'5IZ
MQ1T++=@DX"IHNBSALO<64RI'U&'G6E?#XI4K7PW@2QQ3VQY@]%!>A6+C74H]
MT#<J&QB]^FM56\A=5\=,B&)\:2MFR5@/)(:=B 9:_EB(D+U]'X;UK:D:4%>]
M?>"^W)O6MZ])0-ZWKXZ_^9KV7^#?_P!SO L$W[:\OO>?Y'J5OJ4=7!HA30:1
M?_TK>=,MDMV%FJ:C;K^ZQJUJWL_(1'^;4#:/BKY_F^G\5X%?=_>!^W+K6][]
M)0/AK7QW_P#,U[+_ +G_ -SO L)V3VQYA\_U;F]UZ]U*/3ZQUP<X6YV4=JUX
M,IL8]H:(+N2&XM=K)><-TD<>B.?+,:CKW];X?#YDKTD(@IOW4O _0+=5Z)4/
M0$(Q:[G8!%6K0E//NL0U$SQZ>P,$P$RR-#B0(JI<Z2AO3C[K32/F^*U)3K>]
M!O/;_N$^/?.%[?YEVCLD6DWB*+&FGP3U,Z*;6V,+H<<'2OQ]:J!D6K4E#*M_
M+I_:T_#^-K6![>&?<"\A>D[SKFW$^Q1;Q==AB%@T#9IW1 :_R@4N*W/F?CK-
M40HSX1US6M?)]?ZBOF_BIW\-_ (\M?W6? 5'M-EI5I]!015GI]@,U:QBU<]Z
MU+4-/5\C($EX"I4"A2H,E4,A$<;VXRZXTOY?BA2D[UO83)R/VQYA[M2NE=$Y
M1U*/;:;R <Z6Z*::JUX$(K8]D02.N2'(1^LBB1+210>2]\L-F0O>F_EUKYU)
M3L*]Z^\#]N7>M;UZ2@?#>OCK_P"9KV7_ '?_ +G>!8.;[:\OCN C/44SJ49C
MA!DG^3#;[NJWE;,DELW-KGX70!NL+M36_P Z'/,?,N"E'Q1\WQ^3:5;"OF_O
M _;EUK>]^DH'PUKX[_\ F:]E_P!S_P"YW@6#[E[:\P>;(=#(=LZE'H\3IHR<
M9HSSU5O)S\]&CFA+\V2A%9K!IR!IAH[$W\LK3"U?5_9K>TJ^4(LY_P#=$\(]
M2N]5YS0^]PC]TNQR!6ZP$10>JCUE#1-Y,>#"3-*T6 -B[?>5I/SOO--)_P#C
M*UK V3L_W%O&?GOH);E?8>TQ*;?0<85,*U]VE=),KB1C8Z.6&.;(5RG%Q+OX
MH?*;<UIM]2D?-\%:2K6]:#-<%]Z^3/3MRF\_X9UV+>[>. 2[1,#LU#H %3(*
M#-'#I<_<RTU,&.6EJ:5CH^FE[;N_J?'2=ITK>@B(M]VS[>@(J4"%?14&(4#$
M9PDE%WSGK[VXQ ;*=AS8^W8_/G6'=L265)^9"E(5\/BG>]?#>!-M"]P>6^G<
MDZ)W:C=5C'>4\G7+1T"V(JEZ@-5Y4 9$,2]+$E*O!/D?I#9S3G_!(LCX_/\
M+KXJUO6@@+_X8'[<O_O(P/\ 9KV7_F[P)\NON'RUSOC=!] W+JL8+R#J$N-
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M]S8;1QI2:&K<0;!7"FEDID3YC4)E"P[4K%'.RZ^=BU<F-"V:2&)QZZ8,B'[
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MY@/TUV_^TFN_ZI1O[F _37;_ .TFN_ZI1O[F _37;_[2:[_JE&_N8#]-=O\
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MVW-:VA:=[#'/RNAQM3MR>X\\CZ&'Q54);?&!&M#[0=V(2$K<[;DA.HA\PH_
MU%AN?+(D;FQ_IH5]9OY@R9(;UT-!D$R_6J>*&PT:<ED"5='08,5O:DHTY(ER
MEM,,(VM>M?%2M:^.]:P.1'!=HEL,2HO4*O)BR66Y$:3'JT-YB0P\A+C+[#S>
MU-NLNMJTI*D[VE2=ZWK?PP,843T\(W(>-=GH@AF(H4B4Z4"B(#<99TCH0$3(
M7+>:2RHP65J+%TK>MR)&_IM_,O\ BX'*%C^MG!L R$ZW3C <K#CD!9877AQ
M:2@2VDOQ)T"=$6]%F0Y3"TK;=;6I"T;UO6]ZW@<_]-=O_M)KO^J4;^Y@:P%(
MWRR$BP>N]WYL>+@75L'!06 !*$@K[<AZ(XR6@P93\D<ZB5'<:VEY*-Z<0I._
MVIWK0;/^FNW_ -I-=_U2C?W,#CK#=D:DL0W.IU5N9*;D/1HJZQ!1)DLQ-LZE
M.L,*5IUYN-N2W]12=;TCZB?C\/FU\0]+H[KC.I*GNM4]I,*.S+F*=KHYO42+
M)^K^'DR=K7K3$=_Z"_D6OX)5\BOAO?PW@>V:'[&.ARB!#JE4@0(,9^9.G3:S
M!BPX<2,VIZ3*E27U(9CQH[*-K6M:M)0G6][WK6L#U,#NNRF!TJ-UJGR(IA#3
M@F2Q71SK!1MZ(X09<'/-K4W.0[ :4^G;6U:4RG:]?Q=;W@<[]-=O_M)KO^J4
M;^Y@?BJ[VU/P^;I=<3\V])U\U3BZ^*M_P)U\?X=[_P!S6!Z8X3LTQI,B)U&K
M2F%*<2EZ/5X3[2E-.+9=2EQK:D;4VZVI*M?']BD[UO\ ;K 2 O98:$.2^I5:
M*VX_&BMN2*Q"80Y*F/MQ8D9"G=I2I^5*>0VVC7\9;BM)3K>]ZU@>[5<[:KX_
M+TNN*^&]IW\*G%W\%)W\%)W\/X-IW_#K_<P"JYVU"5*5TNN)2G6U*4JIQ=)2
MG6OCM2M[^&M:UK7[=X'[^FNW_P!I-=_U2C?W,!^FNW_VDUW_ %2C?W,#\W7>
MVIVG2NEUS6UJ^5&MU.+K:E:2I>TIUO\ ])7R)WOX:_W-;W@?OZ:[?_:37?\
M5*-_<P,:N'UAHM' N=?I;9R7!D$XH58 8@M)&Q'F8\HA''*<U,>@QI$EM#CJ
M4;;0MQ*=[UM6M;#)?IKM_P#:37?]4HW]S ?IKM_]I-=_U2C?W,!^FNW_ -I-
M=_U2C?W,!^FNW_VDUW_5*-_<P'Z:[?\ VDUW_5*-_<P'Z:[?_:37?]4HW]S
M?IKM_P#:37?]4HW]S ?IKM_]I-=_U2C?W,!^FNW_ -I-=_U2C?W,!^FNW_VD
MUW_5*-_<P'Z:[?\ VDUW_5*-_<P'Z:[?_:37?]4HW]S ?IKM_P#:37?]4HW]
MS ?IKM_]I-=_U2C?W,!^FNW_ -I-=_U2C?W,!^FNW_VDUW_5*-_<P'Z:[?\
MVDUW_5*-_<P'Z:[?_:37?]4HW]S ?IKM_P#:37?]4HW]S ?IKM_]I-=_U2C?
MW,#SKMCNX*[0J/>9@LY^?#)I,$<%P_R]>G!VOGF09L/7P;UK3.OF2M.O][]N
M_C\$A,^ P& P&!"M[_K4XY_QBV_\DL8$U8# 8# 8# 8# 8# 8# 8# 8# 8#
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M0=H >O 50*J*C-.E2S8BK]68"<[#ZDU!WZ!9^-!AK?E+2VU\@2F9+^>^;PK
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M(<0RTA;JT(4%>^$>]?)GI:Z2^<\<ZY&L-]B5^9:]4\Y3^@\]L)&MC9H\<6.
MA71ZG4I=C&AIQ>&U.='IDIA+F1]/_3^NU\X6_P !@5=]!^T?,GE@G5@7=.IP
M:?8KI!+%JQ5X%=N-XMA4*"D#X9@\BJ\_KMIL4:O#YQ6-'=(/1FX:9+[;7U?J
M*TG825Q7N?)?1?/QW4>*7D/T&BDYQ<4R;$?BV%1#-?(R!!X"9$DXL W7K"#*
M17(\P?/C1ID5U.TNM)W@2Q@,#U.,,.I^5UEIU.G&7M)<;0M.G8[Z9+#OP5K>
MOJ,24:<0K^%*]:5KX;_;@>>D(UO>](1K:MZWO>DZ^.]ZW\VM[_9^W>E?M_\
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M& P(5O?]:G'/^,6W_DEC FK 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8%3N\\-]"].M0PWR3VQT_S97X8%@9.IE)Y%YSOX
MPN7;GD)3MED%NP<MO%ABS9$24S&5'8E-PTHBI6EK3BW%*"$/^B-[9_[U_P!
M?]6CPW_V><!_T1O;/_>O^@/^K1X;_P"SS@/^B-[9_P"]?] ?]6CPW_V><!_T
M1O;/_>O^@/\ JT>&_P#L\X#_ *(WMG_O7_0'_5H\-_\ 9YP'_1&]L_\ >O\
MH#_JT>&_^SS@/^B-[9_[U_T!_P!6CPW_ -GG ?\ 1&]L_P#>O^@/^K1X;_[/
M. _Z(WMG_O7_ $!_U:/#?_9YP'_1&]L_]Z_Z _ZM'AO_ +/. _Z(WMG_ +U_
MT!_U:/#?_9YP'_1&]L_]Z_Z _P"K1X;_ .SS@/\ HC>V?^]?] ?]6CPW_P!G
MG ?]$;VS_P!Z_P"@/^K1X;_[/. _Z(WMG_O7_0'_ %:/#?\ V><!_P!$;VS_
M -Z_Z _ZM'AO_L\X#_HC>V?^]?\ 0'_5H\-_]GG ?]$;VS_WK_H#_JT>&_\
ML\X#_HC>V?\ O7_0'_5H\-_]GG NYRBIW.CT"OU;H74SW:K@*;G(,=-L];I-
M1.6=<DI-FQ'9U>YU7ZO31RAL"2U#1J% 82XW'2MS2G5+6H)$P& P& P& P&
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M5#_@I0!SWM9V(N%%VP'(2%L2)$1:VEZ="<V?+].A^E(GI88;/!C\>@_H&14
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M*.G*Z;KI&U!?R7?/^LW/F.M?C_QWYJFI.0$)-;^,2)^#V03-^/T/[Y]/Y?\
MY(KX_L"OG;O:@#A_<J]QL]2[$18-@*?:'[<-&V::&%!SHGT08.?F9(?5YU9$
ME!<7A"=#X<\G#?-+)N)C)WN&Y\X07=?N[^6:Y5#1,3*LD^V#JA>;=%JIH-*$
M1%P^<DI@JX*(6D:W80D>"%?"EG%RXJYS#T<)/>CJ?;C[5L+!3?;7.(3,*P*
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M:$N7L?\ F/TOJ[99VY\GS;0GX_+H*$%?NB\?I5VZ#5.FUJW5&+1;+:JBP3:
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M?TD+0*;26S5,Y]:XI"=TTN0G=0BW2=4JS4:QP[I4GH\S<+GH"T6^43/<ZGE
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M&4&?T=ZL!N=F2,<K=WIY2(<0:%,A?P,0LW7FTZ;3H?J(M+8=Q> P& P& P.
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M;U\-X&CE^ <?+/V"9J@5@01N!RD'[H5KX04%+723SPV,/U6':R<&$W-."X)
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M,!@0K>_ZU..?\8MO_)+&!-6 P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M$O'LI! 5YI ?5O@,!@,!@,!@,!@,!@,!@,!@0K9_Z[>8_P"0;A_@6!-6 P&
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MM_B'Q*DN1F'D.)V%B;/_ %V\Q_R#</\  L":L!@,!@,"%;W_ %J<<_XQ;?\
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M)@0HD),N7(GRDQ(S,;4F?,7]67-D:90C3TN4YOYG'%?%:U?M5O>\#EX# 8#
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MER'?D0TI20J;9_+GNF'8.D:K?H@K;JF5I7-:K4(M@ZM=JE-VT%8XI!MA%_\
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M$CH=^5F,PC>FDA-6 P& P& P& P& P& P(5L_P#7;S'_ "#</\"P)JP& P&
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MK?=FORVW1A%YIWZK&G8LH+0>,_.!GRWQ]7-#MZ>Z#/<LDDXLVXDNRUI*@-=
M*VS%+%RVXL@T_7UEYR6-LLK)DI+FTNO+=E2 MC@,!@,!@,!@,!@,!@,"%;/_
M %V\Q_R#</\  L":L!@,!@,"%;W_ %J<<_XQ;?\ DEC FK B#N?<^=^<^<&.
MK=3F6"!3 *XZ2DNLTRWWTI&:?4K;LW=>HX2P'E#1D1IV5-E:C_AX4-AU]Y:&
MFU*T$HC"4$R-'F!<EN:,*P8A(=,9WO;,N#.CMRHDEK:M)5MM^.ZE:?CK6_AO
M B3M7H7D?G@;5B_7K8W4A]T.G*Q6)#HXJ1T5L%>YQ>NKD!#214*:IJ:ND<W,
M2(Z7-(_%/QDQF?GDOL-.!M#_ %KEL1MUR=T>B#]1SD2KRDD+:!@.P[1.AM$8
M=9FM2Y[+D.QR(#R'D07-)E*;5I6F_AOXX'A;NL\[H5IH--N5J%5NP=0G%15$
MBEW]06+$7#LPGY0>%.D?3A;+O-D&OPT7;FGY:M[2RA>TJUH.,*[-RPPW&>BW
MVJM-$+@6H05V<>%P6['; DYL82"UE<J6VFPS8Y)W4?:(FWE?7^+?P^?6]8&N
MB?1_%3]UF\\!=  FK:.N<B@3!0J8W.4U:X-,>OQ86A]A2X\EP!6FM.D5-*6D
M>ZXAF1]-U:4[#;(G7>3SV0<B#T_GDUBSFW*U6GXEUK<EFPV-GZ.W0 -QDDM!
M8VUJ2W\T6/MQ]/U$_%/\;7Q#8R5MJH8R$KI>S5\58+-^._38(D9'03-@_*X_
MXLG^2#)4EJ:5_+HO]]?^@ASZ+?\ &7\-?MP(_I7?^,=#'V,O3^E4\R(JMCFU
M4R68.CT"VC$!F0_(1%(NOHAD(6T0I.FY3"W([JHDA*%[5'>T@,P Z]S.R#ZN
M1'7:M(3=*T]<JO"GF1H\H:JD9G<F38AXN7*:FR@L:+KZKDIM"F$-;TO:M)W\
M<#D)ZQRQ>PND=+Y^O=D#KL5=TFY5Q6SU?:VK3AT+\"6_S0.WM&_FE,?48U\-
M_%7[,#:]G0B8BB&S K4!)/\ )53=D(FHB3/YQJO?E*I.WOHZ)_G^_P #]#YO
MJ_C/[S\OU/XN!'ER[QQ3GH*R66Z]7Y[6PE/JDJ]6:<3MH1K0:G0B+@>199D=
M,Q<I(=)EI4)+VF]H<FZ_#IVI[X(P-R%72G'2#8D);*R8*N@1UI:&"CHL@0<K
M!??P$V-N%$E/25@2F_\ ]GF:3N.__P#$6K X!KI7.JV\;CV*_4H#(K407/L;
M!JU A;U?@G)"X@2:;:G3V%BHAB4VIN*X_IM$AQ.TM[5O7PP,F9M]3KM>7;K!
M:*Z"J;4>'*<LYDV-&5YN*0<8:@25FILE@:B/.=DMI97MWY75.)TG>]JU\0P)
M7K'+ 3A=DWTOGX9X!*%03K16Y5T>X$G'H#Y0'#+HEDF5#91D9%=DQ&WM(7(8
M;4XWI2$[WH/+75N7;CE9>NDT'<4$7@U\W)U<:[N.&/%'M1A@0J]^8_3'ER,C
M?TV(SVT//+_BH3O?[,#\=ZQRQC9!+W2Z RH188M1*Z=N5=;V,M<Y]^-"K!#2
MR.MPK#,DQG&VH3GRR7%MJ2E&]IWK080MWOB0(Q7*^6ZUSN$;MO0G^35T6Y;P
M:II3IL8////T)IAN:M;5K;%#'7-P7/D?^/R(^7ZCK25ADA/7N9F8Z)D2[5IN
M')O$[FPN7,,C844]=QSSD:56Z[(DRFV3Q5,IAUK3$53KJG674:3\S:]:#9JS
M<*E=(+Y.G6BNVP;&F.CI)"LFQAZ#'(,-LNOP7Y8N3*8:F,M2&U+:4K2TI6G>
M]?#>OB$7VCTGQ&I%>9 YW0ZX1-=BZ#-YASH77242Q3;'< [$N58Q\=H0]*TT
MS5(\%S95YS:6X"]H;=VEUUIM83E@,!@,#JQ/_=1J86NWSK,3RCZTLGE_FEJZ
M%7+CZG  ^(.\P@#>2W<YSOI][AU,EW,9W$M1Z3::P21)DQJDY+D18#LF)&DL
M[:4Z':8A25I2M&]*0M.E)5K]NE)5K6T[UO\ WMZW@>6!"GHCO-+\R\=MW:K_
M  [*4KM357(* 5-$MG+?:+)=+6#HE(J%6%/S!L.98;A=;,/&0]2942(F1+0J
M0^PSIQU 0%R?VZN[]GJO!^J>8/1OF"]]$J=WM_,%=I9XJ4K_ $.'S9VLZO0L
M*:XIV;KK(L\ AV^#+W'+)':E15N*C+>4RZE(7HP&!3'O7LJ)QWK%=X31^!=U
M]*=@.<\G]:(TKB47ED55/YO$LD>G1+1:;#V/J7)JNP@[9W78D"'#F39[VXDA
MQ3+;37U%!(_FCTC5O3E&/VZOU2]<]-TCH5NY/TGFO3!H4;>>>=(H\F.R?JY[
M58/VRID5)BSHLR+,%%2,"7"F,NMO;VI24!8? 8# A[N]&-]#YT\"K:H7Y\,N
M7+;X*BDGW(HXK+Y?U&G=*;!39+33ZH\<_JI[A;<VA:6_K_.I.TIWK Q0WB,8
M1;^M6Z&3#RE]7OW++S*$FZC$+# CW.!]1&O)B,_F47\2;*)J^Y<0DKY'!9)U
MJ2EM_<?25A!QKRG:Y%[O]YW>!U@)]6ZMYRL!QU%<CT]=?I'GGK)#JP%4]4">
M69N5XV,_#51H@TP(;4(C1%O,.2&I,B2$Y]IXG!ZZ1XT=4_6H9WBW6AG5*])M
M%*A7> \\S5K932HQ,.03#2Q4R2&M[S\*?&E(=@DXL61MM]#2F' T;S-Y=A^<
M8_0F(UQ<LOZY)"W4N1:Y$JBVH0.,0BPC5CW"(DOU=U,XDDI9^SN?AGS3C$=2
MHS/T=:4%6ZI]KNJ5_P#('YW2DSB%66!U7IXKG0@ \(=KEH\S&6+:/VD\27"Z
MI9A'G+\-8K$RIMXQ,//ROH,-LIB.!.?E?Q."\S4P146>B7*U)"6XA:&W(IBW
M5P/8]3.>5?FZ8]^KDRZ6F#<Y3@NK-SY"GU-PE&'W94>)&4K2=!&S'VXJD-A\
MB%@+H, C.8"3HQQH?S,#%EO.$KL2O3)&DRX!:"WSF>7ED-"[,MAF;NR &DP7
M?P^O@YH+.\U\R\\YA1.5T&O,O#0/,:/+IKM>KFMU:@WQPO6AM</GK_SH4[JK
MVTD4_+]R=*(M2ULR'W5:7M3BU*#0Z1XUHE'#\-"P' *XO&?,US\SR&V:)7X,
M>[5^Z1N:IGDRT-A:H\:)HC0'YC@O>I$61(+OJ6KYM;4X$2G?MT4^?3@E, 6P
M14H\3R SY',G@G.!8ZU2@PW3$L3:JX>"G0LRK)E&%RW# O6Y;!.-+4TAZ*YI
M4AP(PC_:@JGYN,(DNK3"<%BGB*R3 RJU89P9?X"YG[7.% QQSIQN .YV99LD
MAAX$09+NI?0U(3.UI'T5!<Y?G) SRMT#S8 L"$MV>E=EJH,PH<D1""-]/FW*
M>*@LBQ[K[<0-546EN$TRQO2/PD5.D(1K>D)#+O<5D'K;9NFD7J\+LM\\_AN0
MG*>2K42WU""2BS[$:D3BK2YHG]9!VY%D5"=@NZC-RH<;2?JHTYO2 T[MOE*!
MUXU?+!HQ3&I5WI_':N\"O_)P74J.I_D5\O%UB%3U6+& WYZX33=-1VMMR8,L
M:[ 8D,2?FU\F!S.4\&N',YUY4)N>T+<Y[Y_Y/3;'9(Z[>7*A>*ULA&G76XQ=
M3 FIEJMLVU3HK^]2/CI$-B1M2OF^BD+7X# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# A6S_UV\Q_R#</\"P)JP& P& P(5O?]:G'/^,6W_DEC FK @/TUPU?H_C%P
MXYN]EN?0KI$T*-%QE7H=V8)UZ7I<2P5@Y4^DUJU50X!L0>0]&?;=BZ=;VM+K
M+C;C:=X&^<[I$WGP6/6/U>>M->"B*I7ZHS9?PTTX($UBJB*ZY^;673:"EL+'
M)HUPC+FS=J?5)E+3KX(TG6@K%[SX)P[T)R$?3N^=2;Y%5/SHU$!VW=@K=9EP
M[M;^>W6@UF<$+V9*H;-EKDJTJ+CTHTK:Y(Y.G4KC?70H*LW'R7XV&NV^?=_3
M-8$QK8[T2I@TG[)R@>@#KK,/T]1ECHTB<PT]8[B,N/4;U^"(RU.D5;"*@N;4
MF!-4Z$_^HO/7 K(3HG[PNT-\F7:;[=-H@W&U!+!(O\_I0>OURTUCG[G6YIY^
M@$ECA,;0[=4U!_*7G5O,,I6\O:@BZX\Q\3V(VO\ .?3O-AI,SU[KWY/"=NW+
M8LJ/TGH=WXE<K'6*]J6ZF4W9 <_GPIAI$?>IWTBZE+VI3C*M!KU;YQY(X(.J
MIA_T@$MFFO2E+ T6&%<Y<L\_<]<HUY K/-_PM9CQ)UD-B*]TV!--D7-**OO:
M;D/;3'6AG882Z^&Z=R7H/F@?3NK<ZJ@]FZ\;;)C.E$*F)/V4+P9/E#8\/RZI
M)I\EJ79;!OS..W,G09@N5&EEDHTIYK\,TT$P^AN3^9_670^1V@MZD"P!\2(6
M& :C3;Q151KNL= 6=+201=N2[/5.AURS_-+6WN8F.PY'=9U&7]54@-5Y!Q+R
MC2#E#[S_ -)VFWS]%2>HVV7-!R^35^A7.9>F9]?"%"-7HL!D:\]S1BO6N,!3
M#^"_Q9<PMS3S_P /I!&$+@?COI@[A9*O>BR#5-F>+KQ&%G!<JE5G5BX&U#M=
M6=MEOE%&83\<"!G=PE.)8EC9$4>0B:3\\!#I!@F$YA?-_ 0,#K%%!= YEU+M
M_8^/="YW%K]K+TBL22!J+T;T;:[LX#:J@(R?HX5KH/8CT"9%&P9:1+(A2=,N
MR8\I:@VVWA_/G'?(U@\O==[P)&&*3YT+VKH5NT<"ZZVF2*@R3UK](0JT]^.(
M;M;G26Y%G8D_@WFOSOX;TA7P^7 I-JM>,33A( KIEZ!""/AQ[J)P07$\D8G4
M:B6KD@[@ ?H=GNDF0ZZ_-L]6KR)<8#J3-!)/Z<*2]LN2&OF"X=(YOYPYGZ2M
MWHNR]_JBNJS>2 3-]KA\_4 *P<0S4>1427=OR-!J2NIUH^.YZ 2S 8U^&1/F
M?-J0_J1$;;#3[OR+QR?[?:^MV?TU053!1_G/;"E,DV[EDJ"!5,,<",CBI^6_
M]<Z2JMYUR:GZ#,S75,Q%3U.P%*W-B?1"RY?S%5[=YTXEQ^M7R2R-X^&YF[SJ
M^:#5"Z02K=&IFZ@(+F:R9'D*7:1QNM3WG--*9_#HD.M26/E4RUO05LZC]JKE
M/6%%&+'T.VZ%/VA=G#P&:OSE+P]\J0,'[1'+S6JLQNTH)60NIX?N6W\ ,)'X
M&"EJ,I2=AI(?[2]5*4"34NA].+S9<"XV9ZI+KH8*.$P>?R[5WMP8,M$.' #+
MNUG,5'O!%<Z60VZB&3^FEI+\9I[4X)4LWVR.7'(K# N\VJM2HUBCV&,6%B*N
M@S EIZ1Z*Z%*GC2C(V+.B'G]^D2L#\7M:VGXT-I$V/-8>EQWPSU%^WV&H-W*
M=%']>MQ>W2^SU7K\ A8JY4RD:$NMBNO5AZONC]P68RT&*EV@G&7*BZ@[C2XT
M25'::VTMIP-DO/@^C7:5)D;N=A#I*=*Z/>3;$4)49B) CJI/GIFW5P,LB&DN
M5@KHGS$8N ?A;;+P$+E);<^,C:DA+/ /,E/\]5T]6*N3(SAM@!<V!2VW(@L/
MII'-^453DT:=%0"BP$,SC0NIM2Y*]?M3*=5]/:4)0G01IQCPY1N-N<[DPK:=
ML4OF]]EW<2^2"U4>W)2WP@?YW "9$4,(@QF5BZ&#@ORIK*6Y1(LRN2\K2%I9
M:"[N P& P/G1L=1]4 _!?HW[;<+Q'Z(L_2NFFO8M,I_;P1?SYKS7)%>D>_\
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MTS%[&(D.BHZ'2(F.ZET@Q&0M*MALT?[@GD*=(1!%=AAG2CT*IS882O5*_'[
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M7R148O0A$.-8$[<T#_-7)^_@W!T\ZVZE(827[K'U=[<6X\VM:Y?[V>JT4H@
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M\_$W5VA3(=(D_KJD\F4)OS79$J<\E.F$ZTZZL*,>@NFT:@7ZR\Y#<)X&;HT
M10^8"8A^N*D$-'+;QX]"JM](I@RHXU?"Z7SQ;E=F,,LMR=M.O(:G,-H^FH/=
MP7JU0N]JA\8.<4X2#Y?9AI3DMV%U\(_#?*G>-5:==8?2HGXV?(A)XNXTTZT$
MV^ATA!)O(D?F+B][P-'ZW8.:5#NEIY[6O.7FYIFQ6>J>:JZ?,4N4X9KLIV#Y
M!F,WFX_E)D,B1SQD?U$)$B1("A<Y1"JB/B2W]:-^7AE?--YY'Z#N,07<O.7
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MZ %U0W*U3J[J08JX-#;86ME7M#OJ$  =MI*8L-[:X\?2=:;0GX:P-^P& P&
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M85L5:83?S_-II^4')@?<=[8:W6GJWP0'= YWLC]&EV<!(ML6N5S<&XW*K/\
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M4[^=$UT=,#6(D5G?CEU=F%)3(2\IF7%DLO(VKY]N+"SV P& P& P& P& P&
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M! =#K^ILAY,=QY>PTSLGKOU)R*\S*D:J-7AU]FY\_H#O1D<"[990L;5D<Y'
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MP0X"L(<Q%(SB13\R&3JL#K56BP)CLU3C0\7 BC!2%:A1&]1X[>!=3 8# 8#
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M^W>OV?M_;K?PWK_SZWK _<!@,!@,!@,!@,!@,!@,!@,"%;/_ %V\Q_R#</\
M L":L!@,!@4+]Q6DY5(%*GTSN$7D-S6*OK,*#*J%=G1K.&?15F94\OU$_P M
MZG"X@ JEE<$.NG2$5@"J5)CLSG$+5%?CAL?-(\>&.\R0&[,BYSQC-]%6>UHA
M!8&[!>Q3LP=T,HZU7 -9!R),J]1B*G946$RU,=^:1K;GU?J+"Z.!6WT[R"E=
MDJ5*%="NK]&J%1Z?6KT8G1;4;HLLPP*'GA::U'NE;M%//5K9A9O25OQ9J7'&
MDK84A;;RTX%*>P^6^2=NA]WYW6>O-\H'4WH7"HAVJF*79:O2ZG"I_&IW.*94
MWG'K'0T7*I%Q-LC$PT@609C1C0Z&E"W'(ZD8$=WC[=@D_9NM&B/K"DP"!R\<
M]>^!&G079=0/BIW5'JF_;8;W4(X2VW]\/UA,*(HY D()MBV7)$>0\^EV,%U_
M+/F<7PGHGHRUPNKJZ3.ZC>GRYB$\[/66K$R7:[YT! ZT?4MQP6\<AL]*2/C.
M,#A*]!1T%"T+0EM+00'3_*/.^=W4M(G]PJ!<J<]B5/KE7KXFH1R)^LW1DE<3
MAVIN$7;59[FR:N FQ+8(R7Y+<& /A;VS$C0W%QT!!G)?!<Z7(L!+J5NYI0YN
MNA#]<DDC&0!NQVDLL?QZ77^OFRD.XN1BG8;HSRN>[LO'_"$BS1!V4J)"4EQA
MP+;>T>;\XM77O'EJO7:7>>& G5=U_GU"3 LYE[I-IFV"B=$VL&/J5B!3QIH"
M.Y4['D%I:)8N"%*3T2F]I?TAT*M2_#@.KS?,_,5^E5M/:[?>N@5,Q6N,E9Q4
MK9)TR@^A"U/#]( V:= YJD11.;E0]2B3Y"F&Z&F .:9GJ#I<EA.7F+S?0QD3
MA'?JS8^23X7'QG;Z+,.3?.9'DY9 &6JC46Y3G6+5:=6FA=/#6_ADEP\3FZ>8
M(.%BNMQFTNMO;#5.7\WY["ZKY/N]9[37;;QJK<+ZITB7<A9P3NI]9?AVHZ:Y
MA8I0^(2)H" ..!^I7&2Z4EOM0W)I2.CYE2&-HCA[N\<?YMZ_[OR"XU?T*(C@
M;=YWOE@HL<-S8_8*Y=J$_4NC\TMY4;VRKVNI#U#?G] B)LT'L@V0;V+CO1_H
M[==DQPL16>'L5#PM8.*Q;*,Z_&5S#ID8(=K[M;HHLNBROV>P (X(QJ=+!!6*
MZLJQ'B&),EYS>XB9LEQ3VW%;"K]>\(N6!JG3E>DZ4:Z;.Y35;28M,*NL6.T6
M[H<6.[*MUICFX-Z$22/G:]]8*RK/.KL:)&TX?<0^R19VE#: LSYZ\R4?A%],
M6JX7BCWOL1.D5H5HT]7Q];L0 0JV7::6=KL8C9;*<#U6VV6[HC:CI?VAQV&P
MVZ])=2W],($])>:>4S[5T_JY/O\ SV@%.H6.NZ/R3E+$V^/)KU^G>4>6TRK6
MS2;''E/TJ5:N#.L1ISVH\,?+LC[Z%L.177GPA:N?9T_!1#A-OTQ..S[30>35
M=\HFED&8-JB\O1QEP<U:G8?27)Y^H6IGDB$RX*);:MLSM:U(<TQ\'@E'IOE2
MOS:OT3S+8^Q@*WL_R[S;<@%]N$4T4<C1N#CA/(R\LY$)W ?'>AN&H@>=%:*F
M"+,P@8?;E,34)=^J%N^1M Z+TCO]@L]_KWTF%\5Y_,FS9@P/"<FTSG;;2S9A
MY&H=?&6BR$3<AIP:PXIR-$@Q=J2A+K:-!UZVGPR]VKM_6+'SST+R;H+)?MYX
M)V4*FCP"+W$G5<V],I&SYH8+T&%&,]GJKG?A,$20=:AR8+@J//>0^XVZRV'+
M_P#@[%W<%:X5T[U5:,<<[O=C\NMU?4K\.2'3+]Z#(UPQU0@$Z4!+6KN$BK^A
M1LY@NAP8L>^-%-?A%?30XD)6Y9X:YP&Z#*OO0>X\U[" G]_BWMNHRJG78==F
MWYRD]9K ,?.B:N1<#,Z)*_>=!)?7;A-R7I06,ZAGZNVWV0V6V^88?0B=;0_V
M.CU*=S3VG;^L5<TTX.MI&PO]!.C.DMTYP1*LXX(.ND7\5+"QV2, J^T/C-RX
M;;3GTG$A;7EU=US"D6,->SXD ;Z3U7MEQ%C'RT-W<3]X5ZMMP& 0B-N,J,%(
M8":B3*9C)7M4O;^T?,G^-L.M;E?@;BY(3YIO?*O2M?USJO.T@]3 U<%/U>NV
M60"Y9YVCF#U="A[Z =$=$L;G!'B1;<MF8ZB#8R+$V*ZI+[D@-B/^'.."[CY(
MYI6NQDJ&7K'*#O/Q.J%2[-!@W"X@*8+*V_IH2W50]&J])Z[:Q#29Y/9QTK(.
MBT:U\KVFEN.!M7GSQOSDA9 W3*9V&B6F=R#HX47\_-^;N5>C4XM3)\TK=:;S
M>,];SOZ9"W,59(_YUN'-FL2R3LQY:EZ?5&8"Z/4Z^)[GY]LW&9_8*9"M_7>3
MV8((O]69%/1DF?R9<1[HU/I\RS$E$AM4.J:GZC;(2&V]M):=D?MVO ZOZU]N
M;B9N5;>65GUBY8NJ$*K#.0[VZ+8*]87QZU:]: :H)U?&;0Q-O%:DPNFQH!AZ
M)*^8DFGH<F?1D3F7HP6BY3X_Y_YPOM2Z.?[#6=6/FU;>-EH[PY8TBCG$"J]-
MKQ,% D&[I8+(-YI!LW0V)L:*M<F(P\)BL:U\Z6-LAR^M>8^>]3[#TOK9KL=*
MKX7LGE8QS<I1[56A\HC^GK,/;@U^\EF[I9M+&AJV4^24W'AC0ZGYVODF/NK:
M:^D$.WGQ@3N7I!CI-W*<U;\\B0'-+*2Z?:V !4C>4U<GY2FQ.;/3I%K2QKE)
MC?!)TI0^?$5"CD; ],:DSOQCT1H)51XKY0.K4"LV7J=#)C0/._'0_H;)L!7T
MQ;<"\R6WH1L+8[M%F61QM\/>AMHCBF53]R&(D8.VA*Y+?P::#4_*'!3' O0G
M1KC;KES0A0ZAQ.G4A/3YIL"UT&]/6"/SE0HW>"2+84D1ZD+9HSC%?CE(\-<)
MF=N/&?(M[5)P-+[7X!#]'OGHF\%O4U KJKR:K3\V#*IPQEN@SFSQ>139=S:C
M])$!;.?$MFWH K1J"J/-0UI$AB1\^TMA+WM090O1W$[!Q5WKQGG4NB]@IG';
M[9B7"+C<%0[OTFDN5"C2VH$-BN+"P)9?J8<L/LXZ6D1'F-M,.2FFUO;;#.M^
M(:I+-E20,OQ$C/9]3USUD#U/X^',S46N/62-!O$>W/P[5%>.3)\Y4^2),,Z@
MS!A%'RR-35-._4"-Y?DOC/#[WR<]W?J%3-![CZ5"CJ!4S?-):X?3NI6&L^A$
M4IR]N?G5E@V'M$^5TYQ^3:I,:'&D-U02VF/&?:9=2$"QO)/%Y=@Y&X$[U:0_
MY;Z%:Y_,#+XSU*N##/=Z;(DVNSES^QINON5SI1X:%:0(LQ1Y<"3"<<;1N<F2
MRA(72\U50CYR:J/-;C<ZR Z%V7J75KU&IESG_FAF+P.CH8H7*^44BPC)3(*7
M8N8UDQ0H:T;<D?BF]D5M-O+4N2@.-Z3Y11.Q^C?*EM3UR4-, C5ZK].K+%:N
M%PY_9;54)H7I9X5+LM/L 2N5*V)%\UFP9T,P^[HN#_,8:6=[;=0L*L\Y\(\S
M+[Y=7*K[#>L+G!CW5><O%1B9XBU3;/8VP_6#,JJ&8%[B0'+S4A%GCCI$UMDS
M#15680QYI*X#^W0F2G^-0:#/,(4;MG"7:RE\/#L_-Z!RV #KE^C<CG]'><&T
M\%KJIZ$+DSW>GS'+@J5'.?BY3:-_)%2XM.PQ)/P%7X%>YESHCW'FU.D\]\XS
M^+08]?H$2I%6P0VC=TI,*T5"#^\9+E/$VX5U)PE>8K2)35@GUF&XV_"2SO;8
M7@$2N;^>@@L".LG&^;<1YMS&['+,(8_+*S)#R:V8#O%;?'8BD&!(NJC/_EPH
MXI<=;OYE)94IU*_JZ<"J_<O'3'HOJ*/20CO]7%4"?RI0L6S&IT$T%+5N76CB
M76[%<QUS"1K9RDX\39FDALA'TY,-#S+<F/IWZR K'0?MJ<JKW0;\;D^@* 4_
M4'GBV!K'6@'+XPCF]>H?0ZW:Q(PQ%_$7PZ &TD04)MDQ8Z1(7\6!32TN_!O4
MA 67+>).8=)-].<C=6I-@L/4>47&I'/I5\%8RLBL7'@?!>.U4J21^IGY)<#4
MK'Q[5G'MN:3&W/+[^DMIY&Y3P:9Z=\?T6O#_ $_WOJ?11NN>6ZB\PEV$+/X4
M?[(P,.<G/<H( K98:P.+66TVH1">YREJ2- QA+.X!24^\G<EC\<L/==O.G'^
M^6#TYQRF=*HL+OUZ-<HZ9U<EOCCIV31N?KYYSRH@.4&U$"L*4'CS"'/5V$>*
M_,XA 8Y*2[N/K:E2GPR._ (4E5>F<O!=3Y40,FCO'K9>9$_E<0Z?)VVL><(7
M YTSKPN!T0?.MD8K&%HNU:_&NQ98FV_\-4].0C6MA8OEW'Z?Y]'].?IMUYQ,
MZ9:NMU\[T:^W1J U9I *S7$/*C52[DXIA!>?8U4Z;-C@')3K+"B<U#S<73;C
MC2PXGK;D-/\ 1X.O5178J52YU0M),=,8-LB[0Q&,WJEV2E#I$$/^JZV\!ZU6
M$F7"M1(K<><'EHB74Q7OV[0&^\2Y[R#@06^:'62AJ.6WK_13M_NNW  8V;M=
M\Z3:[T#J]P)?CWY)*PU,9>6!,5$I[ZVX[;7TF6&UML("E=5\L\@Y=<^/R#/>
M>'G;Z.]50B_.85JIH*1)L]RK7)^C56X!%L+OLDI(])6.LVEPX<LL9V.Y*,!!
M;CHO6FT-K#2Z5]O/EC6N+SJ'WT6)K/.NA5(='!BZ[/JE<N?1>; ^8 +E9:W'
M"WJNIF]0L9?BCSOYLVLDW^&)D6W6INOG6H.QGR_R/FG&N*57G/.I5.L T.-B
MC;5::G $QHMZN$ 9!#6.TV! V83;E6,RN G<U4B3)D;WK2''%?+K K37/(?'
M //>%TFH=,HU2W2"'H8'6K1ST/4:L9/O]HKG1JH<$4R2)*:T,+U<C96):T1]
MR]O30+.W6D+;2ID(O!?;)L@0=*"B^VU2E!K*644MT#EG'IU%9@N#&;8BMN\T
M91U(K'I9+\;<I,TI)DH*JFRVFULIB[VO>PF?_H-N[J8@? M',:3;!7(O1'*8
MY+FW$!]9I\.#W3=;>B;'TN=;SB_R.JD "YKXZ3/DLE)LQY[>X^U?# C4#]NZ
M#SKE/2&7WA'9>E.<1NW/N6O-5^#2B%(,V#J/H'JT'] 'K!8K&BE,L2^T013:
MT.(2B-78SB]J1M$9@+K<-YO?.44WFE%,64':!]?YV\CH=@<A$46:Y=J+EH)V
MV7F/(7*_ Q EG.D#4Z1%4S]5$B8UIM26T*1L)\P& P& P& P& P& P& P& P
M(5L_]=O,?\@W#_ L":L!@,!@4 ]P&+Z%_2$V@W*/1IK=3O$8B?#Q>>S+J.8,
M6WDP4<^X,OO.^ER[5S.68GL03(*O#7K(8+3 S,)IY?Q3H,CQ$97@U9\PBZDF
MFZJ\&1U2/7W*&";JM?EB$'3?X @Y4V8 IBHV0E&VF0;$-Q(C8LT[+BH892SI
MI(7NP*8>YJ)!OW+:5"*]%Y5RP0#[)0;(6M_8H]:(5&*/@_F\1^(R&M[T6O&[
M#._,-(@1Y#[&M2/@ZE?SM)2H*Q=I\N>6;71KY23_ *FJU7@58OPQRP/6B_59
MUNH.43CA_C%:'=(^E;JK/F.72IF)DYE,Z5"^J59:DI0^TRMAP(*->3/*%YL7
M;SO_ $WJC!EC.L5>@E9I1=*%O\SO%=A=4N(NL1R4^R!A9.\-5+L!%J.^VQJ#
M.A#E))P2N]%]2@NSP7FWG+RE=O0-VWZ&I$N3TSI:1]DU;[Y7X,RJVLY<>E]'
MCTDZ0*6V4PY9Y!KH15,*(B,+7H=&:;3%6XV_(="HW,.7<AY[W$Q#ZAVOB(B3
M:/2%,5QO55+TPV>?M'#KUV/H\BI]4NZA@)3?4+A^_74%$>8I9YYN&MC6Y'PV
MXZ&S,^0/*5AW19#'HR)!8#^H^FOTZ+8[+6(L"R.-67G\.%Q;G\4;: :"FN00
M.;AJ]7'-_F+XZ*B4AZ$Y(D[6@.SCJ'&ZSTZQ\FM-B=::7R"UV:WCDN#ALK<I
MVQ<SNW.9+&Y\YIQX0B)'N/X]+K&]*W(A,_-_%U\=!1/@O-.2\Q(^<!83N<GM
M\<_W$@5H%_H8*HSZ Z6Y;X<)\&$<\LYRI&R\$9-_=#4)!G4SYM[G%(;J-)C,
MNL,:"V/(SW!:/31O/1?:^:W"->+KVT^!2_<J5(>M,NW=%N/2;H!#P(I1]DZU
M3UVUV+*0REU;4=G2I"4[4K A'DW&^!CPWE>M0>X\OO>^;<VZORCEOZ;_ '=P
MG>IT$F)'58M#APQ1<JV?F5,97D?G#HU*HLHCIY]^.Q\WTD!C+#YHX\(YG0_/
M/1>_ *_+I_DSN_!H3(]^I\VLI+E-_#U" 5Z P$_.79$"?2JYR]+DN?&2F#(?
M_%R7$L(U])L/*FU[@%0\>0_/Z?1=&HS/8.5] OH"T'3=.$%EUKJ"[)T Q> U
M.N]MLWXVK"8YB2\XMV?/:3%8<6N9\VE/I#3^!^2N1><" 3U,,]!P+/1Z9S+I
M44U8H*:^S4[2*L/1+WT%^=.MC]H.C7 =0FVV7#'_ !>630IA*'RCC.W(R@SU
MU\Z<E[?Z&L/2*SW\+5^I7+DO/"+7-8#50+6B&JHVWG?2Z%>;;5'SZR!@")(U
M4;K;:8D*0^S+6RLFN/N*RP$'U+S3YVJ_8WO,ASM@JYVVM"N!=DZ &LG..7;F
MJ+0.H\D;IX4[;B*UF!M>ZD;XU#:&T^$C;#,N6Y*6MU3PME(6IY[U?G7FWF=H
MI;5@NU]Y[Y<\Z\'-_C@%*&$HQCF\V!=1;73Z<:!%'HMP$RX-+E?CHD?Y/RQ
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M@.EUP5! @25@'6<NU2[H**@%-QAC3.Q3&E;C2'/QTF-$>:"!^U^-/)=3YO)
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M''MI:;;:TAM(6CP(Y[#_ %2]/_\ 9[<__5TC@2+K^#7_ )M?_FP/W 8# 8#
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MPQ-L&T4E)K52]8EF8EL-?2_) SJH?9WO@^=0^AR O7Q:FM+TMA;B-Z5@3/\
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M414L7)#N@_5=6_I( _SP._QG ?JNK?TD ?YX'?XS@/U75OZ2 /\ / [_ !G
M?JNK?TD ?YX'?XS@/U75OZ2 /\\#O\9P'ZKJW]) '^>!W^,X#]5U;^D@#_/
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MEW]"@W\F]_/8#]S7+OZ%!OY-[^>P'[FN7?T*#?R;W\]@/W-<N_H4&_DWOY[
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C# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g417044g34e99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g417044g34e99.jpg
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M P,# P,# P,# P,# P,# P,# __  !$( UP"F0,!$0 "$0$#$0'_Q #   $
M 00# 0$             !P4&" H! P0) @$!  $% 0$               ,"
M! 4&!P@!$   !@(! @,"!@T("0(% 0D  @,$!08!!P@1"1(3%"$5\!:7&5D*
M,4$BU-6VUA=W&%B8.5%A<9$CM3AY@:&QP='A\3(D0B52,S5&*%-60S1$)L;7
M2"D1 0 " @(! @4# @0& P     ! @,$$042(1,Q(A0&!S(5"$%1<9%")&%B
M<I(C0T06&/_:  P# 0 "$0,1 #\ W^
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                   ''7_E_P!>OVP'(   'M  ''M /;_SZ?[NN,@'7I]G
MI_L_ZY <@..O\OP_Y@&,]?A_O^V Y   !QC/4 ^'V_Y0#X?ZO]H#D   ''7X
M9 .O]?\ )_NQ_4 =<?U_8^'^@!SU^'V?]0!@ _X@'PS_ # .,9^'P]H#D  <
M?; /;_)\/]'4!R XSU_F_P!/^O[?M .OV/\ 1_K^U]H!R     9^'VP''7X=
M,_R_\ '(  XSU^U\/A_I .OV/Y_;_L_T '7['\_\W_,!R =0
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M=M?G\HI-)';&,2&36PQ-GJGU 9S@
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MG]B0]+84YA.Z<>;D=*6*W&A)M)^I'0K3+0A6K4WGK&P;'A)C(#IK7<WX^QT
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MB8F+C6R+./C8N-;),XZ/8M&Y$T&S)BT1(DDF3&")IEP4N,8QT 5$
M                                               &-.VN-%>VWL-M
ML24L<Q%/VO'O>W'DD>P19J-3P6]W^N7\U/F.N7*OO:#/KA K4G_RCX<*>/[&
M &%VS.TKJG8L3KO"]X>&LVH=;\:*%KB1M^OZ5L6I,G/&EKN^*B9FV:[L[92
MN#6YP6^99K(,U#-\MS(H+M%T%B>,!D \X'Z\/Q7UCQCA+1.TPVF9FF7G5VT:
M17-?5.Q4O:=#L>;= WN%J$%4V.M6R7OY58KF)Q$>[G<>Y6:JD-A0RF0C6P\
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MHU*DFHX*;HO0_P F/PC3[EP_>'<[O9TS]+]O;/5:.I3I\4XLVA>M*]9UU_\
M?S7QZ3/'UNIMYN<^2]?#+-[5QS%GEZ;LIPS@QUIQDS5R6M[GK%^?GO$^//\
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M;22H6Y$VRM'5KVA]UW"RJD=Q7OA'XPTBJ4*8N%.-Z''4V)9BSR13^SST/]R
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M'M <@./;U^'MP YS_, ?#^8!Q\,@.0   <>WV_Z@'(#C[?\ S_W .0#'7[8
M XQ_4 Y  ''V\?Z0'(![0 !Q[?A\/L8 <@ !\,  #C[?^_\ J <@   XP Y
M '&0'(#CI]O_ '?: <@   ?\P  P XSU_G_U?9 <@./;\/A_( Y <?;_ *?A
M_2 Y  ' #D!Q_K_X@.0       <9^S_0 Y <?#^G_G[ '(#CV_#_ )_R@.0'
M&/Z/;[0'(    #CJ Y
M
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M@U;))1LX@29F'ILR4=DD6HFD ^X8
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M/R^0&87+ODWRNT-R'XW:UI6N^*ECHFU*-MNX/9ZZ2NQHRWUNPZ)UX]V3LPL
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M'BS5&UUQO#2V(:Q5K:M.IUPJMCQ"6)FLNR.20:Y(JFNV?.4%B&P&?
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M,YL%(8/IDV<(/&Z#MJJ1=LZ12<MUT\^)-9!=,JJ*J9O_ %$43-C.,_R9 =X
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M?&6V:WNNI36*Y6.=L$58=3-73&AO)BR2+]>:L^(=B[,CG#]9?SR%+YOBR7J
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MEP4N"EQ@I2XZ%+C&,8*7'LP7&,>S!<8^Q_, _0
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M_J]/Z5.6OXDZO ;+0      UL.^)_CZ^KX?YB+S^[Z& V3P
M
M                            !K2]V[^-']7I_2IRU_$G5X#9:      &
MMAWQ/\?7U?#_ #$7G]WT,!LG@
M
M      #6E[MW\:/ZO3^E3EK^).KP&RT      -;#OB?X^OJ^'^8B\_N^A@-D
M\
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MD7.,FZ8]H#T/'K2.:KO7[ENR9MB>8NZ=K$;MD4^N"^-597)4TR=<X]N<XQU
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MNB%B86R'S&M;]%V1TUG.J*RSC"2.<'SC&< ,:;GVI;98W"QHSDI88U".@)N
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M      &MAWQ/\?7U?#_,1>?W?0P&R>
M
M            -:7NW?QH_J]/Z5.6OXDZO ;+0      UL.^)_CZ^KX?YB+S^
M[Z& V3P                        '&,XS]C(#D  .OP_U
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M.$(&#;.G#YM"Q+9\[9HQ[IXA',TG3E@WQG"#)PX31(LLS0QG/@2-G)"X^QC
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M:2/3K37:-7"O&[F3+A>70^)#BSE/3XZ1<W&'BTG!I&81D"IOL.2)9;9RCA3
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MQ=^FH0B>2)F4P'JOW-SC+KW7%DVO(;0A[!2:K8V51F9:D85MZ*%ID:V:V1L
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M^J2V)"IMF!(DY[%()-L2#%O9FJE@6CV)FD>:>DT;:\P[7(DGA;)RYR7&28R
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MUH?9,O#6._N9&P2S^7M]HAYWXS?&69DU7/GJ34I8,F=O%$_+(NH?.,E*3H7
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M2M5:UDM1VR\;&2KIFKEQ,QQ6BBCUOX5D,F"V:+SVYG24V6J..+JUK/,SDLA
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M*K_<84"!3]Q_E&5M4DTN&UA<RT_0KK8)#&(C:B-;BI*)>VM*JRSBQ%HKE1O
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ML >9L\:/2949NFSM,N28,=LNDN3&5$4W">,F2,<N,G06(?'\I#8S]C.,@/2
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M06N=<Z_AXXKF9EI=1Y$QC.IO"IK+'PY.@=OA3Q*85.8,R0
M :TO=N_C1_5Z?TJ<M?Q)U> V6@     !K8=\3_'U]7P_S$7G]WT,!LG@
M
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M4 QGJ Y^']8#CK\/9_QZ .0''7^;/P_U .?A]KX>P!QU_P!O3_< YZ@..O\
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M))3(84O]R]]>H4&U&=ZLJ.S+H[K4;FG/*[J:K5=&$N$=&O)=<E@BW.XIK,S
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M]A?-XR N55G))W!LK.TCX>Q1$D]=5J2SCW?86[1D\677@WWBQY+LI<MU>N/
M?("ZNF,@'0 Z?#^3_H Y  #I_MZ@'V0 !QT_Y '3'P^'VP'(!T^'_0 ^'^X
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M
M                     #6E[MW\:/ZO3^E3EK^).KP&RT      -;#OB?X^
MOJ^'^8B\_N^A@-D\
M                                                          :T
MO=N_C1_5Z?TJ<M?Q)U> V6@     !K8=\3_'U]7P_P Q%Y_=]# ;)X
M
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M/\?7U?#_ #$7G]WT,!LG@
M
M  #6E[MW\:/ZO3^E3EK^).KP&RT      -;#OB?X^OJ^'^8B\_N^A@-D\
M
M                                       :TO=N_C1_5Z?TJ<M?Q)U>
M V6@    &-/)FZ;UHE.Q-Z0U^ZV,_/'6%A(14&WAI&TQ<JY9-LU:P1<+8K'5
M(B<BXYVDX*\:^M(X.95 Q"F3*MT#75[GMFV!:^5OU>*1V:1 MJ;]RJVQ2I\I
M0;&9<1L6O36<2YMD'69B?@*S;UV"9#2,:T>N$FCC.28,7/4A0VP
M
M                                 !K2]V[^-']7I_2IRU_$G5X#9:
M   8A\O89=Y6*=-.MH4J@5F"LCKXPPNQ=C6#4E0NN9**=-8EH[OM2FZ]8X^2
M@W9,NFK9)P9NZSX_.3/Y:>2AKP]QN/E(WDI]730E+BA>L*=R:WNXJP1\B:<@
M5(-V[I[B)85BSN9>>E[;6HQHH5!G*2#M:0>I$P=;.#9\. VV@
M
M                              !K2]V[^-']7I_2IRU_$G5X#9:
M8L<F2Z=9?FVLNRMTM]$6B$L$VGK2Y8GZO$R;J2DJ\Y2LL%&L+='2\9->KK[8
MZJY$FV72*+?)R*)I^;@X:ZW<J@Z7!\I?J\I:!9XV[5N6[FMXL"%TC9A";Q;'
MLV_J+Z4GI!TR8144C+/Y!50SE!BV09HJXR5(G3'7(;:
M
M                          UI>[=_&C^KT_I4Y:_B3J\!LM     ,2>6$
M+R8EX:GK\9RU+XSPDA8)A96TK0B":,V6!785+SSS<+,>.L*N7[HDLFP,SDUV
MYBIH.4B&6\0?!CNR,+K'<NOJZS78:\VYM^.XG-*3"UAF*W.21UEBTM5/Q/:E
M!5R!*UPD8N$$4&N/3H^%,QU3E,H8-IT
M
M             :TO=N_C1_5Z?TJ<M?Q)U> V6@     !K8=\3_'U]7P_S$7G
M]WT,!LG@
M                                                 #6E[MW\:/ZO
M3^E3EK^).KP&RT     A?;6J9;:+BHIM=EW[7T37G,[(/DM>V*1JTM*R[J+]
M'6I)>3CUTR2+6L/C'<^ZY!%[#R!SXP[;+E3(4!K)=SI*^Q'./L94W9]W_.+=
MZ=W5YU.4MZ,9F$CI*/M=;UA<ZZWCH0TC)>YTXJ#FD6RS=,Y6V'"9S($(D8J9
M VU0
M                                             !K2]V[^-']7I_2I
MRU_$G5X#9:     8*\Z9V#B:=5$75DWI 6(KJU6"$+I)U=3X<QE?K:Y+&OL2
MO4:UTV;M-(8I2S?QM6KTDB1VJBJTZ&(<!K^]P#W6TWM]6UKC%S;'$I2NX/*4
M>Z%O4I8)JV-;U4VU%A[2RFI2SS5CF'BC62;F*@91\Y*5IY12'\!<%P&W8
M
M                                       -:7NW?QH_J]/Z5.6OXDZO
M ;+0    #"3FK8#PE;HY(C:&R-=6Y:7L;Z%9Z\KKNP)V2)BZP\/8\WE6$JUF
MM=9H]>0<MW+J7BR8<,%\HF,@]3R9LH&O=W 'T4ZWS]6Y91VQC[<?0'<,F*]:
MMD'F264EMN<8A1B6F3;6@D;#YL[/,N=1-%^=NFJX3)C*A2J8,7 ;=@
M
M                                    UI>[=_&C^KT_I4Y:_B3J\!LM
M     /G_ ,^9*R,:E5L5;8IJ"^;1^P9UXO$V1]2[D>,BX%BS]^UBSQ57M,PY
MQ5Y:99K.H)HFBO.X532P93"9FZP? _N#)QC;DK]7G91,FVE6L?W/]@LE7*E0
M)0[4211D:?[W;['JJ<5"EBMD)2IEO>^/3$,HXSYAC*&,90X;>
M
M                                UI>[=_&C^KT_I4Y:_B3J\!LM
M , >>*D4A':<=S<$M9&+&\2;\D32ZOKRW[O/)LX%5S%/]51&SX:<K!THMZD5
M:94*@5XFV*B9$Y<8.4P?!3N%V"4M?)'ZN]99I[#R,G-]S6^/W3MBUKS*P',I
M(U(A$]CM:DRC*PCM%!),J<\5@V1;8?E/X2_9SD-ND
M
M                       :TO=N_C1_5Z?TJ<M?Q)U> V6@    'SZY^R#>
M%@=4S;Z5LU78,K?-(N+AJE:)QOJ!4>5QRF@EJ]I+R#))ZRELIY2G2I)/EBLB
MDSAODOC70#X!\ZNBF]/JXSLB41A"0[D]WD&KYBO'N)R;:NY.J*HSVP3Q4K.1
MQ=F2Y<^=/$2>+E)(&.7J3.,I$#<!
M
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M!-NJ]8).D%'K-)W@QFJKMJ0^5VZ;G"9LIF.7&#XQGIUZ /:
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M;1V!I^>GH]MMG2TI :[)Q^VO3M@U3<V$)^XILF3>BWNIKP=.0*=PUF/'Y:V
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M'I,09H9G$3C>%B*2]A?_ &U=TW=>5D-G''\_\N?]H#D
M             :TO=N_C1_5Z?TJ<M?Q)U> V6@     !K8=\3_'U]7P_S$7G
M]WT,!LG@                                   =/^(!T^'^K_8  '3X
M?ZO]@           *6Z@X5](Q\N]AXMY+1/G8BI1U'M'$C&X<%\"^(]ZJB=R
MS\\GL/Y9B^+'LSU 50
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MG]_ 'SVW:+^D8XD?+)4_OX ^>V[1?TC'$CY9*G]_ 'SVW:+^D8XD?+)4_OX
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M\_ 0!\T_VROV!^)?R%:\_ 0!\T_VROV!^)?R%:\_ 0!\T_VROV!^)?R%:\_
M0!\T_P!LK]@?B7\A6O/P$ ?-/]LK]@?B7\A6O/P$ ?-/]LK]@?B7\A6O/P$
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M/]LK]@?B7\A6O/P$ ?-/]LK]@?B7\A6O/P$ ?-/]LK]@?B7\A6O/P$ ?-/\
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M-K8ED%[ 35^OJO23SJK7!\-33"\!&L7$GAIA0WDE6,?"7BSX,8ZYZA/
M
M
M
C                                           /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
